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THESIS ABSTRACT 
 
Haemorrhage is a leading cause of trauma morbidity and mortality, with many deaths 
potentially preventable.  Hyperfibrinolysis is a central characteristic of trauma-induced 
coagulopathy (TIC) which develops rapidly and is associated with poor outcomes.  
Tranexamic acid (TXA) improves survival in trauma haemorrhage but its uptake worldwide 
remains variable, in part because its effects on the coagulation system during trauma 
haemorrhage have not been described.  Further uncertainty regarding patient selection for 
TXA therapy has emerged following the description of an early viscoelastic haemostatic assay 
(VHA) diagnosed hypofibrinolytic phenotype in whom TXA may potentiate thrombotic 
complications.  The patient characteristics and mechanisms leading to this apparent 
hypofibrinolytic phenotype are poorly understood. 
 
Over 900 trauma patients prospectively recruited to a multicentre observational cohort 
study had blood drawn within 2-hours of injury for VHA and fibrinolysis plasma protein 
analysis.  Patients were categorised according to VHA maximum lysis (ML) and D-dimer (DD) 
levels.  Patients with MLLOW exhibited heterogeneity in clinical and injury characteristics and 
outcomes.  Those who died were severely injured, with a high incidence of traumatic brain 
injury and a 7-fold higher D-dimer.  Patients with MLLOW+DDHIGH had a hyperfibrinolytic 
biomarker profile, with the fibrinolytic mediator S100A10 identified as a potential driver of 
fibrinolysis, which can ex-vivo artificially reduce ML.  Empiric TXA could benefit this occult 
hyperfibrinolytic phenotype. 
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Over two subsequent observational studies, the effects of TXA on the coagulation system 
during trauma haemorrhage and the effect of TXA infusion and timing of treatment on 
thrombotic events were investigated.  Early empiric TXA avoided VHA-hyperfibrinolysis and 
provided a degree of protection from TIC.  Whilst univariate analysis suggested increased 
thromboses with later TXA treatment in patients receiving TXA bolus+infusion, neither the 
TXA infusion nor time to bolus were associated with thrombotic events after multivariate 
analysis.   A single TXA bolus may provide a lower effective therapeutic dose with reduced 
complications. 
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symbols are used throughout. 
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1.1 BACKGROUND 
Traumatic injuries account for the death of almost 5 million people worldwide each year[1] 
with this number projected to rise by 40% by the year 2030.[2]    Haemorrhage is responsible 
for 30-40% of deaths following trauma and is the most common cause of early in-hospital 
mortality within the first few hours following major trauma.[3]  Of those patients with 
potentially survivable injuries, who subsequently die, the majority do so because of 
haemorrhage.[4]  Early coagulopathy exacerbates bleeding and is itself a poor prognostic 
indicator.   Patients with Trauma-induced Coagulopathy (TIC) are eight times more likely to 
die within the first 24 hours[5] and more likely to require a massive transfusion[6], with 
increased risk of multi-organ failure (MOF) and longer critical care and hospital stay.[5]  A 
greater understanding of the mechanisms underpinning TIC is key to the development of 
effective treatment strategies aimed at reducing the number of preventable deaths from 
haemorrhage. 
 
Fibrinolysis activation occurs almost universally following severe injury and is of central 
importance to the coagulation dysfunction that develops following trauma.[7] Physiological 
fibrinolysis is a proportionate response to increased fibrin generation following tissue 
trauma[8], whereas excessive or systemic fibrinolytic activation is inappropriate and 
potentially lethal. Acute Traumatic Coagulopathy (ATC)[9] is an early and endogenous 
haemostatic abnormality of which global hypocoagulation, systemic 
hyperfibrinolysis[10,11], early fibrinogen depletion and platelet dysfunction[12] are key 
components.  ATC is triggered by massive tissue injury in conjunction with hypoperfusion 
(shock) in the early phase after major trauma.[10] Hyperfibrinolysis is defined by 
disproportionately increased fibrinolytic activity with respect to fibrin formation[13], and is 
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associated with poor clot integrity, excessive bleeding and worse coagulopathy, in addition 
to increased morbidity and mortality.[3]   
 
Controversy currently exists over patient selection for antifibrinolytic therapy[14] and is a 
reflection of our limited understanding of both the mechanism and dynamics of fibrinolytic 
activation after traumatic injury. Hyperfibrinolysis in trauma has yet to be properly defined 
with many different arbitrary definitions used in the literature (Table 1). Sensitive diagnostics 
for a rapid and current assessment of the fibrinolytic system are lacking[8] despite the 
increasing use of viscoelastic haemostatic assays (VHA) (e.g. rotational thromboelastometry 
(ROTEM; Tem International GmbH, Munich, Germany) and thromboelastography (TEG; 
Haemonetics, Braintree, USA)) to define fibrinolytic activation states. Correlation of lysis 
parameters with laboratory gold standards of fibrinolysis - e.g. plasmin-α2-antiplasmin 
complex (PAP) - levels has proven difficult to interpret, and therefore the clinical sequela of 
acute hyperfibrinolysis and/or early hypofibrinolysis has yet to be accurately described. In 
particular, the impact of a highly activated (or inhibited) fibrinolytic system on bleeding risk, 
organ failure and thrombotic complications is unclear. Understanding the drivers of trauma-
induced fibrinolysis, the temporal relationship to injury and resuscitation, as well as optimal 
treatment strategies are priorities for the trauma research community.  
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Table 1 Summary of studies of hyperfibrinolysis in trauma 
 
a Includes trauma and non-trauma patients presenting to the ED; b Denominator for trauma patients not available; c No fibrinolysis defined as PAP < 1500 µg/L.  ECLT, 
euglobulin clot lysis time; EPL, estimated percent lysis; EFI, enzymatic fibrinolysis index (EXTEM ML – APTEM ML); LY30, clot lysis 30 minutes after maximal amplitude; 
ML, maximum lysis 60 minutes after the onset of clot formation; n/a, data not available from original publication 
 Year Definition of hyperfibrinolysis used 
Number of 
patients 
studied 
% patients with 
hyperfibrinolysis 
Mortality - with 
hyperfibrinolysis (%) 
Mortality - without 
hyperfibrinolysis (%) 
ROTEM studies 
Levrat[15] 2008 ECLT < 90 minutes (and MCF ≤ 18 mm) 87 6% 100% 11% 
Schochl[16] 2009 EXTEM ML = 100% 33 100% 88% n/a 
Theusinger[17] 2011 EXTEM ML > 15% (552) a 13 patients b  77% 33% 
Tauber[18] 2011 EXTEM ML > 15% 334 7% 57% 11% 
Kutcher[19] 2012 EFI > 10% 115 20% 52% 13% 
TEG studies 
Carroll[20] 2009 LY60 > 15% 161 2% 67% 8% 
Kashuk[21] 2010 EPL > 15% 61 18% 64% 24% 
Cotton[22] 2012 LY30 > 7.5% 1996 2% 76% 10% 
Ives[23] 2012 EPL > 15% 118 11% 92% 10% 
Chapman[24] 2013 LY30 ≥ 3% 73 15% 64% 18% 
Pommerening[25] 2014 LY30 > 3% 1625 11% 18% 10% 
Moore[26] 2014 LY30 ≥ 3% 180 18% 44% n/a 
Moore[27] 2016 LY30 ≥ 3% 2540 18% 34% n/a 
Biomarker studies 
Raza[7] 2013 PAP >1500 µg/L AND EXTEM ML < 15% (moderate) PAP >1500 µg/L AND EXTEM ML > 15% (severe) 303 
Moderate 57% 
Severe 5% 
Moderate 12.1% 
Severe 40% 1%
 c 
Cardenas[28] 2014 PAP 1500 – 20000 µg/L (moderate) PAP >20000 µg/L (severe) 163 
Moderate 45% 
Severe 10% 
Moderate 25% 
Severe 31% 4.1%
 c 
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1.2 REGULATION OF FIBRINOLYSIS 
The coagulation and fibrinolytic systems are both activated following trauma and exist in a 
dynamic equilibrium.[7,29] Plasmin is essential for vascular homeostasis, required for the 
timely breakdown of fibrin clots following coagulation in order to prevent propagation of the 
clot distant to the site of injury and maintain vascular patency.  Plasminogen may be 
activated either by tissue-type or urinary-type plasminogen activators (tPA and uPA 
respectively) or by the contact pathway. tPA is a serine protease produced and secreted 
primarily by pre-capillary arteriole and post-capillary venule endothelial cells[30–32] and is 
the primary plasminogen activator in the vasculature. In response to vascular injury or the 
presence of thrombin, additional stores of tPA from endothelial Weibel-Palade bodies[33] 
and possibly by poorly characterized other small storage granules[34] are released.[35]  Both 
tPA and plasminogen bind to the surface of fibrin which acts as a cofactor for tPA with the 
net effect being enhanced plasmin generation in the presence of fibrin.[36]  In this manner, 
the fibrinolytic system is self-regulating with fibrin being both degraded by plasmin as well 
as initiating and accelerating fibrinolysis. 
 
Fibrinolytic activation is tightly controlled by plasminogen activator inhibitor 1 (PAI-1) which 
principally inhibits tPA, α-2 antiplasmin (α2AP) which inhibits plasmin and thrombin 
activatable fibrinolysis inhibitor (TAFI) which indirectly limits fibrin breakdown.[36] PAI-1 is 
found within two distinct pools within the blood - plasma and platelets.[37] Circulating levels 
of PAI-1 are relatively low in comparison to the rich source within platelet α-granules.[37]    
Platelet-rich thrombi are resistant to tPA-mediated fibrinolysis[38], however, platelet 
contribution to plasma levels of PAI-1 and the degree to which platelets modulate trauma-
induced hyperfibrinolysis is uncertain. Overall platelet count is typically preserved after 
injury, although platelet dysfunction contributes to ATC and is associated with increased 
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mortality.[12,39]  Whilst initial studies suggested that only 10% of platelet PAI-1 was in an 
active configuration[40–42] subsequent research has discovered that platelets actually 
retain high levels of active PAI-1[43,44] capable of complexing and inactivating the 
plasminogen activators.  
 
Moore et al.[45] demonstrated that platelet lysate mixed with whole blood ex vivo, resulted 
in a faster clotting time and reduced tPA-mediated fibrinolysis measured by TEG in 
accordance with earlier studies describing the anti-fibrinolytic function of platelet PAI-
1.[38,46]  Platelets are additionally a source of α2AP[38], TAFI[47] and factor XIII[48], all of 
which promote clot stabilization. Platelet-mediated fibrinolytic inhibition could in theory 
explain the improved outcomes associated with early transfusion of high ratios of platelets 
to red blood cells in patients with traumatic haemorrhage.[49–51]  In our study of 161 
bleeding trauma patients with serial blood sampling during active haemorrhage for multiple 
electrode aggregometry (Multiplate) and thromboelastometry (ROTEM)[52], we found 
platelet transfusions did not appear to influence platelet aggregation but were associated 
with a significant reduction in EXTEM maximum lysis (ML).  Furthermore, platelet 
transfusions were associated with increased levels of circulating PAI-1 and reduced tPA levels 
which may represent a primary anti-fibrinolytic mode of action in conferring outcome 
benefit. Platelets, however, are not purely antifibrinolytic but contain plasminogen, 
plasminogen activators and a reservoir of plasmin on their surface and therefore have 
profibrinolytic potential.[53]  The net effect of pro and anti-fibrinolytic actions of platelets 
and their effect in modulating TIC requires further exploration. 
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Figure 1  Schematic representation of the AIIt complex on the endothelial cell surface  
Adapted from [54] 
 
The vascular endothelium plays an active role in haemostasis, coagulation and fibrinolysis 
and endothelial surface plasminogen receptors play an important regulatory role.  The 
protein complex annexin A2 heterotetramer (AIIt) is an endothelial cell surface plasminogen 
receptor composed of two annexin A2 (ANXA2) molecules bound by a dimer of the protein 
S100A10 positioned in the centre (Figure 1).[55]  The role of ANXA2 appears to be to anchor 
S100A10 to the cell surface membrane via its phospholipid-binding sites.  S100A10 then 
initiates the fibrinolytic process by binding both tPA and plasminogen via its C-terminal lysine 
residue.  S100A10 additionally co-localises plasminogen with the uPA/uPA receptor (uPAR) 
complex.[56,57]  The net effect of bound plasminogen being co-localised with its activators 
tPA and uPA on the endothelial cell surface is one of significantly increased plasmin 
formation.  ANXA2 and S100A10 proteins subsequently bind plasmin.  The binding of tPA and 
plasmin to the S100A10 subunit protects these proteins from otherwise rapid inactivation by 
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the circulating inhibitors PAI-1 and a2AP respectively.  The plasmin formed by S100A10 
additionally partakes in an exponential activation cycle by activating uPA from its pro-
enzyme (pro-uPA) to its active form which is then in turn capable of further plasmin 
generation.[58]  The S100A10 protein therefore plays an important role in plasminogen 
binding and plasmin generation at the endothelial cell surface.  
 
1.3 THE FIBRINOLYTIC SYSTEM IN TRAUMATIC COAGULOPATHY   
ATC is an endogenous process, driven by the combination of endothelial hypoperfusion and 
tissue injury, with hyperfibrinolysis, hypocoagulation, increased thrombin generation and 
early fibrinogen depletion identified as key components (Figure 2).[10,59] Present in up to 
25% of trauma patients, ATC occurs in the first hour after injury, before significant fluid 
resuscitation or haemodilution has occurred.[9,60] During resuscitation of the bleeding 
trauma patient, ATC is compounded by ongoing blood loss and treatment strategies which 
utilise hypocoagulable fluids e.g. crystalloids, with ensuing haemodilution, hypothermia and 
acidaemia development contributing to a global failure of the coagulation system.  Trauma-
induced coagulopathy (TIC)[61] describes collectively the innate component of ATC and all 
subsequent coagulopathies which develop, typically  iatrogenic and related to suboptimal 
fluid resuscitation or delayed haemorrhage control.[62]  A temporal switch in coagulation 
status from the initial hypocoagulability of TIC to a hypercoagulable response occurs over 
hours to days after major trauma.[63,64] A biphasic response has similarly been described in 
the fibrinolytic system[65,66] with an initial acceleration of clot lysis lasting for several hours 
after injury, followed by prolongation of clot lysis lasting between four to eleven days.[67]   
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Figure 2 Pathogenesis of trauma-induced coagulopathy [62] 
 
Hypofibrinogenaemia is commonly encountered in bleeding trauma patients, with levels 
below 2.29 g/L strongly associated with increased mortality.[68]  Fibrinogen replacement can 
ex vivo correct coagulopathy[59] with pilot trial data[69] finding a potential outcome benefit 
for patients treated with early fibrinogen supplementation.  Several larger randomised trials 
are now underway to assess the efficacy of fibrinogen concentrate and cryoprecipitate in the 
early phase of haemostatic resuscitation[70–72].  The exact mechanism of early fibrinogen 
loss is not clear but hypothermia and acidosis are known to disrupt fibrinogen 
metabolism[73] and more recently direct fibrinogenolysis[74,75] has been postulated as a 
potential mechanism. 
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Activation of the Protein C (PC) pathway has been identified in both clinical human studies 
and experimental animal models as a potential mediator of hyperfibrinolysis in ATC.[76–79] 
Recently published mechanistic data demonstrates an important role for activated protein C 
(aPC) in driving both systemic fibrinolysis and possibly fibrinogen depletion.[11]  In addition 
to its inhibitory effect on thrombin generation, aPC in excess binds to and neutralizes PAI-1, 
resulting in de-repression of shock-mediated tPA release from the endothelium leading to 
uninhibited activation of fibrinolysis.[6,76,80] PAI-1 rather than TAFI appears to exert greater 
control over the fibrinolytic state after trauma.[7,10]  In an experimental model of trauma 
haemorrhage using transgenic mice with reduced capacity to activate PC, fibrinolysis and 
fibrinogen depletion were significantly attenuated with relative protection from ATC, 
confirming a mechanistic role for aPC in hyperfibrinolysis.[11]   
 
Gando and colleagues alternatively consider traumatic coagulopathy to reflect disseminated 
intravascular coagulation (DIC) with a fibrinolytic phenotype, characterized by activation of 
the tissue-factor dependent coagulation pathway, insufficient anticoagulant mechanisms 
and increased fibrinolysis.[81,82] Primary and secondary fibrin(ogen)olysis are considered to 
be pathologically activated following trauma in response to shock-induced endothelial tPA 
release[81,83,84] and DIC respectively.[82] Activation of neutrophil elastase-mediated 
fibrinolytic pathways is additionally believed to contribute to the hyperfibrinolytic state.[85] 
Subsequently it is proposed that insufficient anticoagulant mechanisms (e.g. low protein C 
and antithrombin levels) combined with PAI-1-mediated inhibition of fibrinolysis shifts the 
patient into DIC with a thrombotic phenotype.[81,82,86]   
 
Central to both the aPC and the DIC with thrombotic phenotype hypotheses is the 
mechanism of shock-induced hyperfibrinolysis. Tissue hypoperfusion in isolation e.g. cardiac 
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arrest, is capable of initiating hyperfibrinolysis[87,88] and similarly increasing levels of tissue 
injury will initiate fibrinolysis[10], evidenced on ROTEM by shortened lysis onset time (20% 
lysis of maximum clot firmness).[87]  Sympathoadrenal activation following severe trauma 
leads to a surge in circulating catecholamines which are hypothesised to contribute to 
coagulopathy and hyperfibrinolysis by means of endothelial activation and glycocalyx 
degradation.[89–91] The combination of both tissue injury and haemorrhagic shock in 
patients suffering major trauma causes a surge in tPA release from the endothelium driving 
a massive fibrinolytic response.[10,86] Almost 90% of severely injured patients defined as 
Injury Severity Score (ISS) greater than 15 have plasmin-α2-antiplasmin complex (PAP) levels 
on admission of at least twice the upper limit of normal.[7] The fibrinolytic response to 
trauma and shock is a dynamic process which evolves over time and may be exacerbated 
further by clinical interventions e.g. surgery, resuscitation. The timeframe from injury in 
which these changes occur, and the specific drivers for any up or down-regulation in the 
fibrinolytic pathways are not known, in part due to limitations in our ability to measure 
ongoing fibrinolysis rather than prior activation (e.g. PAP).     
 
1.4 DIAGNOSIS OF HYPERFIBRINOLYSIS IN TRAUMA 
Detection of post-injury changes in the fibrinolytic system in a clinically meaningful 
timeframe (i.e. to guide therapy) is challenging. Diagnostics currently available to quantify 
fibrinolysis are laboratory measures of fibrin degradation, measurement of individual 
proteins of the fibrinolytic system and VHA. The Euglobulin Clot Lysis Time (ECLT)[92,93] is a 
validated assessment of overall fibrinolysis in vivo, however, has little clinical utility in trauma 
due to the prolonged assay time and loss of plasma inhibitors (i.e. antiplasmin) in the 
acidification process. A further limitation is that ECLT is performed on diluted platelet poor 
plasma rather than whole blood and it is not capable of assessing the response to 
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antifibrinolytic therapy since these agents are normally discarded within the supernatant 
during processing.[94] Excessive fibrin degradation may be indicated by raised D-dimer levels 
although elevated levels are encountered in most patients following injury[7] and are 
strongly correlated to injury severity[10]. Kutcher et al.[19] found that patients with VHA-
detectable hyperfibrinolysis have significantly higher D-dimer levels, but that as a clinical 
marker on its own, D-dimer was not predictive of hyperfibrinolysis after adjusting for injury 
severity and shock.    
 
The fibrinolytic response to trauma is characterised by quantification of specific fibrinolytic 
proteins and complexes which are primarily measured by ELISA.[7,10,28,76,89,95,96] 
Measurement of tPA and PAP complex levels in combination with fibrinolytic inhibitor levels 
(PAI-1, α2AP, TAFI) enables a comprehensive, albeit static, assessment of the fibrinolytic 
system, but is confined to the research setting due to the time it takes to process each assay. 
A functional, global assay (such as a viscoelastic test or a plasma-based clot lysis assay) may 
provide better overall evaluation of the status of the fibrinolytic system.[97]  Any increase in 
fibrinolytic activation (PAP>1500 µg/L, twice the upper limit of normal) has been shown to 
be associated with a 12-fold increase in 28-day mortality and greater transfusion 
requirements compared to those with ‘normal’ levels of fibrinolytic activity (PAP < 1500 
µg/L).[7] However, measurement of circulating levels of PAP or the downstream D-dimer 
fragment represents recent plasmin generation (and fibrinolysis) but not necessarily the 
extent of ongoing fibrinolysis. Development of a point-of-care test capable of rapidly 
quantifying the extent of fibrinolytic activation e.g. PAP or α2AP may assist in guiding therapy 
although in isolation would still only represent an assessment of prior fibrinolytic activity. 
However, in combination with a dynamic assay such as a VHA, both rapid and serial read-
outs of fibrinolytic biomarker levels has the potential to better determine the degree of 
ongoing fibrinolysis.   
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1.5 ROLE OF VHA IN TRAUMA HAEMORRHAGE & DIAGNOSIS OF HYPERFIBRINOLYSIS 
The major advantage of VHAs over other diagnostics is near patient testing and speed, with 
provision of a comprehensive assessment of clot formation dynamics including fibrinolysis in 
whole blood (Figure 3). ROTEM and TEG are capable of rapidly diagnosing ATC[20,98,99] and 
are superior to conventional clotting tests e.g. Prothrombin Time in predicting the need for 
massive transfusion in trauma.[100] An international panel of trauma researchers has 
recommended that VHA use should be considered during the early phases of trauma 
resuscitation and remains the only test capable of diagnosing hyperfibrinolysis in a clinically 
relevant timeframe.[101] However, the latest National Institute for Health and Care 
Excellence (NICE) guideline on the management of major trauma[102] concludes that there 
is currently insufficient evidence to support the superiority of VHA over standard laboratory 
coagulation tests to target treatment. A recent Cochrane systematic review has suggested 
that at present in the setting of trauma, VHA should only be used for research purposes.[103] 
Whilst VHA can provide results rapidly, there is a need for randomised clinical trial data to 
ascertain any superiority over standard laboratory tests as a tool to guide trauma 
resuscitation.[104,105] For these reasons European and UK guidelines[102,106] currently 
recommend early empiric treatment of hyperfibrinolysis in the bleeding trauma patient 
rather than waiting for VHA-confirmation of increased fibrinolysis.  
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Figure 3  ROTEM graphical output for the EXTEM and FIBTEM assays showing normal coagulation 
(left) and hyperfibrinolysis (right).   
Adapted from [107] 
 
Extrapolation of the incidence and outcomes associated with hyperfibrinolysis in trauma 
from the literature is confounded by a number of methodological issues: (1) inconsistency in 
threshold definitions for VHA detected hyperfibrinolysis; (2) lack of standardization of VHAs 
with consequent lab-to-lab variation; (3) wide variation in patient populations; (4) 
discrepancies in sampling protocols that vary between minutes of injury to 12 hours; and (5) 
a lack of clarity between VHA versus biomarker diagnosed hyperfibrinolysis. 
 
VHA detected hyperfibrinolysis is reported in 2 – 20% of trauma patients presenting to the 
Emergency Department (ED) and is associated with mortality rates up to 100% (Table 1).[15–
23] Hyperfibrinolysis is currently defined by ROTEM as a reduction in maximum clot firmness 
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(MCF) of greater than 15% (ML > 15%), 60 minutes after the onset of clot formation. The 
continuous ROTEM variable of lysis onset time (LOT) may detect severe hyperfibrinolysis 
faster[87,108], although this has not been validated in trauma patients. Three distinct 
temporal patterns of ROTEM-detected hyperfibrinolysis have been described: (1) fulminant 
lysis described as complete clot lysis (EXTEM ML of 100%) within 30 minutes and associated 
with the highest mortality; (2) intermediate lysis as that occurring between 30 and 60 
minutes; and (3) late lysis occurring beyond 60 minutes.[16] Defining TEG hyperfibrinolysis 
according to the manufacturer’s recommendation of clot lysis exceeding 7.5%, 30 minutes 
after maximum clot amplitude (LY30 > 7.5%), Cotton et al.[22] reported hyperfibrinolysis to 
be uncommon but highly lethal.  Chapman et al.[24] subsequently found the lower threshold 
of 3% to be superior at diagnosing clinically relevant hyperfibrinolysis and predicting both 
massive transfusion and mortality. Consequently, TEG hyperfibrinolysis is now widely 
defined as LY30 ≥ 3%.[25,27,109]  
 
1.5.1 Is VHA-diagnosed fibrinolysis an accurate reflection of the status of the fibrinolytic 
system? 
VHAs accurately identify patients with the highest degree of fibrinolysis, but appears 
relatively insensitive at detecting lower levels of fibrinolytic activation[7], through rapid 
inhibition of free tPA by PAI-1 following blood draw.[110] Using a composite measure of PAP 
and VHA on admission to ED, Raza et al.[7] have shown fibrinolytic activation following 
severe trauma to be extremely common. Patients without VHA hyperfibrinolysis (ML < 15%) 
were categorized as ‘normal’ fibrinolytic activity if PAP < 1500 µg/L and ‘moderate’ 
fibrinolytic activity if PAP >1500 µg/L. Patients with PAP > 1500 µg/L combined with VHA 
hyperfibrinolysis (ML > 15%) were classified as ‘severe’. Whilst only 5% of patients were 
classified as ‘severe’, the largest proportion of patients (57%) had ‘moderate’ fibrinolytic 
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activation which was not detected by ROTEM. PAP levels were closely related to injury 
severity, with approximately 90% of patients with ISS>15 demonstrating biomarker 
confirmed hyperfibrinolysis. In a similar study utilizing PAP and TEG, Cardenas et al.[28] 
found that 45% of patients had PAP>1500 µg/L with an associated 6-fold increase in overall 
mortality despite there being no evidence of hyperfibrinolysis on TEG (median LY30 1.1 % 
(0.2 – 2.4) (Table 1).     
 
Differences in ROTEM and TEG methodology and the reagents used (Table 2) alters the 
sensitivity to fibrinolysis across platforms and individual assays. Harr et al.[111] reported that 
functional fibrinogen TEG (FFTEG) and FIBTEM were comparable in their ability to detect 
fibrinolysis faster than the other VHA assays. KaolinTEG appears superior in its ability to 
detect fibrinolysis in a dose-dependent manner across various tPA concentrations whereas 
RapidTEG detects lysis at high concentrations of tPA only. The more powerful clot activation 
required to generate faster results by RapidTEG, results in a clot more resistant to tPA-
induced fibrinolysis which may result in under-diagnosis of hyperfibrinolysis. VHA and 
biomarkers of fibrinolysis by definition do not measure the same entity, PAP reflects prior 
activation of fibrinolysis in vivo whereas VHAs quantify coagulation and to some extent 
fibrinolytic potential. Clarification of the status of the fibrinolytic system and therapeutic 
requirements of a bleeding trauma patient with grossly elevated PAP or D-dimer levels, but 
who does not meet the diagnostic threshold for VHA hyperfibrinolysis is clearly a research 
imperative. 
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Table 2 Commonly employed VHA assays to measure coagulation and fibrinolysis 
  
VHA 
Platform 
Assay  Reagents used Description 
TEG KaolinTEG Re-calcified with calcium chloride and activated with Kaolin 
Assessment of clot formation, fibrin polymerisation and fibrinolysis 
via the intrinsic pathway 
TEG RapidTEG Re-calcified then activated with Kaolin and tissue factor (RapidTEG Reagent) 
Extrinsic pathway assessment of clot formation, fibrin 
polymerisation and fibrinolysis with faster results than Kaolin TEG. 
TEG 
Functional 
Fibrinogen TEG  
Re-calcified then activated with lyophilized tissue factor and a platelet inhibitor that 
binds to glycoprotein-IIb/IIIa receptors (Functional Fibrinogen Reagent) 
Assessment of the fibrinogen contribution to clot formation after 
blocking platelets 
ROTEM EXTEM 
Re-calcified with calcium chloride (star-tem) and activated with thromboplastin 
(tissue factor) derived from rabbit brain (ex-tem) 
Assessment of clot formation, fibrin polymerisation and fibrinolysis 
via the extrinsic pathway 
ROTEM FIBTEM 
Re-calcified and platelets inhibited with cytochalasin D (fib-tem) and activated with 
ex-tem 
Assessment of the fibrinogen contribution to clot formation after 
blocking platelets 
ROTEM APTEM 
Re-calcified and fibrinolysis inhibited with aprotinin (ap-tem) and activated with ex-
tem 
Assessment of clot firmness after blocking hyperfibrinolysis with 
aprotinin 
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The circumstances required for VHA to detect ‘severe’ hyperfibrinolysis have yet to be 
confirmed. In one study tPA levels of nearly five times normal and α2AP levels below 75% of 
normal were shown to be required before ROTEM hyperfibrinolysis was visualised.[7] The 
authors hypothesise that free tPA within the ROTEM cup is required to generate plasmin and 
that only in the presence of low antiplasmin levels is there reduced inhibition of newly 
formed plasmin, resulting in ROTEM-detectable hyperfibrinolysis. Platelet dysfunction may 
additionally influence the ability of VHA to detect hyperfibrinolysis since impairment of ADP-
induced platelet activation following trauma is associated with increased sensitivity to tPA-
mediated fibrinolysis.[112] Alternatively the pattern of biomarker positive fibrinolysis with 
negative VHA lysis may represent prior excessive lytic activity which has rapidly reverted to 
normal or hypofibrinolysis during the early phase response to trauma. A further explanation 
may lie in the relative availability of promoters or inhibitors of fibrinolysis within the VHA 
with respect to thrombin generation potential since both clot strength and lysis are products 
of one another.   
 
1.5.2 VHA-diagnosed hypofibrinolysis 
At the opposite end of the spectrum, it is similarly unclear what the implications of low VHA 
fibrinolysis are for the trauma patient. Whilst the upper boundary for ‘normal’ VHA 
fibrinolysis (ML ≤ 15%[113] or LY30 < 3%[24]) is commonly quoted, no lower boundary has 
been reported and it has recently been suggested that patients with VHA hypofibrinolysis 
have worse clinical outcomes.[26,27]  The concept of “fibrinolytic shutdown” based on VHA 
results was described by Moore et al.[26] in 2014.  In a study of 180 patients with an ISS ≥15, 
patients were categorised into 3 groups according to citrated Kaolin TEG clot lysis (Ly30) 
assayed from blood obtained within the first 12 hours from injury.  Fibrinolysis was 
categorised as hyperfibrinolysis (Ly30 ≥ 3%), physiological fibrinolysis (Ly30 0.81 – 2.9%) and 
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shutdown (Ly30 0 – 0.8%).  The threshold value of Ly30 0.8% to define the upper limit of the 
shutdown group was selected as the point with the greatest specificity and sensitivity for 
mortality based on a receiver operating characteristic curve using patients with Ly30 <3%.  
The distribution of fibrinolysis was described as: 64% shutdown, 18% physiological and 18% 
hyperfibrinolysis (Figure 4).  Mortality rates were found to have a ‘U’ shaped distribution, 
being lowest in the physiological group (5%) compared to the shutdown (26%) and 
hyperfibrinolytic groups (44%).  One of the criticisms of this initial work was the fact that 
blood samples were taken anytime up to twelve hours from injury during which time 
temporal changes to the coagulation and fibrinolytic systems occur.  
 
 
Figure 4  Incidence and associated mortality rates of the three reported fibrinolytic phenotypes 
Figure adapted from Moore et al.[26] who studied 180 severely injured trauma patients (ISS ≥ 15).  
 
In a subsequent multicentre study of 2,540 trauma patients[27], with rapid TEG performed 
on blood drawn within 60 minutes of injury, a similar distribution of patients between the 
three fibrinolytic phenotypes was described.  The mortality rates were similarly high in the 
shutdown and hyperfibrinolytic phenotypes, with the risk of mortality found to be 
independent of injury and patient characteristics.  The clinical implication of fibrinolytic 
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shutdown as described by the authors of this work is that further inhibition of fibrinolysis 
with anti-fibrinolytics in this subgroup of patients would potentially have an adverse effect 
on survival.[14,114]   However, debate exists amongst trauma researchers with suggestion 
that there is a need for randomised trial data to investigate outcomes for patients with 
fibrinolytic shutdown who receive antifibrinolytics.[115] 
 
Further investigation is required to phenotype VHA hypofibrinolysis to understand whether 
all patients with this entity are the same. In particular, what biomarker patterns are 
associated with VHA hypofibrinolysis, the mechanisms that drive low fibrinolytic activity, the 
temporal relationship with injury, shock and resuscitation as well as clinical sequela e.g. 
mortality, VTE, organ failure. Improvements in the sensitivity of existing VHAs or 
development of diagnostic tools with greater definition to identify and characterise trauma 
patients with hyper or hypofibrinolysis are urgently required. 
 
1.6 WHO SHOULD RECEIVE ANTIFIBRINOLYTIC TREATMENT? 
Treatment of hyperfibrinolysis provides an opportunity to improve upon the poor outcomes 
associated with TIC, but given the lack of a validated diagnostic tool in trauma haemorrhage, 
selecting who to treat requires an evidence-based clinical decision. The CRASH-2 trial 
randomized 20,211 injured patients to receive an antifibrinolytic or placebo based on 
pragmatic inclusion of all adult trauma patients who were bleeding or were suspected to be 
bleeding.[116] Patients who received empiric dosing of tranexamic acid (TXA) had a lower 
overall mortality (14.5% vs 16%) and a lower risk of death due to bleeding (4.9% vs 5.7%). 
Subgroup analysis from CRASH-2 found the greatest survival benefit to be in those patients 
with a systolic blood pressure less than 75 mmHg[116], and was confirmed in a single centre 
48 
 
retrospective UK study[117] which additionally reported reduced MOF in shocked patients 
who received TXA. Similarly, antifibrinolytic therapy administered empirically to military 
casualties with combat associated traumatic haemorrhage was associated with lower in-
hospital mortality.[118] Again, the greatest benefit was observed in patients requiring a 
massive transfusion with TXA independently associated with survival. Given the current lack 
of evidence regarding the diagnostic accuracy of VHA[103] and in light of the results from 
the CRASH-2 trial[116], the evidence supports an empiric based approach to antifibrinolytic 
therapy in suspected trauma haemorrhage. Some clinicians choose to withhold 
antifibrinolytic treatment until VHA hyperfibrinolysis is detected due to concern over 
potentiating thrombotic complications, although this approach is not evidence-based 
practice.  
 
1.7 HOW SHOULD HYPERFIBRINOLYSIS BE TREATED? 
The primary method of targeted reversal of hyperfibrinolysis in trauma is currently with the 
antifibrinolytic TXA. Important questions remain, however, over the optimal dosing regime, 
timing, which patient subgroup derives most benefit and later thrombotic events. Early 
haemorrhage control and reversal of shock may in theory attenuate fibrinolytic activation 
through improved endothelial oxygenation and reduced tPA generation. Damage control 
resuscitation with a balanced transfusion strategy including early fresh frozen plasma[119] 
(a source of α2AP) and platelets may further dampen fibrinolytic activation[52] through 
increased PAI-1 delivery.   
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1.7.1 Evidence for the use of Tranexamic Acid in trauma 
TXA (trans-4-aminomethylcyclohexane-1-carboxylic acid) (Figure 5) is a synthetic derivative 
of the amino acid lysine. It exerts an antifibrinolytic effect by competitively blocking the 
lysine binding sites on plasminogen, thereby preventing the interaction of plasmin(ogen) 
with fibrin[120] and at higher concentrations is a non-competitive inhibitor of 
plasmin.[121,122] First described over five decades ago[121,123] TXA has found widespread 
global clinical application in part due to it being readily available, cheap and having a proven 
safety profile. It is used routinely in the elective surgical setting, including gynaecological, 
orthopaedic, cardiac and liver transplant surgery where it has been shown to reduce blood 
loss and the need for blood transfusion without increased thromboembolic events.[124,125] 
TXA is considered a relatively old pharmacological agent although is currently being 
evaluated in international clinical trials of traumatic intracranial bleeding (Clinical 
Randomization of an Antifibrinolytic in Significant Head Injury; CRASH-3)[126] and non-
traumatic gastrointestinal haemorrhage (Haemorrhage Alleviation with Tranexamic acid – 
Intestinal system; HALT-IT).[127] The randomised controlled WOMAN trial (World Maternal 
Antifibrinolytic Trial) has recently reported a reduced risk of death due to bleeding from 
postpartum haemorrhage in women treated with TXA.[128] 
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Figure 5  The molecular structure of tranexamic acid 
A synthetic amino acid TXA consists of a cyclohexane core, an amine (NH2) and carboxylic acid 
(CO2H).  
 
The seminal study of TXA use in trauma haemorrhage (CRASH-2) was the first trial to 
demonstrate improved survival from bleeding with an antifibrinolytic. TXA was administered 
as a 1g bolus over 10 minutes followed by a second 1g infusion over eight hours. The 
beneficial effects of early TXA therapy (bolus dose within 3 hours) in reducing all-cause 
mortality and death due to bleeding did not vary significantly by baseline risk of death.[129] 
TXA can therefore be administered safely to all patients with traumatic bleeding with no 
evidence to suggest it should be reserved only for high risk patients with the most severe 
haemorrhage.[130] Performed in 40 countries, the CRASH-2 results did not identify any 
effect of geographical location on the efficacy of TXA on reducing death from bleeding.[131] 
In fact, countries with the most advanced healthcare systems appeared to derive the 
greatest relative risk reduction. Haemorrhage is the leading cause of preventable death 
globally from trauma and empiric use of TXA within three hours of injury is likely to save 
many lives[131] and be highly cost-effective.[132,133]     
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TXA for the management of haemorrhage following combat injury and was evaluated in the 
retrospective MATTERs[118] and MATTERs II studies.[134] In study of 896 combat casualties, 
the MATTERs study concluded that patients receiving TXA (n=293) had a significantly lower 
overall in-hospital mortality (17.4% vs 23.9%). However, a potential confounding factor is 
that the TXA cohort received a greater volume of cryoprecipitate. In order to specifically 
address this, the MATTERs II study examined 1332 patients to investigate the effect of TXA 
and cryoprecipitate on survival. In-hospital mortality was highest in patients who received 
neither TXA nor cryoprecipitate (23.6%) and was lowest in patients who received both TXA 
and cryoprecipitate (11.6%). The individual benefit of TXA and cryoprecipitate therapy was 
similar; both associated with an odds ratio (OR) of 0.61 and 95% CIs of 0.42 to 0.89 and 0.40 
to 0.94 respectively. Combined TXA and cryoprecipitate therapy had an additive rather than 
a synergistic effect with an OR of 0.34 (95% CI, 0.20 – 0.58).  In a recently published 
multicenter observational study, treatment with TXA and transfusion of high ratios of 
platelets or plasma to red blood cells (RBC) were independently associated with increased 
survival and decreased need for massive transfusion.[135]   
 
Based upon this body of evidence, NICE[102], the Cochrane Collaboration[136], the 
Association of Anaesthetists of Great Britain and Ireland (AAGBI)[137] and the European 
“STOP the Bleeding Campaign”[106,138] recommend that empiric intravenous TXA be given 
to all trauma patients with active or suspected active haemorrhage as soon as possible and 
within three hours of injury. In order to achieve early administration, ideally within the first 
hour, it is recommended that procedures be in place for delivery of the first dose of TXA pre-
hospital at the scene of injury.[106] 
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The survival benefit from antifibrinolytic therapy is greatest when it is administered early, 
within the first hour following trauma.[139]  In a recent meta-analysis of data from both the 
CRASH-2 trial and the WOMAN trial, which investigated the effect of TXA in post-partum 
haemorrhage, the beneficial survival effect of TXA was found to reduce by 10% for every 15 
minute delay in instigating TXA treatment.[140]  Beyond three hours, no survival benefit was 
seen.  Whether patients with confirmed (biomarker or VHA diagnosed) hyperfibrinolysis 
derive additional benefit is not known. Furthermore the precise mechanism by which TXA 
confers survival benefit is unknown with some evidence to suggest it has anti-inflammatory 
action[117,141,142] in addition to its primary anti-fibrinolytic effects. As a result the relative 
efficacy of TXA on early bleeding vs late deaths from MOF and sepsis is unclear. Paradoxically, 
late administration beyond three hours in the CRASH-2 trial was associated with increased 
risk of death due to bleeding. Possible explanations are that late delivery reflects poorer 
outcomes associated with delayed trauma care or is secondary to PAI-1-mediated 
suppression of fibrinolysis with resultant microvascular thromboses.[81] If hyperfibrinolysis 
transitions rapidly into a hypofibrinolytic state then further blockade of fibrinolysis with 
delayed antifibrinolytic therapy has the potential to be harmful although the effects of TXA, 
or other agents on hypofibrinolysis have yet to be characterized. Recently, a novel hypothesis 
based on data from a murine model of severe Traumatic Brain Injury (TBI) has been 
proposed.[143]  Whilst both tPA and uPA levels in the brain increased following injury, they 
did so at different rates, with tPA peaking soon after TBI (within three hours) and uPA 
demonstrating a delayed peak after approximately eight hours. TXA blocks tPA-mediated 
fibrinolysis, however it actually enhances uPA-mediated fibrinolysis.[144]  The delayed and 
protracted rise in uPA following injury combined with the ability of TXA to enhance uPA-
mediated fibrinolysis provides a potential mechanism for the paradox of increased 
haemorrhage-related mortality with delayed therapy. Further research to evaluate the 
importance of uPA-mediated fibrinolysis in non-TBI related trauma is required along with the 
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potential role of therapeutics capable of attenuating both tPA and uPA in bleeding after 
major injury. 
 
1.7.2 Alternative antifibrinolytic therapy in trauma 
The alternate antifibrinolytic agents aprotinin and epsilon aminocaproic acid (EACA) have 
some unfavourable properties compared to TXA and hence were not selected for clinical trial 
evaluation in trauma haemorrhage. Compared with TXA, the synthetic lysine analogue EACA 
is ten times less potent[145] and has not been shown to be associated with reduced 
transfusion requirements in elective surgery.[146] Aprotinin was withdrawn from the market 
after it was found to be associated with increased mortality in a randomized trial of patients 
undergoing cardiac surgery.[147] However, due to methodological deficiencies with this 
study the conclusions were called into question and the European Medicines Agency have 
since lifted the suspension.[148] Aprotinin is a potent, long acting antifibrinolytic and future 
clinical trials should be considered to determine the efficacy in trauma haemorrhage as well 
as any additional benefits over TXA. In the search for an ideal antifibrinolytic to treat 
hyperfibrinolysis, a greater understanding of the pathophysiology of fibrinolytic pathways in 
trauma is required to determine optimal pharmacodynamics and how best to monitor the 
effect of any drug on fibrinolytic activity. 
 
1.7.3 Benefits of TXA beyond haemostasis 
There is a growing appreciation of the interactions between the coagulation, fibrinolytic and 
immune systems in response to trauma.  Plasmin not only degrades fibrin but can 
additionally activate inflammatory cells such as monocytes, macrophages and dendritic cells, 
and stimulate the production of cytokines and free radical species, highlighting the 
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importance of the fibrinolytic system in inflammation, immune response and elimination of 
infections.[149]   
 
Trauma patients who survive the initial insult of traumatic haemorrhage frequently develop 
multiple organ dysfunction syndrome (MODS) and sepsis as a consequence of the 
overwhelming systemic inflammatory response and suppression of the body’s ability to fight 
infections.[150,151]  In a prospective cohort study of severely injured patients, empiric 
administration of TXA was associated with a reduction in MODS and all-cause mortality in 
shocked patients.[117]  The survival benefit and reduction in myocardial infarction rates 
observed in the CRASH-2 trial may be partly attributable to an anti-inflammatory effect of 
TXA.  Measurement of gene expression in patients undergoing cardiac surgery has shown 
that antifibrinolytics are associated with less upregulation of pro-inflammatory and more 
upregulation of anti-inflammatory genes.[152]  In an animal model of traumatic 
haemorrhage, TXA has been shown to attenuate the loss of lung barrier function with the 
result being reduced levels of inflammatory proteins associated with acute lung injury 
measured in the lungs of rats resuscitated with TXA.[153].   Future studies to understand the 
knock-on effect that early massive fibrinolytic activation has on the immune system are 
additionally warranted and could lead to the development of new therapeutics capable of 
attenuating both the acute fibrinolytic and inflammatory responses to trauma. 
 
1.8 THROMBOTIC RISK OF ANTIFIBRINOLYTIC THERAPY IN TRAUMA 
A principal concern with the use of antifibrinolytics is potentiation of a prothrombotic state, 
either immediately after trauma during increased thrombin generation, or during the acute 
phase of recovery from major injury. Without thromboprophylaxis, multi-trauma patients 
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have a baseline risk of hospital-acquired venous thromboembolism (VTE) exceeding 
50%[154], with increasing age an important clinical predictor.[155] As trauma care advances, 
more patients survive beyond the initial 24 hours from injury and consequently more 
patients will be at risk of VTE. Some authors are concerned VTE rates are influenced directly 
by antifibrinolytic therapy[14]; however, TXA has been shown to improve survival and is 
often administered to those at greatest risk of VTE e.g. major trauma, shock, critical care 
utilization and invasive procedures. In the surgical setting, a recent meta-analysis concluded 
that the risk of thromboembolic events with antifibrinolytic use was uncertain.[125] In a 
retrospective cohort study of 872,416 patients undergoing total hip or knee arthroplasty in 
the United States, antifibrinolytic therapy was associated with lower rates of blood 
transfusion without any increase in VTE.[156] CRASH-2 represents the largest randomized 
trial to evaluate antifibrinolytic use in trauma patients and found no increase in clinically 
significant vascular occlusive events with TXA compared to placebo (1.7% vs. 2.0%). In fact, 
patients who received TXA had a lower incidence of myocardial infarction post-injury.[116] 
Whilst the MATTERs study reported higher unadjusted rates of VTE in patients receiving an 
antifibrinolytic (TXA vs. No TXA: PE, 2.7% vs. 0.3% and DVT, 2.4% vs. 0.2%), the difference 
was nonsignificant on multivariate analysis and the investigators attributed the difference to 
the higher injury burden and degree of shock in the TXA group.[118]   
 
In order to reduce the incidence of VTE in this inherently high-risk group of patients, rather 
than avoiding early antifibrinolytic therapy, future research should focus on the role of 
proactive targeted thromboprophylaxis. Development of new methods to monitor 
fibrinolytic status as the trauma patient transitions from hyperfibrinolysis to a 
hypofibrinolytic state would permit earlier insertion of retrievable vena cava filters, or use of 
higher prophylactic doses of anticoagulants. Additionally the role of antiplatelet therapy in 
prevention of post-traumatic thrombotic events needs greater clarification.   
56 
 
 
1.9 CONCLUSION 
Fibrinolytic activation within the limitations of current assays is presumed almost universal 
following trauma. Assessing hyperfibrinolysis through biomarker assays (e.g. PAP) remains 
the gold standard.  Rapid evaluation of current or active fibrinolysis remains a challenge and 
whilst the relative insensitivities of current VHA platforms are acknowledged, they remain 
the only way to assess fibrinolysis in a clinically relevant time-frame.  Current evidence-based 
guidelines recommend that all bleeding trauma patients (both suspected and confirmed), 
those that require immediate blood transfusion and all severely injured patients with 
evidence of haemorrhagic shock receive early empiric antifibrinolytic therapy in the form of 
TXA.    
 
However, the mechanism by which TXA exerts its beneficial effects on patient outcome has 
not yet been described.  Patients presenting with different fibrinolytic phenotypes e.g. VHA-
hypofibrinolysis have still to be fully characterised and the mechanism leading to this pattern 
of fibrinolysis has yet to be elucidated.  These gaps in our knowledge combined with 
uncertainty surrounding the optimal dosing regimen and timing of TXA treatment in trauma 
and potential for increased thrombotic events have led to variations in clinical practice 
globally.     
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1.10 THESIS AIMS & HYPOTHESES 
 
1. Determine the characteristics of trauma patients with low levels of fibrinolysis as 
detected by viscoelastic haemostatic assay (VHA) and explore the underlying 
mechanisms of this subtype. 
 
Hypothesis 1a Patients with VHA-hypofibrinolysis represent a heterogeneous 
group of patients and not all low levels of fibrinolysis (as detected 
by VHA) are pathological 
Hypothesis 1b Patients with VHA-hypofibrinolysis and poor clinical outcomes can 
be separately identified from those with good outcomes based upon 
injury and clinical characteristics 
Hypothesis 1c Patients with VHA-hypofibrinolysis and poor clinical outcomes have 
a non-tPA mediated hyperfibrinolytic biomarker profile. 
 
2.   Investigate the effect of early tranexamic acid (TXA) on the coagulation and 
fibrinolytic systems in patients with traumatic haemorrhage. 
 
Hypothesis 2a Early TXA induces functional changes on the coagulation and 
fibrinolytic systems which are detectable by VHA 
Hypothesis 2b Early TXA rapidly arrests fibrinolysis according to plasma protein 
markers but does not induce an early prothrombotic state  
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3.   Investigate the effect of the TXA infusion and time from injury to TXA treatment on 
clinical outcomes including thrombotic events 
 
Hypothesis 3a A single bolus dose of TXA is sufficient to avoid VHA-
hyperfibrinolysis during trauma haemorrhage 
Hypothesis 3b Exposure to the TXA infusion is associated with increased incidence 
of thrombotic events 
Hypothesis 3c Prolonged time to administration of TXA treatment is associated 
with increased incidence of thrombotic events 
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METHODS 
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2.1 STUDY OVERVIEW 
This thesis forms part of a larger ongoing research programme aiming to investigate and 
better understand the coagulation and immune system changes that occur in the human 
body in response to traumatic injury.  The prospective observational study titled “Activation 
of Coagulation and Inflammation in Trauma II” (ACIT II; UK CRN ID 5637) provided the ethical 
framework by which trauma patients were recruited and data obtained for analysis.  The 
ACIT II study was devised by Dr Ross Davenport and Professor Karim Brohi and first received 
ethical approval in November 2007 from East London and The City Research Ethics 
Committee (07/Q0603/29) to recruit 500 patients.  The study began in 2008 at The Royal 
London Hospital (RLH), London, with subsequent expansion of recruitment to participating 
trauma centres across Europe and the United States of America.  The participating centres 
are all members of the International Trauma Research Network (INTRN).  In 2013, the ACIT 
II ethical approval was extended to permit recruitment of 5000 patients across all 
participating research sites.  Six European INTRN partner sites in Amsterdam, Copenhagen, 
Cologne, Oslo, Oxford and the RLH are currently participating in a European Commission 
funded project titled “Targeted Action for Curing Trauma Induced Coagulopathy” (TACTIC) 
under the FP7 HEALTH-Contract No. F3-2013-602771.   
 
2.2 STUDY DESIGN 
A prospective observational cohort study of trauma patients admitted to RLH was conducted 
(Chapters 4 and 5).  ACIT II data from patients recruited at five out of the six sites (excluding 
Oxford) participating in the TACTIC project was analysed in Chapter 3.  The Author partook 
in all aspects of patient screening, recruitment to ACIT II and follow-up as a member of the 
research team at the RLH between August 2013 and July 2016. The Author was the lead 
research fellow for the ACIT II study during this time.  Between four to eight research fellows 
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worked together on a shift-basis to cover research recruitment to ACIT II seven days a week.  
Recruitment hours were between 08:00 to 22:00, extending to 24-hour recruitment from 
January 2016 onwards.  Patients triggering the trauma team activation were screened for 
eligibility in the resuscitation room (Resus) within the Emergency Department (ED), recruited 
and followed up until discharge or day 28 of admission. 
 
2.2.1 ACIT II inclusion criteria 
All trauma patients triggering a trauma team activation were eligible for inclusion in ACIT II.  
The trauma team are activated based upon physiological, anatomical and mechanism of 
injury criteria either pre-hospital or on arrival of the patient in the ED (Table 3).  A three-tier 
trauma team response for adult trauma is in operation at RLH (Table 4).  Patients activating 
the Code Red Trauma Team were of particular interest in order to study fibrinolytic activity 
and the effects of tranexamic acid during trauma haemorrhage.  The RLH major haemorrhage 
protocol (“Code Red”; Appendix 2) was activated when a patient with suspected traumatic 
haemorrhage had a systolic blood pressure below 90 mmHg and a poor response to initial 
fluid resuscitation.   
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Table 3  Criteria for trauma team activation at The Royal London Hospital 
Physiological Respiratory rate <10 or >29 breaths per minute 
 Systolic blood pressure < 90 mmHg 
 Glasgow Coma Scale < 14 
  
Anatomical Chest trauma with altered physiology 
 Amputation proximal to wrist or ankle 
 Suspected pelvic fracture 
 Suspected open or depressed skull fracture 
  
Mechanism Person hit by train 
 Occupant ejected from vehicle 
 Fatality in same vehicle as occupant 
 Person trapped under vehicle 
 Fall from > 2 meters 
 Polytrauma with burns 
 Penetrating trauma (neck to groin or proximal to elbow / knee) 
 Explosions 
 Industrial accidents 
 
   
Table 4  The Royal London Hospital “three-tier trauma team” response 
Category Team Criteria for activation 
Tier 1 Trauma Team In the absence of anatomical or physiological injury 
Tier 2 Advanced Trauma Team With evidence of anatomical or physiological injury 
Tier 3 Code Red Trauma Team 
Presence of physiological instability in patients requiring 
(or likely to require) activation of the massive 
haemorrhage protocol and damage control surgery or 
radiological intervention 
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2.2.2 ACIT II exclusion criteria 
 Age < 16 years 
 Patients transferred from another hospital 
 Patients presenting more than 120 minutes after time of injury 
 Patients who have received > 2000mls intravenous fluid prior to ED arrival 
 Patients with burns > 5% of their total body surface area 
 Patients taking anticoagulant medication (except aspirin) 
 Patients with a known bleeding diathesis 
 Patients with moderate to severe liver disease (Child’s classification B or C) 
 
These exclusion criteria were determined when the ACIT II study was first designed in 2007.  
The study aims to investigate the trauma patient’s early response to traumatic injury and as 
such those arriving in hospital greater than two hours from injury or those who may have 
received prior interventions at another hospital are excluded.  Those receiving large volumes 
of crystalloid pre-hospital are excluded as they are likely to have coagulopathy due to 
dilution.  Similarly, the specific high volumes of fluids required by burns patients means they 
are also at risk of dilutional coagulopathy and are excluded from this work.  In an attempt to 
study those patients developing TIC only, those with a known bleeding diathesis whether 
inherited, secondary to liver cirrhosis or medication-induced, were excluded. 
 
2.2.3 Consent process 
The ACIT II study is designed to examine the immediate coagulation and immune response 
to trauma.  As such, patients must be screened, recruited and initial blood samples obtained 
at the earliest opportunity after arriving in the ED (within 20 minutes).  Most patients (but 
potentially not all) are incapacitated at the time of ED arrival (e.g. due to critical injury, pain, 
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sedation or mechanical ventilation).  Due to the unplanned nature of trauma, the patient’s 
next of kin are unlikely to be present at the time of ED arrival and if they are present, are 
likely to be worried and distressed.  Discussing a research study in full at this stage would be 
inappropriate.  The standard Good Clinical Practice guidelines for informed consent whereby 
a study would be discussed with a patient or their next of kin in advance and they are given 
an opportunity to ask questions and allowed a period of time to consider their decision to 
partake or not, is not compatible with this type of time-critical research.  Therefore, in 
accordance with the Mental Capacity Act (2005) a hierarchy of consent was used to enable 
recruitment of trauma patients unable to provide personal consent prior to collection of the 
initial blood sample. 
 
Initial agreement to enrol a patient in ACIT II was obtained from the Trauma Team Leader 
(usually an ED Consultant or Registrar who was independent from the research group and 
familiar with the study and its consenting process) acting as a Professional Consultee.  
Following signed confirmation of the Professional Consultee agreement, blood samples and 
data were collected in accordance with the study protocol. 
 
Subsequently, patients were visited on a daily basis to assess whether they had regained the 
physical and mental capacity to give consent themselves.  In the case where they had not yet 
gained capacity to consent, written agreement was sought from their next of kin (Personal 
Consultee) as soon as it was deemed appropriate to do so.  A written information sheet was 
provided to the Personal Consultee.  The patient continued to be assessed on a daily basis 
for their capacity to consent and this was sought if appropriate, even when Personal 
Consultee agreement had previously been obtained.  Patients were informed of what study 
procedures had already been performed and where provided with a written information 
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sheet.  Patients were given the option of withdrawing from the study or continuing to 
participate.  If a patient or Personal Consultee declined to give consent/agreement for 
continuation with the study at any stage, his/her wishes were respected.  The Police assisted 
in the identification of unidentified patients and in contacting next of kin.  All attempts to 
obtain informed consent and discussions with patients or their next of kin around consent 
were logged in a secure electronic database.  Hard copies of all signed consent forms were 
filed in the medical records.   
  
2.3 BLOOD SAMPLING 
Following Professional Consultee agreement, enrolled patients had a baseline sample of 
20ml venous or arterial blood obtained within 20 minutes of ED arrival.  A standard panel of 
blood tests were obtained simultaneously as part of routine trauma care and sent to the 
hospital laboratory for measurement of: full blood count (FBC), prothrombin time (PT), 
activated partial thromboplastin time (APTT), International Normalised Ratio (INR), 
fibrinogen, D-dimer, urea and electrolytes (U&E) and group and save.  All patients had an 
arterial or venous sample taken for blood gas analysis including measurement of base deficit 
(BD) and lactate as part of routine clinical care. 
 
Patients who required a blood transfusion had a further 20ml research blood sample drawn 
after transfusion of the 4th, 8th and 12th unit of packed red blood cells (PRBC).  A further 20ml 
of blood was drawn from all patients admitted to hospital at 24 and 72 hours from baseline 
blood draw. 
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Research blood samples were collected in specific vacutainers.  Blood for rotational 
thromboelastometry (ROTEM®) analysis, was collected in a 2.7ml citrated vacutainer 
(0.109 Molar / 3.2% sodium citrate; Becton, Dickinson and Company, Plymouth, UK).  Blood 
for coagulation and fibrinolysis protein assays was collected in two 4.5ml glass citrated 
vacutainers (0.109 Molar / 3.2% sodium citrate; Becton, Dickinson and Company, Plymouth, 
UK). 
 
Additional research vacutainers collected alongside the coagulation vacutainers as part of 
the ACIT II study (e.g. Proteomics, PAXgene RNA tube, TEG and Multiplate samples) are 
shown in Figure 6 but were not utilised within this thesis and therefore their processing is 
not described further herein.   
 
2.3.1 Rationale for PRBC sampling interval 
One of the primary aims of the ACIT II study is to investigate the coagulation changes that 
occur following injury and assess the effect resuscitation practices have on the coagulation 
system during trauma haemorrhage.  As such repeated blood samples have to be taken from 
the patient during trauma haemorrhage.  The method of interval sampling chosen in the ACIT 
II study, which was already well established when I joined the Centre for Trauma Sciences in 
2013, was to take samples at baseline and then after every 4th unit PRBC transfused up to 
the 12th unit.  Different factors such as availability of blood products, rate of trauma 
haemorrhage, timing of definitive haemorrhage control or where haemorrhage stops 
spontaneously, could all influence the rate and number of PRBC units transfused.  In essence 
the time over which each trauma patient’s bleeding episode lasts is unique to that patient.  
The decision to administer a blood transfusion is a clinical one made by the treating clinicians 
who are independent to this study process.   As such, PRBC transfusions are a surrogate 
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marker for trauma haemorrhage.  A sampling strategy at set PRBC intervals allows for 
consistent data collection throughout each individual patient’s bleeding episode.  
 
An alternative strategy of sampling at set time intervals (e.g. every 15, 30 or 60 minutes 
during haemorrhage) could have been adopted instead.  However, a time-based strategy has 
the potential to either over sample and take too many samples in the slowly bleeding patient 
or sample too infrequently in the rapidly bleeding patient.  The rapidly exsanguinating 
trauma patient in RLH can easily be transfused greater than 12 units PRBC within a 60 minute 
interval.  A sampling strategy based upon PRBC intervals allows for data collection at baseline 
and then again at 3 further points during haemorrhage allowing for temporal changes in 
coagulation and fibrinolysis to be investigated.  A time-based strategy of sampling every 60 
minutes in the same rapidly exsanguinating patient would mean that data collection occur 
only twice and that potentially valuable opportunities to understand pathophysiology and 
identify when interventions could be beneficial to the patient are missed. 
 
2.3.2 Blood sample processing and storage 
All research samples were processed in the Trauma Research Laboratory located within the 
RLH and frozen at -80°C within two hours of blood draw.  Samples were obtained and 
processed by the Author or else one of the otherwise attending research fellows.  A team of 
four research assistants assisted with the sample processing.  All members of the team 
initially underwent a period of training and shadowing/observation.  Sample processing 
protocols were taught according to a Standard Operating Procedure (SOP).  All members of 
the team were supervised initially by a more senior member of the research team before 
performing analysis unsupervised in order to ensure consistency and adherence to the SOP.  
Ongoing supervision was provided by senior members of the research team for quality 
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control.  In 2013, when the ACIT II study was extended to run at European partner 
institutions, the RLH SOPs were shared with each new site.  During the period of expansion 
of the research programme to partner sites, research fellows from partner institutions 
attended RLH to observe our recruitment and sample processing procedures and to partake 
in a period of training.  This helped to establish an accurate duplication of the study 
procedures in their respective centres for the purpose of study standardisation across all 
sites.   
 
Blood samples were processed as per the ACIT II flow chart (Figure 6).  The filled 4.5 ml 
vacutainers were centrifuged for 10 minutes at 1,750 G in a Clinispin Horizon 853VES 
Laboratory Centrifuge (Woodley Equipment Company Ltd, Bolton, UK). The top 2/3 of single-
spun plasma was removed and then centrifuged for a further 10 minutes at 1,750 G. This 
double-spun plasma was stored in three 0.5 ml aliquots in separate 0.6 ml Cliklok 
microcentrifuge tubes (Simport, Jencons, UK).  A 0.5 ml aliquot of the bottom 1/3 of single-
spun plasma was stored in a separate 0.6 ml Cliklok microcentrifuge tube.  The remaining 
single-spun plasma, “buffy coat” and top layer of red cells were aliquoted into a 1.5 ml 
Fisherbrand microcentrifuge tube (Fisher Scientific, UK).   
 
All sample aliquots were barcoded and stored in grid labelled cardboard cryoboxes at -80°C 
in a freezer within the Trauma Research laboratory.  Temperature logs were maintained for 
all fridges and freezers within the laboratory, which were fitted with temperature alarms.  At 
regular intervals, samples were transferred from the research laboratory to the University’s 
long term storage freezers within the Blizard Institute Laboratory, Queen Mary University of 
London.  The long term storage freezers were maintained by the University and had regular 
internal and external quality control checks.  Temperatures were monitored remotely by an 
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external firm; the Author was one of the contacts initially alerted to and responsible for 
investigating the alarming of any of our freezers due to their being out with the target 
temperature range. 
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Figure 6  ACIT II blood sample processing flow chart 
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2.4 ROTATIONAL THROMBOELASTOMETRY (ROTEM®) 
A rotational thromboelastometry (ROTEM) device measures the viscoelastic properties of 
whole blood under low shear conditions to provide a quantitative and qualitative indication 
of the coagulation state of a whole blood sample.  The device provides a graphical output of 
changes in clot formation and fibrinolysis.   
 
2.4.1 Measurement principle 
The ROTEM delta system was used for all analyses.  The measuring principle of the ROTEM 
delta is based upon a fixed cylindrical cup filled with blood and a permanently oscillating 
vertical axis (Figure 7).  The axis is supported by a high precision ball bearing which oscillates 
left and right through an angle of 4.75 °.  A disposable plastic pin is placed over the axis and 
this is inserted into the fixed cup containing citrated whole blood in addition to specific 
reagents.  The rotation of the pin/axis is detected optically by detection of a light shone at a 
mirror plate at the upper end of the axis.  Movement of the pin is unrestricted when no clot 
has formed.  As a clot forms between the cup surface and pin, movement of the pin is 
obstructed.  Computer software interprets the pin movement and provides the standard 
ROTEM graphical output (Figure 8) and common measurement parameters (Table 5).  Four 
channels on the device allow for simultaneous measurement of four different ROTEM assays 
each of which can assess specific aspects of the coagulation system.   
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Figure 7 ROTEM (delta) device and detection method [107] 
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Figure 8 ROTEM output trace with illustrated key parameters [107] 
 
Table 5  Description of measured ROTEM parameters 
Parameter Unit Description Interpretation 
CT 
Clotting Time 
Seconds 
Time from beginning of test  
to detection of first clot 
(amplitude 2 mm) 
Initiation phase 
Lag-phase of thrombin generation 
(dependent on activity of 
coagulation factors) 
CFT 
Clot Formation Time 
Seconds 
Time from CT until clot 
firmness reaches 20 mm 
Amplification phase 
Initial clot strengthening by 
formation of fibrin fibres 
α-angle Degrees 
Kinetics of clot development 
– angle between the 
horizontal middle axis and 
tangent to the curve through 
the 2mm amplitude point 
Thrombin burst 
Maximum velocity of clot 
formation (dependent on platelet 
function and fibrin polymerisation) 
CAx 
Clot amplitude at x 
mm 
Mechanical clot quality at 
fixed time point e.g. CA5 at 5 
mins 
Propagation phase 
Clot strength at fixed time point 
determined by platelets,, 
fibrinogen and Factor XIII 
MCF 
Maximum Clot Firmness 
mm Mechanical clot quality 
Maximal clot strength – 
determined by balance of 
platelets, fibrinogen and Factor XIII 
with fibrinolysis 
ML 
Maximum lysis 
% 
Degree of fibrinolysis relative 
to MCF at end of 
measurement (i.e. % clot 
firmness lost) 
Clot termination 
Functional measure of fibrinolysis 
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2.4.2 Sample processing 
The ROTEM assays measured in parallel within ACIT II are: 
 EXTEM  Activated clotting via extrinsic pathway using tissue factor 
 INTEM  Activated clotting via intrinsic pathway using ellagic acid 
 FIBTEM As EXTEM plus addition of cytochalasin D to inhibit platelets 
 APTEM  As EXTEM plus addition of aprotinin to inhibit fibrinolysis. 
 
Only EXTEM and FIBTEM assays have been used for this body of work.  The reason for 
selecting these assays is that they have most commonly been used by researchers 
investigating TIC.  The Cochrane Injuries Group identified that the tissue factor-activated 
assay, EXTEM, was the focus for researchers assessing the accuracy of ROTEM for detection 
of TIC.[103]  A further reason for selecting these assays is that both have direct clinical utility 
with EXTEM capable of measuring clot formation, fibrin polymerisation and fibrinolysis, 
whilst FIBTEM allows for an assessment of fibrinogen status with the ability to detect 
fibrinogen deficiency.  Both assays are currently being measured in the iTACTIC randomised 
control trial assessing the utility of VHA to guide transfusion therapy in trauma 
haemorrhage[157], further highlighting the clinical relevance of studying these specific 
assays. 
 
The sampling process for the EXTEM and FIBTEM assays is described below.  All pipetting and 
mixing steps were performed in a standardised manner using the automated electronic 
pipette program.   
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The 2.7 ml citrated vacutainer was placed into the well of the warming plate of the ROTEM 
device to incubate at 37°C for 10 minutes.  The ROTEM reagents were removed from the 
fridge to sit at room temperature for 10 minutes prior to use.  The individual reagents were: 
star-tem® (recalcitrant), ex-tem® (thromboplastin), in-tem® (ellagic acid), fib-tem® 
(cytochalasin-D) and ap-tem® (aprotinin).  The four channels were prepared with a 
disposable plastic cuvette placed into each test block and a disposable plastic pin positioned 
on the vertical axis.  For the EXTEM assay, 20 µl of 0.2 mmol/l CaCl2 (star-tem®) for 
recalcification and 20 µl of recombinant tissue factor (ex-tem®) were placed into the test 
cuvette, after which 300 µl of citrated blood was added.  For the FIBTEM assay, 20 µl of fib-
tem® (containing cytochalasin D and 0.2 mmol/l CaCl2) and 20 µl ex-tem® were placed into 
the test cuvette, after which 300 µl of citrated blood was added.  Samples were analysed for 
60 minutes.  Data was extracted from the ROTEM devices on a monthly basis and entered 
into the ACIT II database.  Both continuous internal and routine weekly external quality 
control testing was performed on all ROTEM machines.  The co-efficient of variation for 
ROTEM provided by the manufacturer is shown in Table 6. 
 
Table 6  ROTEM repeatability and reproducibility (coefficient of variation %) 
Precision CT CFT α-angle CA10 MCF 
Intra-assay 6 8 1 2 3 
Inter-instrument 7 – 13 5 – 8 2 – 3 2 – 3 1 – 3 
 
 
2.5 COAGULATION AND FIBRINOLYSIS PROTEIN ASSAYS 
The double-spun platelet depleted plasma, prepared and stored as described in section 2.3.1, 
was subsequently used to measure levels of key coagulation and fibrinolysis protein levels.  
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Samples were analysed in two batches.  The first batch of samples analysed were for the first 
324 ACIT II patients recruited to RLH and were performed prior to the Author joining the 
research team.  The second batch of samples included those being analysed as part of the 
TACTIC programme of work.  This much larger second batch included RLH ACIT II patients 
numbered 325 – 1099 and all of the participating TACTIC partner’s ACIT II samples.  European 
sites recruiting to ACIT II shipped frozen plasma samples packaged in dry ice to London, 
utilising specialist ‘same-day’ or ‘overnight’ courier services.  Samples were transferred to a 
-80°C freezer immediately on arrival to RLH.  All samples were then processed either in the 
central RLH Haematology laboratory using a Sysmex automated analyser (where assay 
capability existed) or manually by the method of enzyme-linked immunosorbent assay 
(ELISA).   
 
The Author was involved in requesting and managing the transfer of all samples to London 
for the second batch of analyses.  The Author subsequently performed ELISAs on these 
samples along with three laboratory technicians and had overall responsibility for 
assimilating the results and managing the dataset.  All personnel performing ELISAs were 
trained in the method by the same senior scientist and underwent regular observation for 
quality control and standardisation purposes.   
 
2.5.1 Sysmex automated system analyser 
Plasma samples for analysis were transferred to the RLH Central Haematology Laboratory -
80°C freezer and were subsequently analysed by trained laboratory staff according to the 
laboratory’s Standard Operating Procedures.  Frozen plasma aliquots were thawed to 37°C 
using a water bath prior to all analyses.  The number of freeze-thaw cycles was kept as low 
as practically possible.  A Sysmex CS2100i analyser (Sysmex UK Ltd, Milton Keynes, UK) was 
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used in combination with Siemens reagents (Siemens AG, Munich, Germany).  The 
coagulation assays performed and methods used are detailed in Table 7.  There were minor 
differences in the reference range of some assays used for the first and the second batch of 
samples analysed, although the variability of each assay remained consistent.   
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Table 7  Summary of assays performed on the Sysmex CS2100i automated analyser 
Parameter 
Reference 
Range 
RLH 0-324 
Reference Range 
RLH 325+ & All 
INTRN samples 
Units Reagent Reagent Supplier Method 
Intra-assay 
variability 
(normal 
sample) 
Inter-assay 
variability 
(normal 
sample) 
PT 9.4-12.4 9.4-12.2 secs 
Siemens Innovin Sysmex UK Clotting 1.3% 2.0% 
INR 0.9-1.1 0.9-1.1 ratio 
APTT 21-31 21-31 secs 
Siemens Actin FS Sysmex UK Clotting 4% 4% 
APTT ratio 0.8-1.2 0.8-1.2 ratio 
Fibrinogen 1.50-4.50 1.56 – 4.0 g/l Siemens Thrombin Sysmex UK Clauss 5.9% 2.3% 
Factor II 78-117 70 – 146 iu/dL 
Siemens Innovin and Siemens Factor 
II deficient plasma 
Sysmex UK 
Clotting by multi-dilution 
analysis 
2% 7% 
Factor V 66-114 62 – 150 iu/dL 
Siemens Innovin and Siemens Factor 
V deficient plasma 
Sysmex UK 
Clotting by multi-dilution 
analysis 
2% 7% 
Factor VII 50-150 67 – 143 iu/dL 
Siemens Innovin and Siemens Factor 
VII deficient plasma 
Sysmex UK 
Clotting by multi-dilution 
analysis 
2% 7% 
Factor VIII 52-153 52 – 153 iu/dL 
Siemens Actin FS and Siemens Factor 
VIII deficient plasma 
Sysmex UK 
Clotting by multi-dilution 
analysis 
2% 7% 
Factor IX 58-138 58 – 138 iu/dL 
Siemens Actin FS and Siemens Factor 
IX deficient plasma 
Sysmex UK 
Clotting by multi-dilution 
analysis 
2% 7% 
Factor X 50-150 65 – 152 iu/dL 
Siemens Innovin and Siemens Factor 
X deficient plasma 
Sysmex UK 
Clotting by multi-dilution 
analysis 
2% 7% 
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Factor XI 58-148 58 – 148 iu/dL 
Siemens Actin FS and Siemens Factor 
XI deficient plasma 
Sysmex UK 
Clotting by multi-dilution 
analysis 
2% 7% 
Factor XIII 70-140 55 – 155 iu/dL Siemens Berichrom F XIII Sysmex UK Chromogenic method 5% 6% 
Von Willibrand 
Antigen 
50-160 50 – 156 iu/dL Siemens vWF Ag Sysmex UK Latex immunoassay 1.4% 0.9% 
Antithrombin 81-119 81 – 119 iu/dL 
Siemens Berichrom Antithrombin III 
(A) 
Sysmex UK Chromogenic 1.3% 4.6% 
Protein C 72-162 72 – 162 iu/dL Siemens Berichrom Protein C Sysmex UK Chromogenic 1.3% 1.9% 
Free Protein S 
Antigen 
62-120 60 – 139 iu/dL Stago Liatest Free Protein S Diagnostica Stago Latex immunoassay 2.4% 2.6% 
α2-antiplasmin 76-126 68 – 136 iu/dL Siemens Berichrom α2-antiplasmin Sysmex UK Chromogenic 0.5% 3.2% 
Soluble Fibrin 
Monomer 
Complexes 
<6 0 – 6 µg/mL Stago Liatest Fibrin Monomer Diagnostica Stago Latex immunoassay 2.5% 3.6% 
D-Dimer <550 0 - 440 ng/mL Siemens Innovance D-Dimer Sysmex UK Latex immunoassay 4.1% 4.3% 
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2.5.2 Enzyme-linked immunosorbent assays (ELISAs) 
2.5.2.1 Measurement principles 
ELISAs rely upon the reaction between an antibody and an antigen.  ELISAs can be performed 
either in a solution (fluid phase) or on the surface of a plastic (solid phase).  Solid phase assays 
are more sensitive and in this study, the 96-well rigid polystyrene microtiter plate was 
utilised as the solid phase.  Microtiter plates can be coated with either an antigen or an 
antibody.  The ELISAs used in this study are examples of two-site antibody-coated assays, 
also known as sandwich ELISAs.  A sandwich ELISA uses two antibodies to bind an antigen 
between them (Figure 9).  The principle steps in a sandwich ELISA are that the first antibody 
(the capture antibody) is bound to the microtiter well and it captures the desired antigen.  
The second antibody (the detection antibody) is labelled with an enzyme conjugate and 
attaches to another site (or epitope) on the antigen, creating the sandwich.  Addition of a 
substrate which reacts with the enzyme leads to a colour signal being produced.  After 
stopping the reaction, measurement of the absorbance with a spectrophotometer permits 
quantification of the captured antigen.    A sandwich ELISA is a non-competitive process. 
 
 
Figure 9  Schematic representation of the sandwich ELISA 
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2.5.2.2 Measurement process 
All ELISAs were performed in the Blizard Institute Laboratory, Queen Mary University of 
London according to the manufacturer’s instructions.  Frozen plasma aliquots were thawed 
to 37°C using a water bath prior to all analyses.  The number of freeze-thaw cycles was kept 
as low as practically possible.  A summary of the assays performed by ELISA is detailed in 
Table 8.  ELISA kits from the same manufacturer with the same reference ranges were used 
for both the initial and the second larger batch of samples analysed.  ELISA kits were stored 
according to the manufacturer’s instructions.  All plates were analysed with standards, 
controls and patient samples in duplicate.  Where the variation between duplicate results 
was >20%, the samples were repeated.  The mean control sample on each plate was verified 
to be within the range set by the manufacturer (Figure 10).  Given the large number of ELISA 
plates used, this served as the quality control measure for individual ELISA plate performance 
and validity.  If the measured control value fell out with the specified target range, the 
samples on this plate were repeated on a new plate where sufficient plasma allowed.  In the 
case the measured protein concentration was higher than that of the highest standard or 
lower than the lowest standard, where sufficient plasma was available, the sample was re-
tested at a lower/higher concentration as appropriate.   
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Figure 10  ELISA plate validation - trend in mean PAP control values 
Graph demonstrates mean control values from each individual PAP ELISA plate assayed between 
December 2013 and April 2014.  Control value results were confirmed to lie within the expected 
range (dashed lines) set by the manufacturer, as a quality control measure of plate validity.  The 
control result highlighted in orange measured outside of the range advised by the manufacturer and 
the samples on this plate were repeated. 
 
All plate washing steps were performed using an auto strip ELx50 automatic plate washer 
(BioTek, Winooski, USA).  The absorbance (OD) of each well was determined at 450 ± 10 nm 
with a SIAFR Synergy HT plate reader (BioTek, Winooski, USA) using KC4 v3.4 software.  The 
mean absorbance value for each duplicate standard, control and plasma samples was 
calculated.  Standard curves were constructed by plotting mean absorbance for each 
standard against its concentration and curve fitted by linear regression analysis using 
Graphpad Prism v5 (Graphpad Software Inc., San Diego, USA) in accordance with the 
manufacturers’ and Graphpad Prism instruction manuals.  Using the mean absorbance value 
for each plasma sample, the corresponding concentration was determined from the 
standard curve using linear regression, taking into account the dilution factor of the sample.  
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Table 8  Summary of assays performed by ELISA 
Parameter 
Reference 
Range 
RLH 0-324 
Reference Range 
RLH 325+ & All 
INTRN samples 
Units Reagent Reagent Supplier Method 
Intra-assay variability 
(normal sample) 
Inter-assay variability 
(normal sample) 
PAP 120-700  120-700 µg/L PAP micro 
DRG Instruments GmbH, 
Germany 
Immunosorbent 
assay 
2.1 – 6.3% 3.5 – 11% 
tPA 2–12  2–12 ng/mL Asserachrom tPA  Diagnostica Stago SAS, France 
Immunosorbent 
assay 
5.1 – 7.3% 3.6 – 4.2% 
PF 1+2 69-229 69-229 pmol/L 
Enzygnost F 1+2 
monoclonal 
Siemens Healthcare 
Diagnostics Products GmbH, 
Germany 
Immunosorbent 
assay 
3.6 – 5.5% 4.4 – 11.2% 
PAI-1 4-43 4-43 ng/ml Asserachrom PAI-1 Diagnostica Stago SAS, France 
Immunosorbent 
assay 
4.2 – 5.7% 2.7 – 2.9% 
uPA - 62.5 – 4,000 # pg/ml uPA (URK) Human Abcam, UK 
Immunosorbent 
assay 
3.4 – 5.3% 5.4 – 6.8% 
S100A10 - 0.156 – 10 # ng/ml Human S100A10 Abbexa, UK 
Immunosorbent 
assay 
<10% <12% 
  
PAP, plasmin-α2-antiplasmin complex; tPA, tissue plasminogen activator; PF 1+2, prothrombin fragment F 1+2; PAI-1, plasminogen activator inhibitor-1; uPA, urokinase 
plasminogen activator.  #Expected normal values not given by manufacturer therefore range of the assay is shown. 
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2.5.2.3 Plasmin-α2-antiplasmin complex assay protocol  
All reagents and the 96-well anti-PAP antibody (monoclonal) coated test plate were left at 
room temperature for 10 minutes prior to use. Each vial of lyophilized standard and control 
was reconstituted with 1 ml distilled water.  Wash solution was made by diluting 30 ml of 
wash solution concentrate with 1170 ml of deionized water.  200 µl enzyme conjugate 
concentrate (rabbit anti-human plasminogen antibody conjugated to horseradish 
peroxidase) was diluted with 11 ml of conjugate diluent.  Thawed, double-spun plasma 
samples were diluted 1:10 by mixing 10 µl plasma with 90 µl assay buffer.   
 
50 µl of assay buffer was dispensed into each well followed by 50 µl of each standard, control 
or plasma sample in duplicate and mixed.  The plate was left to incubate for 15 minutes at 
room temperature (20 - 25°C).  All wells were then aspirated and washed three times using 
an auto strip ELx50 plate washer (BioTek, Winooski,, USA).  100 µl of enzyme conjugate was 
dispensed into each well using a multichannel pipette and incubated for 15 minutes at room 
temperature.  All wells were then aspirated and washed three times.  100 µl of 
tetramethylbenzidine (TMB) substrate solution was added to each well and incubated for 15 
minutes at room temperature.  The enzymatic reaction was stopped by adding 100 µl of stop 
solution (0.5 mol/L sulfuric acid) to each well.  The absorbance of each well was read with a 
microtiter plate reader within 30 minutes. 
 
2.5.2.4 Prothrombin fragment F 1+2 assay protocol 
The test plate coated with monoclonal mouse antibodies to human F 1+2 and all reagents 
were left at room temperature for 10 minutes prior to starting.  The washing solution was 
prepared by diluting 100 ml of wash solution concentrate with 1900 ml deionized water.  The 
250 µl anti-human prothrombin monoclonal mouse antibody conjugated with peroxidase 
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was mixed with 14 ml conjugate buffer.  The control plasma and standard vials were 
reconstituted by adding 1 ml distilled water to each vial and incubated for 15 minutes at 
room temperature.  1.5 ml Chromogen TMB was diluted with 15 ml buffer to form the 
chromogen working solution, which was stored in a closed drawer to protect from light.  
Thawed double-spun plasma samples were diluted 1:10 with sample buffer.   
 
50 µl sample buffer was dispensed into each well followed by 50 µl of standards, control or 
plasma samples and mixed.  The test plate was covered with adhesive foil and incubated for 
30 minutes at 37°C in a water bath.  The wells were aspirated and washed twice using the 
automated plate washer.  100 µl of conjugate solution was dispensed into each well using a 
multichannel pipette, the plate was covered with adhesive foil and incubated for 15 minutes 
at 37°C in a water bath.  The wells were again aspirated and washed twice using the 
automated plate washer.  100 µl of chromogen buffer solution was dispensed into each well, 
plate covered with adhesive foil and then incubated at room temperature protected from 
light for 15 minutes.  Foil was removed and 100 µl stopping solution added to each well.  The 
absorbance of each well was read with a microtiter plate reader within 30 minutes.     
 
2.5.2.5 Plasminogen activator inhibitor-1 assay protocol 
A 96-well plate coated with mouse monoclonal anti-human PAI-1 F(ab’)2 fragments and all 
reagents were left for 30 minutes at room temperature before starting.  The lyophilized 
mouse monoclonal anti-human PAI-1 antibody coupled with peroxidase was reconstituted 
with 8 ml phosphate buffer, left to stand for 30 minutes at room temperature then the vial 
vortexed before use.  The concentrated wash solution was diluted 1:20 with distilled water 
before use.  The standard and control vials of lyophilized human plasma were reconstituted 
with 0.5 ml distilled water.  Vials were left at room temperature for 30 minutes and were 
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vortexed before use.  The reconstituted standard was diluted 1:10 with phosphate buffer to 
create the starting solution (t) which was diluted t:2, t:4, t:8, t:16 and t:32 to obtain the lower 
calibrator levels.  Plasma samples were diluted 1:10 using phosphate buffer.  The control 
sample was prepared for testing at two dilutions – 1:10 and 1:20.   
 
200 µl of standards, control or diluted double spun plasma were pipetted into each well in 
duplicate.  The plate was covered and incubated for 60 minutes at room temperature.  The 
wells were aspirated and washed five times using the automated plate washer.  200 µl of 
reconstituted mouse monoclonal anti-human PAI-1 antibody coupled with peroxidase was 
added to each well.   The plate was covered and incubated for 60 minutes at room 
temperature.  The wells were aspirated and washed five times using the automated plate 
washer.  200 µl of TMB was added to each well and incubated for 5 minutes at room 
temperature before addition of 50 µl stop solution (1 mol/L sulfuric acid).  After 15 minutes, 
the absorbance was measured with a microtiter plate reader.   
 
2.5.2.6 Tissue plasminogen activator assay protocol 
A 96 well plate coated with mouse monoclonal anti-human tPA F(ab’)2 fragments and all 
reagents were left for 30 minutes at room temperature before starting.  The lyophilized 
mouse anti-human tPA antibody coupled with peroxidase was reconstituted with 8 ml 
phosphate buffer, left to stand for 30 minutes at room temperature, then vortexed.  
Concentrated washing solution was diluted 1:20 with deionized water before use.  The 
standard and control vials of lyophilized human plasma were reconstituted with 0.5 ml 
deionized water.  Vials were left at room temperature for 30 minutes and were vortexed 
before use.  The reconstituted standard was diluted 1:10 with phosphate buffer to create 
the starting solution (t) which was diluted t:2, t:4, t:8 and t:16 to obtain the lower calibrator 
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levels.  Plasma samples were diluted 1:10 using phosphate buffer.  The control sample was 
prepared for testing at two dilutions – 1:10 and 1:20.    
 
200 µl of standards, control or diluted double spun plasma were pipetted into each well in 
duplicate.  The plate was covered and incubated for 120 minutes at room temperature.  The 
wells were aspirated and washed five times using the automated plate washer.  200 µl of 
reconstituted mouse monoclonal anti-human tPA antibody coupled with peroxidase was 
added to each well.  The plate was covered and incubated for 120 minutes at room 
temperature.  The wells were aspirated and washed five times using the automated plate 
washer.  200 µl of TMB was added to each well and incubated for 5 minutes at room 
temperature before addition of 50 µl stop solution (1 mol/L sulfuric acid).  After 15 minutes, 
the absorbance was measured with a microtiter plate reader. 
 
2.5.2.7 Urokinase plasminogen activator assay protocol 
The uPA ELISA was performed by Paul Vulliamy and Scarlett Gillespie (Centre for Trauma 
Sciences, QMUL) according to the following protocol: the 96 well anti-human uPA antibody 
coated microplate and all reagents were brought to room temperature prior to use.  The 
biotinylated anti-human uPA antibody was diluted 1:100 with antibody diluent buffer and 
mixed thoroughly.  The avidin-biotin-peroxidase complex (ABC) was diluted 1:100 with ABC 
diluent buffer and mixed thoroughly.  A 0.01 mol/L solution of PBS was formed by adding 
8.5 g NaCl, 1.4 g Na2HPO4 and 0.2 g NaH2PO4 to distilled water (200 ml) and adjusting pH to 
7.2 – 7.6, before adjusting the total volume to 1000 ml with distilled water.  A 10 ng/ml uPA 
stock standard was prepared by reconstituting the lyophilised recombinant human uPA 
standard with 1 ml sample diluent buffer and kept at room temperature for 10 minutes.  An 
eight point standard curve was prepared using a 4,000 pg/ml top standard from the 10 ng/ml 
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stock standard followed by serial 1:2 dilutions using sample diluent buffer.  The eighth 
standard remained a diluent-only blank.  Thawed double-spun plasma was diluted 1:2 by 
adding 100 µl sample to 100 µl sample diluent buffer. 
 
100 µl of prepared standards and diluted plasma samples were added to each well before 
covering the plate and incubating at 37°C in a water bath for 90 minutes.  The seal was 
removed, contents discarded from each well and plate blotted onto an absorbent paper 
towel.  100 µl of biotinylated anti-human uPA antibody was added to each well.  The plate 
was re-sealed and incubated for 60 minutes in a water bath at 37°C.  The plate was washed 
three times with 0.01 mol/L PBS using the automated plate washer.  100 µl of ABC working 
solution was added to each well, the plate sealed, and incubated for 30 minutes in a water 
bath at 37°C.  The plate was washed five times using the automated plate washer.  90 µl TMB 
was added to each well, plate sealed and incubated at 37°C in a water bath for 20-25 minutes 
in the dark.  100 µl TMB stop solution was added to each well and the absorbance read by a 
microtiter plate reader within 30 minutes. 
 
2.5.2.8 S100A10 assay protocol 
The S100A10 ELISA was performed by Paul Vulliamy and Scarlett Gillespie (Centre for Trauma 
Sciences, QMUL) according to the following protocol.  All samples and kit were brought to 
room temperature prior to use.  The concentrated wash buffer was diluted 1:30 with 
deionized water.  A six point standard curve was prepared using a 20 ng/ml top standard 
solution followed by serial 1:2 dilutions using sample diluent buffer.  The 120 µl detection 
reagents A and B were prepared by centrifuging briefly before diluting each 100-fold with 
12 ml diluent A and B respectively, and mixing thoroughly.   
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100 µl of the diluted standards, standard diluent buffer (zero control) and prepared 
undiluted plasma samples were added to the respective wells.  The plate was agitated, 
covered and incubated for 60 minutes at 37°C in a water bath.  The cover was removed, well 
contents discarded and 100 µl of the detection reagent A working solution added to each 
well.  The plate was re-sealed and incubated for 60 minutes at 37°C in a water bath.  The 
plate was aspirated and washed three times with wash buffer using the automated plate 
washer.  100 µl of detection reagent B working solution was added to each well, the plate 
sealed and incubated for 30 minutes at 37°C in a water bath.  The solution was discarded and 
plate washed five times with wash buffer.  90 µl TMB substrate was added to each well, the 
plate sealed and incubated at 37°C for 10-20 minutes in the dark.  50 µl stop solution was 
added to each well and the absorbance measured immediately by a microtiter plate reader.   
 
2.6 DATA COLLECTION 
In addition to the blood sampling and analysis described, the following data points were 
recorded for each patient. 
 
2.6.1 Patient and injury characteristics 
Patient observations on scene, on ED admission and at the time of all blood sampling, 
including heart rate, systolic blood pressure (SBP), respiratory rate, temperature and 
Glasgow coma score (GCS) were recorded alongside timings.  Patient demographics including 
sex and age were documented.  Injury characteristics including date, time and mechanism 
(including blunt vs penetrating) were recorded.  Injury severity was collated from the RLH 
trauma registry (or equivalent service in other European hospitals) as soon as available.  
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Injuries were scored and classified according to the Abbreviated Injury Score (AIS) to provide 
a composite overall Injury Severity Score (ISS) based on anatomical injury severity.[158] 
 
2.6.2 Fluid, blood products and haemostatic medications administered 
All intravenous fluids and blood products administered over the first 24 hours from the time 
of injury were recorded.  Intravenous fluids were categorised as crystalloids, colloids or 
hypertonic saline.  Blood products included packed red blood cells (PRBC), fresh frozen 
plasma (FFP), platelets and cryoprecipitate.  The timing of blood product delivery during the 
first 24 hours was recorded.  The administration of tranexamic acid and its timing was 
recorded. 
 
2.6.3 Outcome measures 
Patients were observed daily during the first 28 days of their hospital admission or until the 
point of hospital discharge or death if this occurred earlier.  Outcome measures were 28-day 
survival, hospital length of stay (LOS), critical care LOS (combined total of days in high 
dependency and intensive care), ventilator free-days (28 minus number of days requiring 
mechanical ventilation), vasopressor free-days and SOFA organ score for patients whilst in 
critical care.  Occurrence of venous thromboembolism (deep vein thrombosis (DVT) or 
pulmonary embolism (PE)) or other adverse event (including myocardial infarction, stroke) 
was documented. We defined these outcomes as a clinical diagnosis supported by a 
confirmatory test result: duplex ultrasound for DVT; CT pulmonary angiogram for PE; 
electrocardiogram changes and elevated troponin for MI; and CT head for ischemic stroke.    
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2.7 STATISTICAL ANALYSIS 
Statistical analysis was performed using GraphPad Prism version 5 (GraphPad Software Inc., 
San Diego, USA), Microsoft Excel 2013 (Microsoft Inc., Redmond, USA) and IBM SPSS 
Statistics version 25 (IBM, Armonk, United States).  Normal quantile plots were used to assess 
normality.  Data without a normal distribution are expressed as median (interquartile range) 
and analysed using Mann-Whitney U-test or Kruskal-Wallis test with Dunn’s multiple 
comparison test.  Normally distributed data are expressed as mean ± 95% confidence 
intervals and analysed with Student’s t test.  Percentages were analysed using Chi-squared 
or Fisher’s exact tests, with linear trends over time analysed with Chi-squared test for trend. 
Correlation between continuous variables was assessed with Spearman’s correlation 
coefficient. Differences in survival were compared with Log-rank (Mantel-Cox) test.   
 
Multivariate analysis was performed using IBM SPSS Statistics.  Multivariate logistic 
regression models were created to investigate the effect on late outcomes, of TXA infusion 
(binary variable [yes/no]) or time from injury to TXA bolus (continuous variable in minutes) 
alongside other factors achieving a univariate significance of p < 0.2.   
 
A p-value of <0.05 was considered statistically significant throughout unless otherwise 
stated.  Box-whisker plots represent median, interquartile range with 5th and 95th percentiles 
unless otherwise stated.  
 
The Author performed all statistical analysis with advice from both supervisors. 
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2.8  SPECIFIC ROLE OF THE AUTHOR WITHIN THE ACIT II STUDY 
Between August 2013 and July 2016, the Author was a full-time Clinical Research Fellow 
within The Centre for Trauma Sciences, Queen Mary University of London and an Honorary 
Clinical Research Fellow at The Royal London Hospital (RLH).  During this time, the Author 
was the lead fellow for the ACIT II research study.  The Author worked alongside between 
four to eight other Fellows on a shift-basis to cover research recruitment to ACIT II seven 
days a week.  Recruitment hours were between 08:00 to 22:00, extending to 24-hour 
recruitment from January 2016 onwards.  The Author partook in all aspects of patient 
screening, recruitment to ACIT II, sample and data collection and follow-up as a member of 
the research team at the RLH.  The Author and other research fellows performed 
venepuncture in order to obtain blood samples from trauma patients and then performed 
sample processing and analysis on for example ROTEM machines themselves as part of the 
data collection process.     
 
As the lead fellow, I acted as rota master from 2014 to August 2016.  The additional 
responsibilities of the lead fellow role included: day-to-day study oversight within RLH, 
monitoring patient data collection on a day-to-day basis for completeness and accuracy, 
training new research fellows and students and acting as a point of contact for any other 
fellows or research staff with queries.  The Author had responsibility for the extraction and 
“cleaning” of all ROTEM data during this period. 
 
The Author performed a lead role in all ELISA analysis.  The Author was trained in the 
technique of ELISA by a senior scientist within the group.  The Author measured four different 
plasma protein levels each using ELISA for approximately 550 patient samples over a 5 month 
period.  The Author then requested and co-ordinated the sending of plasma samples from 
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each international INTRN site to London.  Two research assistants were employed to carry 
out the remaining plasma protein analysis on these INTRN samples.  The Author assisted in 
the training of these new team members and performed oversight of all aspects of sample 
analysis and data processing.  The Author was responsible for data validation and “cleaning” 
of final biomarker data.  For those plasma samples analysed within the RLH Central 
Haematology Laboratory, the Author organised and catalogued all INTRN frozen plasma 
samples ready for analysis and liaised directly with the senior biomedical scientist performing 
the analysis, to obtain the results. 
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Chapter 3 
 
 
 
AN OCCULT HYPERFIBRINOLYTIC SUBTYPE PRESENTING WITH EARLY 
ROTEM HYPOFIBRINOLYSIS FOLLOWING TRAUMATIC INJURY 
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3.1 CHAPTER ABSTRACT 
OBJECTIVE: To determine the characteristics of trauma patients with low levels of fibrinolysis 
as detected by viscoelastic haemostatic assay (VHA) and explore the underlying mechanisms 
of this subtype. 
 
BACKGROUND: Hyperfibrinolysis is a central component of acute traumatic coagulopathy but 
a group of patients present with low levels of VHA-detected fibrinolysis. There is concern 
that these patients may be at risk of thrombosis if empirically administered an antifibrinolytic 
agent. 
 
METHODS: A prospective multicentre observational cohort study was conducted at five 
European major trauma centres. Blood was drawn on arrival, within two hours of injury, for 
VHA (ROTEM) and fibrinolysis plasma protein analysis including the plasminogen activator 
S100A10. An outcomes-based threshold for ROTEM hypofibrinolysis was determined and 
patients grouped by this and by D-dimer (DD) levels.   
 
RESULTS: 914 patients were included in the study. The VHA maximum lysis (ML) lower 
threshold was determined to be <5%. Heterogeneity existed within the MLLOW group, with 
survivors sharing similar clinical and injury characteristics to MLNORMAL (5-15%) patients. Those 
who died were critically injured with a preponderance of traumatic brain injury (TBI) and had 
a 7-fold higher D-dimer level (died vs survived: 103,170 vs 13,672 ng/ml, p<0.001). The 
MLLOW+DDHIGH group demonstrated a hyperfibrinolytic biomarker profile, low tPA levels but 
high plasma levels of S100A10. S100A10 was negatively correlated with %ML (r=-0.26, 
p<0.001) and caused a significant reduction in %ML when added to whole blood ex-vivo. 
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CONCLUSIONS: Patients presenting with MLLOW+DDLOW have low injury severity and normal 
outcomes. Patients with MLLOW+DDHIGH are severely injured, functionally coagulopathic and 
have poor clinical outcomes.  These patients have low tPA levels and are not detectable by 
ROTEM.  S100A10 is a cell surface plasminogen receptor which may drive the 
hyperfibrinolysis at the endothelium in these patients and which when shed artificially 
lowers %ML ex-vivo. 
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3.2 INTRODUCTION 
Trauma patients rapidly develop an endogenous Acute Traumatic Coagulopathy (ATC) which 
is associated with poor outcomes including transfusion requirements, critical care utilization 
and death.[5,9,159]  Hyperfibrinolysis is a central characteristic of ATC[10,11] and early 
empiric antifibrinolytic administration has been shown to improve overall 
survival.[116,118,134]  There is controversy as to whether antifibrinolytics should be 
administered empirically or given only to patients with diagnostic evidence of 
hyperfibrinolysis.[14,115]  This controversy centres on the potential risks of inducing a 
thrombotic event in patients without active fibrinolysis and the role of viscoelastic 
haemostasis assays (VHAs) in the diagnosis of hyperfibrinolysis.[160]  This confusion has led 
to a wide variation in antifibrinolytic practice worldwide. 
 
Our research group has previously shown that a large number of patients with biomarker 
evidence of hyperfibrinolysis are not detected by current rotational thromboelastometry 
(ROTEM) viscoelastic devices.[7]  Around 60% of trauma patients had an ‘occult’ 
hyperfibrinolysis with elevated plasmin-α2-antiplasmin (PAP) and D-dimer (DD) levels, 
increased mortality and blood product utilization, but no evidence of hyperfibrinolysis on 
ROTEM viscoelastic assay.  Several studies have subsequently identified that high mortality 
is associated with a hypofibrinolytic pattern on thromboelastography (TEG) and that this 
represents a group of patients in whom fibrinolysis has been switched off.[27,109]  This 
fibrinolysis ‘shutdown’ pattern appears to be the most common fibrinolytic phenotype and 
the implication is that administration of antifibrinolytics to these patients could induce 
arterial or venous thrombotic events and death. It remains unclear though whether all low 
VHA detected lysis is abnormal; whether this is a heterogeneous group not differentiated by 
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VHA; what the underlying mechanisms are that lead to these different patterns of 
fibrinolysis; and which are associated with poor outcomes.   
 
We hypothesized that not all low levels of fibrinolysis as detected by VHA were pathological. 
Our first aim was to determine whether low VHA-fibrinolysis represented a homogeneous or 
heterogeneous group of patients. If heterogeneous, we aimed to determine which patients 
had poor outcomes and to understand how they might be identified within the whole low 
VHA-fibrinolysis cohort. We further aimed to characterize the injury characteristics and 
outcomes of these patients, to shed light on the mechanism of this form of trauma-induced 
coagulopathy. We conducted an analysis of clinical data and samples from trauma patients 
prospectively enrolled into our platform study of trauma-induced coagulopathy. 
 
3.3 METHODS 
The study was first approved by East London and The City Research Ethics Committee 
(07/Q0603/29) then subsequently by each local ethics committee and conducted according 
to the Declaration of Helsinki. Deferred written informed consent was obtained from each 
patient or their next of kin. Blood samples from healthy volunteers taking no regular 
medications were obtained after written informed consent (07/Q0702/24). 
 
3.3.1 Study design 
A prospective multicentre observational cohort study, the Activation of Coagulation and 
Inflammation in Trauma (ACIT) study (UK CRN ID 5637) was conducted at five European 
major trauma centres in London, Oslo, Copenhagen, Amsterdam and Cologne. All centres are 
members of the International Trauma Research Network (INTRN). Patients were excluded 
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from ACIT if they arrived >2 hours post injury; were transferred from another hospital; 
received >2000ml crystalloid pre-hospital; or had sustained burns >5% of their body surface 
area. Patients were retrospectively excluded if they declined to give consent to the use of 
their research samples, had severe liver disease, a known pre-existing bleeding diathesis, or 
were taking anticoagulant medication (excluding aspirin) pre-injury. Of patients in the ACIT 
study recruited between January 2008 and July 2014, all adults (>15 years) who were either 
severely injured (ISS ≥ 15), shocked (lactate ≥ 2 or base deficit ≥ 4), coagulopathic (INR > 1.2 
or ROTEM EXTEM CA5 ≤ 35 mm) or transfused ≥ 4 packed red blood cell (PRBC) units within 
the first 12 hours and did not receive tranexamic acid (TXA) had multiple biomarker assays 
performed as part of the TACTIC program of work and are analysed in this study.[105]  These 
severely injured, shocked, coagulopathic or bleeding inclusion criteria were set in order to 
select a group of trauma patients expected to have high degrees of fibrinolytic activation, so 
that low VHA fibrinolysis could be specifically investigated. 
  
3.3.2 Data collection 
Research personnel at each centre screened and enrolled patients.  Data were collected 
prospectively and included patient demographics, time of injury, mechanism of injury (blunt 
or penetrating), Injury Severity Score (ISS), vital signs on-scene and on arrival in the 
emergency department (ED), total number of blood products and volume of intravenous 
fluids administered within the first 12 hours from injury. Patients were observed for 28 days 
from injury for the occurrence of venous thromboembolic events (deep vein thrombosis 
(DVT) or pulmonary embolism (PE)), and overall mortality (up to 28 days from injury). 
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3.3.3 Blood Sampling 
The baseline research blood sample was drawn within 20 minutes of the patient’s arrival in 
the ED along with standard trauma laboratory tests.  A point-of-care arterial blood gas 
analysis was performed simultaneously for base deficit (BD) calculation.  Blood for rotational 
thromboelastometry (ROTEM®) analysis, was collected in a 2.7ml citrated vacutainer (0.109 
Molar / 3.2% sodium citrate; Becton, Dickinson and Company, Plymouth, UK).  Blood for 
coagulation and fibrinolysis protein assays was collected in a 4.5ml glass citrated vacutainer 
(0.109 Molar / 3.2% sodium citrate; Becton, Dickinson and Company, Plymouth, UK).  The 
filled 4.5ml vacutainer was centrifuged within 1 hour of collection and double-spun plasma 
subsequently stored at -80°C.   
   
3.3.4 Functional Coagulation Analysis 
Functional coagulation analysis was performed within one hour of blood draw at 37°C on a 
ROTEM® delta instrument (Tem International GmbH, Munich, Germany) using the 
automated electronic pipette according to the manufacturer’s instructions.  The 
methodology and parameters of ROTEM® have been described previously.[161]  The EXTEM 
assay, measuring tissue-factor initiated clotting was run for 60 minutes and the maximum 
lysis (ML) determined. For spiking experiments, recombinant S100A10 (Abbexa, Cambridge, 
UK) or vehicle was added to the ROTEM cup prior to the start of the test. 
 
3.3.5 Coagulation and Fibrinolysis Plasma Protein Assays 
Plasma stored at -80°C was transferred from each site to London for further protein analysis.  
Plasma was thawed to 37°C immediately before all analyses.  Prothrombin fragment 1+2 (PT 
Frag 1+2; Enzygnost® F 1+2 (monoclonal); Siemens Healthcare Diagnostics Products GmbH, 
Marburg, Germany), tissue plasminogen activator (tPA; Asserachrom® tPA, Diagnostica 
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Stago, Asnières sur Seine, France), plasminogen activator inhibitor-1 (PAI-1; Asserchrom® 
PAI-1; Diagnostica Stago), plasmin-α2-antiplasmin complex (PAP; PAP micro ELISA; DRG 
Instruments GmbH, Marburg, Germany), urokinase (uPA, Abcam, UK) and S100A10 (Abbexa, 
Cambridge, UK) were measured using sandwich enzyme-linked immunosorbent assays 
(ELISAs).  Prothrombin time (and INR) (Siemens Innovin, Sysmex UK), fibrinogen (Siemens 
Thrombin reagent, Sysmex UK) and α2-antiplasmin levels (Siemens Berichrom α2-
antiplasmin, Sysmex UK) were determined in the hospital laboratories with a Sysmex CS2100i 
automated analyser (Sysmex UK) according to standard protocols.  Latex immunoassays 
were used to quantify the levels of D-dimer (Siemens Innovance D-dimer; Sysmex UK) also 
with the Sysmex CS2100i automated analyser. 
 
3.3.6 Definitions 
Major haemorrhage was defined as administration of at least 4 units of PRBCs within 12 
hours of admission, and massive haemorrhage as at least 10 PRBC units in 12 hours. Severe 
traumatic brain injury was defined as a brain abbreviated injury score (AIS) of 3 or higher. 
Coagulopathy was defined as an International Normalized Ratio (INR) > 1.2.  We defined VHA 
hyperfibrinolysis as a ML >15%.[7] 
 
3.3.7 Statistical analysis 
Statistical analysis was performed using GraphPad Prism version 5 (GraphPad Software Inc., 
San Diego, USA) and Microsoft Excel 2013 (Microsoft Inc., Redmond, USA).  Normal quantile 
plots were used to assess normality.  Data without a normal distribution are expressed as 
median (interquartile range) and analysed using Mann-Whitney U-test or Kruskal-Wallis test 
with Dunn’s multiple comparison test.  Percentages were analysed using Chi-squared or 
Fisher’s exact tests. Correlation between continuous variables was assessed with Spearman’s 
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correlation coefficient. Differences in survival were compared with Log-rank (Mantel-Cox) 
test.  A p-value of <0.05 was considered statistically significant.  Box-whisker plots represent 
median, interquartile range with 5th and 95th percentiles unless otherwise stated. 
 
3.4 RESULTS 
A total of 2465 subjects were enrolled in the ACIT study during the recruitment period across 
the five study sites. Of these, 1318 patients met the inclusion criteria and were eligible for 
enrolment into this study. Twenty-five patients co-enrolled in the CRASH-3 trial were 
excluded, along with 169 who received TXA, 196 who did not have a baseline ROTEM 
performed and 14 who did not have a D-dimer measured, leaving 914 patients for analysis. 
 
3.4.1 Determination of ROTEM Maximum Lysis thresholds for hypofibrinolysis. 
We first determined our study threshold for low VHA fibrinolysis as this has not been 
previously defined for ROTEM.  The method used to determine the different VHA fibrinolysis 
groups was in line with the method described by Moore et al.[26] using TEG in order to 
directly compare the two VHA platforms and then further explore the low VHA fibrinolysis 
group further.  A histogram of mortality for each % maximum lysis (ML) suggested a lower 
inflection point at less than 5% and below (Figure 11A). As confirmation a receiver operating 
characteristic curve for mortality was generated using patients with a ML value of ≤15%.  The 
point of ML <5.5% had the optimal performance by the Youden’s index with a sensitivity of 
61.6% and specificity of 58.4%.  Mortality was doubled in patients with ML <5% (15% vs 7.1% 
for ML 5-15%, p<0.001). We therefore defined MLLOW as ML <5%; MLNORMAL as ML 5-15%; and 
MLHIGH as ML>15%[7].  These 3 groups of patients showed a U-shaped mortality curve, similar 
to previous studies of hypofibrinolysis (Figure 4) in trauma[27,109] (Figure 11B).  A similar 
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pattern was identified when incidence of admission coagulopathy (Figure 12) and 
requirement for red blood cell transfusion (Figure 13) were stratified by admission ML, with 
ML < 5% again representing a lower inflection point for these outcomes.   
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Figure 11  Overall mortality stratified by admission % maximum lysis (ML) 
A: Histogram of 28-day mortality for each % maximum lysis (ML) on admission showing a lower 
inflection point at ML < 5% (dashed line).  B: Overall 28-day mortality showed a U-shaped 
distribution when patients were grouped according to admission ML value.  
MLLOW < 5%; MLNORMAL 5 – 15% and MLHIGH >15%.  ***p<0.001 vs MLNORMAL. 
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Figure 12  Incidence of coagulopathy on admission stratified by admission % ML 
A: Histogram of arrival coagulopathy (INR > 1.2) incidence for each % ML on admission showing a 
lower inflection point at ML < 5% (dashed line).  B: The incidence of coagulopathy demonstrated a 
U-shaped distribution similar to mortality. ***p<0.001 vs MLNORMAL.   
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Figure 13  Incidence of major haemorrhage stratified by admission % maximum lysis (ML) 
A: Histogram of major haemorrhage (requirement of ≥ 4 red blood cell units in first 12 hours) for 
each % ML on admission suggesting a similar lower inflection point at ML < 5% (dashed line).  B: 
Presence of major haemorrhage demonstrated a similar U-shaped distribution to mortality and 
coagulopathy. **p<0.01, ***p<0.001 vs MLNORMAL.  
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3.4.2 Characterisation of patterns associated with mortality in the MLLOW cohort 
To explore the heterogeneity of the MLLOW group, we began by examining the differences 
between MLLOW patients who lived and those who died. The survivors in this group had very 
similar admission characteristics, injury patterns and outcomes to MLNORMAL patients. The 
MLLOW survivors were statistically older, more shocked and more severely injured, but these 
differences were small (Table 9). Their outcomes in terms of VTE, massive transfusion rates, 
critical care and hospital lengths of stay were the same as for MLNORMAL patients. In contrast 
the MLLOW patients who died were much older, with critical injury (median ISS 29), lower GCS 
than any other cohort (median 7) and 85% of them had a traumatic brain injury (Table 9). 
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Table 9 Characteristics of the study cohort 
 
Number of Patients 
MLNORMAL 
576 
MLLOW 
273 
MLLOW Survived 
232 
MLLOW Died 
41 
MLHIGH 
65 
 
Admission characteristics 
     
Age, years 35 (25 – 51) 42 (31 – 58) 40 (29 – 55)^^ 59 (38 – 73)** 43 (24 – 58) 
Male, n (%) 464 (81%) 212 (78%) 186 (80%) 26 (63%)* 48 (74%) 
SBP, mmHg 133 (112 – 149) 130 (110 – 149) 130 (112 – 148) 130 (95 – 164) 121 (93 – 140) 
GCS 15 (12 – 15) 14 (8 – 15) 15 (11 – 15) 7 (3 – 13)** 14 (10 – 15) 
BD, mmol/L 1.1 (-0.7 – 3.5) 2.2 (0.4 – 4.8) 2.0 (0.3 – 4.4)^^ 3.5 (0.9 – 6.6)* 6.7 (1.4 – 15.2) 
INR > 1.2, n (%) 66 (11%) 64 (23%) 38 (16%) 26 (63%)** 28 (43%) 
EXTEM ML, % 8 (6 – 10) 3 (2 – 4) 3 (2 – 4)^^ 2 (1 – 4) 24 (18 – 100) 
D-Dimer, ng/ml 7150 (1320 – 29311) 19313 (3980 – 64988) 13672 (2887 – 47130)^^ 103170 (58618 – 182656)** 
15608 (3077 – 
55939) 
Injury to sample time, minutes 75 (50 – 98) 81 (53 – 104) 79 (52 – 103) 92 (68 – 107) 75 (55 – 99) 
 
Injury characteristics 
     
Blunt, n (%) 464 (81%) 249 (91%) 211 (91%)^^ 38 (93%) 55 (85%) 
ISS 13 (5 – 25) 20 (9 – 29) 17 (9 – 29)^^ 29 (25 – 38)** 17 (4 – 29) 
AIS Head & Neck ≥ 3, n (%) 153 (27%) 110 (40%) 75 (32%) 35 (85%)** 17 (26%) 
AIS Thorax ≥ 3, n (%) 192 (33%) 116 (42%) 94 (41%) 22 (54%) 21 (32%) 
AIS Abdo/pelvis ≥ 3, n (%) 58 (10%) 26 (10%) 25 (11%) 1 (2%) 8 (12%) 
AIS Extremity ≥ 3, n (%) 149 (26%) 76 (28%) 69 (30%) 7 (17%) 24 (37%) 
 
Fluid & Blood products 
     
Pre-baseline crystalloid, ml 0 (0 – 250) 200 (0 – 500) 150 (0 – 500)^^ 500 (0 – 1000)* 225 (0 – 1000) 
Pre-baseline PRBC, units 0 (0 – 0) 0 (0 – 0) 0 (0 – 0)^ 0 (0 – 0) 0 (0 – 0) 
12hr Crystalloid, ml 1000 (0 – 2000) 1000 (350 – 2388) 1000 (250 – 2075) 1625 (425 – 2788) 1500 (500 – 3150) 
12hr PRBC, units 0 (0 – 0) 0 (0 – 2) 0 (0 – 1)^ 0 (0 – 5)* 2 (0 – 8) 
107 
 
 
All values are median with interquartile range unless specified. Continuous data compared with Mann-Whitney U-test. Categorical data compared with Fisher’s exact 
test. ^p<0.05, ^^p<0.001, MLNORMAL vs MLLOW Survived. *p<0.05, **p<0.001, MLLOW Survived vs MLLOW + Died. SBP, systolic blood pressure. GCS, Glasgow coma score. BD, 
base deficit. INR, international normalized ratio. ML, maximum lysis. ISS, injury severity score. AIS, abbreviated injury score. PRBC, packed red blood cells. VTE, venous 
thromboembolism. 
  
 
Outcomes 
     
Massive Transfusion, n (%) 8 (1.4%) 6 (2.2%) 4 (1.7%) 2 (4.9%) 13 (20%) 
VTE, n (%) 9 (1.6%) 5 (1.8%) 5 (2.2%) 0 (0%) 1 (1.5%) 
24hr mortality, n (%) 11 (1.9%) 13 (4.8%) 0 (0%)^ 13 (31.7%)** 16 (24.6%) 
28-day mortality, n (%) 41 (7.1%) 41 (15.0%) 0 (0%)^^ 41 (100%)** 20 (30.8%) 
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MLLOW patients who died were nearly three times as likely to receive a massive transfusion 
and were four times as likely to be coagulopathic on admission (63% INR >1.2) than MLLOW 
patients who survived (Table 9).  Despite the low ML, D-dimer levels in patients who died 
were extremely high (median 103,170 ng/ml), compared to 13,672 ng/ml in survivors 
(p<0.001, Table 9, Figure 14).  These D-dimer differences were replicated when analysing 
coagulopathic vs. non-coagulopathic patients (Figure 15) and red cell transfusion 
requirements (Figure 16).  For further analysis we therefore set a D-dimer threshold at 
30,000 ng/ml (approximately the upper quartile in MLNORMAL patients, Table 9) and used this 
as a biological marker to explore the heterogeneity within the MLLOW patient cohort. 
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Figure 14  Admission D-dimer levels stratified by ML and 28-day mortality outcome 
D-dimer levels were significantly elevated in those patients who died compared to survivors, 
irrespective of ML group. ***p<0.001 comparing survived vs died within each ML group.   
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Figure 15  Admission D-dimer levels stratified by ML and presence of coagulopathy 
Patients with coagulopathy on admission had significantly higher D-dimer levels compared to 
patients without coagulopathy, irrespective of admission ML. ***p<0.001 comparing coagulopathy 
vs no coagulopathy within each ML group. 
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Figure 16  Admission D-dimer levels stratified by ML and presence of major haemorrhage 
Patients treated for major haemorrhage had significantly higher D-dimer levels irrespective of 
admission ML value. ***p<0.001 comparing major haemorrhage vs no major haemorrhage within 
each ML group. 
 
 
More than half (58%) of patients with MLLOW on admission had low D-dimer levels. Patients 
with MLLOW and DDLOW were essentially identical to patients who were MLNORMAL in terms of 
injuries, admission physiology and outcomes (Table 10).  The only significant difference 
between the two groups was that MLLOW + DDLOW patients were more likely to have received 
pre-baseline crystalloid (51% vs 37%, p=0.002).  
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Table 10 Characteristics and outcomes of patients grouped by fibrinolytic profile 
 
Number of Patients 
MLNORMAL 
576 
MLLOW + DDLOW 
157 
MLLOW + DDHIGH 
116 
MLHIGH + DDLOW 
38 
MLHIGH + DDHIGH 
27 
 
Admission characteristics 
     
Age, years 35 (25 – 51) 39 (29 – 52)^ 48 (34 – 66)* 44 (24 – 53) 41 (24 – 59) 
Male, n (%) 464 (81%) 127 (81%) 85 (73%) 29 (76%) 19 (70%) 
GCS 15 (12 – 15) 15 (13 – 15) 12 (5 – 15)** 15 (13 – 15) 11 (9 – 14) 
SBP, mmHg 133 (112 – 149) 134 (115 – 149) 126 (100 – 148)* 124 (110 – 140) 98 (87 – 128)+ 
BD, mmol/L 1.1 (-0.7 – 3.5) 1.5 (-0.3 – 3.9) 3.3 (1.3 – 6.0)** 3.0 (1.0 – 7.8) 11.4 (6.8 – 21.9)++ 
INR > 1.2, n (%) 66 (11.5%) 18 (11.5%) 46 (40%)** 11 (29%) 17 (63%)+ 
EXTEM ML, % 8 (6 – 10) 3 (2 – 4)^^ 2 (1 – 4)* 19 (16 – 36) 98 (25 – 100)++ 
D-Dimer, ng/ml 7150 (1320 – 29311) 5635 (1416 – 13504)^^ 75738 (48291 – 131466)** 5056 (906 – 11496) 84286 (46600 – 178106) 
Injury to sample time, minutes 75 (50 – 98) 72 (48 – 93) 93 (73 – 114) ** 73 (48 – 90) 92 (62 – 105) 
 
Injury characteristics 
     
Blunt, n (%) 464 (81%) 136 (87%) 113 (97%)* 30 (79%) 25 (93%) 
ISS 13 (5 – 25) 13 (5 – 23) 29 (20 – 38)** 9 (2 – 25) 29 (10 – 38) 
AIS Head & Neck ≥ 3, n (%) 153 (27%) 41 (26%) 69 (59%)** 7 (18%) 10 (37%)+ 
AIS Thorax ≥ 3, n (%) 192 (33%) 41 (26%) 75 (65%)** 6 (16%) 15 (56%) 
AIS Abdo/pelvis ≥ 3, n (%) 58 (10%) 10 (6%) 16 (14%)* 4 (11%) 4 (15%) 
AIS Extremity ≥ 3, n (%) 149 (26%) 42 (27%) 34 (29%) 13 (34%) 11 (41%) 
 
Fluid & Blood product totals 
     
Pre-baseline crystalloid, ml 0 (0 – 250) 100 (0 – 500)^ 375 (0 – 750)** 0 (0 – 500) 500 (0 – 1500) 
Pre-baseline PRBC, units 0 (0 – 0) 0 (0 – 0) 0 (0 – 0) 0 (0 – 0) 0 (0 – 0.5)+ 
12hr Crystalloid, ml 1000 (0 – 2000) 1000 (0 – 1500) 1632 (600 – 2763)** 1600 (0 – 3000) 1500 (750 – 3900) 
12hr PRBC, units 0 (0 – 0) 0 (0 – 0) 0 (0 – 4)** 0 (0 – 4) 6 (1.5 – 16)++ 
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Outcomes 
Massive Transfusion, n (%) 8 (1.4%) 1 (0.6%) 5 (4.3%) 5 (13.2%) 8 (29.6%)++ 
VTE, n (%) 9 (1.6%) 0 (0%) 5 (4.3%)* 1 (2.6%) 0 (0%) 
Critical Care LOS (survivors) 0 (0 – 3) 0 (0 – 2) 7 (2 – 14)** 5 (1 – 19) 12 (1 – 21) 
Hospital LOS (survivors) 7 (2 – 16) 7 (2 – 17) 23 (13 – 40)** 5 (1 – 19) 26 (12 – 38) 
24hr mortality, n (%) 11 (1.9%) 4 (2.5%) 9 (7.8%) 2 (5.3%) 14 (51.9%)++ 
28-day mortality, n (%) 41 (7.1%) 6 (3.8%) 35 (30.2%)** 4 (10.5%) 16 (59.3%)+ 
Time to death, days 2 (1 – 7) 1 (0 – 6) 2 (1 – 7) 2 (0 – 7) 0 (0 – 1)++ 
 
All values are median with interquartile range unless specified. Continuous data compared with Mann-Whitney U-test. Categorical data compared with Fisher’s exact 
test. ^p<0.05, ^^p<0.001, MLNORMAL vs MLLOW + DDLOW. *p<0.05, **p<0.001, MLLOW + DDHIGH vs MLLOW + DDLOW. +p<0.05, ++p<0.001, MLHIGH + DDHIGH vs MLLOW + DDHIGH. GCS, 
Glasgow coma score. SBP, systolic blood pressure. BD, base deficit. INR, international normalized ratio. ML, maximum lysis. ISS, injury severity score. AIS, abbreviated 
injury score. PRBC, packed red blood cells. VTE, venous thromboembolism. LOS, length of stay in days. 
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3.4.3 Characteristics of patients presenting with low ML but high D-dimer levels 
Mortality was 30% in the MLLOW+DDHIGH cohort compared to only 3% in the MLLOW+DDLOW 
group (p<0.001, Table 10). Deaths occurred later in the MLLOW+DDHIGH cohort compared to 
MLHIGH+DDHIGH patients, who tended to die on the day of admission (Figure 17, Table 10).   
MLLOW+DDHIGH patients were more severely injured overall (median ISS 29) and were more 
than twice as likely to have a severe head or torso injury as the MLLOW+DDLOW cohort. 
MLLOW+DDHIGH patients were also more shocked and coagulopathic (by INR) on admission and 
had greater fluid and blood product requirements in the first 12 hours than those with 
MLLOW+DDLOW. Overall MLLOW+DDHIGH patients appeared to be severely injured and bleeding 
and were more like the MLHIGH+DDHIGH group. The MLHIGH+DDHIGH patients had a greater 
severity of shock and much higher transfusion requirements, but were less likely to have 
sustained a severe traumatic brain injury (Table 10). 
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Figure 17  Kaplan-Meier curves for survival in patients grouped by fibrinolytic profile 
Overall: Log-rank (Mantel-Cox) test for all groups, p<0.0001.   
Comparing individual groups: MLLOW + DDLOW vs MLNORMAL, p=0.15; **MLLOW + DDHIGH vs MLLOW + 
DDLOW, p<0.0001; ^^MLHIGH + DDHIGH vs MLLOW + DDHIGH, p = 0.0003. 
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3.4.4 Influence of time from injury on fibrinolytic profile 
The time from injury to baseline blood sampling was longer in those patients presenting with 
DDHIGH (Table 10).  The association between time from injury and fibrinolytic profile was 
analysed by breaking down time from injury into quartiles.  There was no association 
between time to baseline sampling after injury and functional fibrinolysis measured by ML 
(Figure 18).  However, patients sampled 76 minutes or longer after injury (quartiles 3 and 4) 
were found to have significantly higher levels of D-dimer compared to those sampled within 
the shortest quartile (<53 minutes; Figure 19). 
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Figure 18  Association between time from injury to baseline sampling and maximum lysis 
Whiskers represent minimum and maximum.   
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Figure 19  Association between time from injury to baseline sampling and D-dimer level 
***p<0.001 vs <53 mins  
 
 
Along with having the highest D-dimer levels, those patients sampled beyond 76 minutes 
from injury (quartiles 3 and 4), correspondingly were the most severely injured patients with 
significantly greater injury severity scores (Figure 20).  Those patients in the 4th quartile with 
the longest duration of time from injury to baseline sampling had a greater degree of shock 
(Figure 21).  
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Figure 20  Association between time from injury to baseline sampling and injury severity 
***p<0.001 vs <53 mins 
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Figure 21  Association between time from injury to baseline sampling and degree of shock 
**p<0.01 vs <53 mins 
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3.4.5 Coagulation profiles of patients with low ML but high D-dimer levels 
We examined the fibrinolytic mechanisms in these patient cohorts (Figure 22 - Figure 27). 
Across all low D-dimer cohorts, prothrombin fragments (PF1+2), fibrinogen, PAP, tissue 
plasminogen activator (tPA), plasminogen activator inhibitor (PAI-1) and α2-antiplasmin 
(α2AP) levels were similar.  
 
Patients with MLLOW+DDHIGH had the highest levels of prothrombin fragments of all cohorts, 
associated with a reduction in fibrinogen levels (Figure 22 & Figure 23). As expected they also 
had high PAP levels indicative of increased fibrinolytic activity (Figure 24).  Surprisingly tPA 
levels in patients with MLLOW+DDHIGH were low and comparable to the MLNORMAL and 
MLLOW+DDLOW cohorts (Figure 25). Plasma levels of PAI-1 were the same across all groups 
(Figure 26).  Antiplasmin levels were low in the MLLOW+DDHIGH group (72 vs MLNORMAL 102 u/dL, 
p<0.001) and even lower in MLHIGH+DDHIGH patients (median 42.0 u/dL, p<0.001 vs. MLNORMAL; 
Figure 27). 
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Figure 22  Prothrombin fragment levels in patients grouped by fibrinolytic profile 
Prothrombin fragment (PF 1+2) levels across all maximum lysis (ML) and D-dimer (DD) groups with 
the highest levels seen in the MLLOW + DDHIGH patients.  **p<0.001, MLLOW + DDLOW vs MLLOW + DDHIGH 
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Figure 23  Fibrinogen levels in patients grouped by fibrinolytic profile 
** p<0.001, MLLOW + DDLOW vs MLLOW + DDHIGH; + p<0.05, MLLOW + DDHIGH vs MLHIGH + DDHIGH 
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Figure 24  Plasmin-α2-antiplasmin complex in patients grouped by fibrinolytic profile 
Plasmin-α2-antiplasmin complex (PAP) across all ML and DD groups indicating high levels of 
fibrinolytic activity in patients with DDHIGH irrespective of ML.  ^p<0.05, MLLOW + DDLOW vs MLNORMAL; 
**p<0.001, MLLOW + DDLOW vs MLLOW + DDHIGH; +p<0.05, MLLOW + DDHIGH vs MLHIGH + DDHIGH 
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Figure 25  Tissue plasminogen activator (tPA) levels in patients grouped by fibrinolytic profile 
Despite an overall hyperfibrinolytic biomarker profile, patients with MLLOW + DDHIGH did not exhibit 
the rise in tPA seen in those patients with MLHIGH + DDHIGH.  ^p<0.05, MLLOW + DDLOW vs MLNORMAL; 
*p<0.05, MLLOW + DDLOW vs MLLOW + DDHIGH; ++p<0.001, MLLOW + DDHIGH vs MLHIGH + DDHIGH 
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Figure 26  Plasminogen activator inhibitor (PAI-1) levels in patients grouped by fibrinolytic profile 
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Figure 27  α-2-antiplasmin levels in patients grouped by fibrinolytic profile 
Bars represent mean ± 95% CI.  **p<0.001, MLLOW + DDLOW vs MLLOW + DDHIGH; ++p<0.001, MLLOW + 
DDHIGH vs MLHIGH + DDHIGH 
 
 
3.4.6 Mechanism of occult hyperfibrinolysis in trauma patients 
As MLLOW+DDHIGH patients had high thrombin generation and high fibrinolytic activity but no 
elevations in the expected plasminogen activators nor increased levels of 
plasminogen/plasmin inhibitors, we, therefore, proceeded to measure levels of uPA and 
S100A10, a principally membrane-bound plasminogen receptor and fibrinolysis mediator, in 
a subgroup of 179 patients.   
 
These analyses were performed by Paul Vulliamy.  The results are detailed in Appendix 1 and 
discussed below. 
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3.5 DISCUSSION 
In this multicentre study of over 900 patients, we have shown that low levels of VHA detected 
fibrinolysis are physiological in over half of all cases and have very good outcomes, 
comparable to patients with normal fibrinolysis. Conversely, some patients with low VHA-
fibrinolysis are severely injured, functionally coagulopathic, have high transfusion 
requirements and high mortality. These patients have a hyperfibrinolytic biomarker profile 
with high levels of thrombin, plasmin and D-dimer generation but have relatively low levels 
of tPA. We have identified S100A10 as a possible explanation for localised activation of 
plasmin on the endothelial cell surface in these patients which when shed into the plasma 
artificially lowers the observed VHA ML% parameter ex-vivo. Together these results support 
the existence of an occult hyperfibrinolysis in severely injured patients, not detectable by 
existing diagnostic tools and which is associated with very poor outcomes.  
 
S100A10 is a membrane-bound plasminogen receptor which complexes with annexin A2 in 
a hetero-tetramer formation to bind tPA and plasminogen on the cell surface in close 
proximity to the uPA receptor (uPAR).[55,162,163] S100A10 is widely expressed in body 
tissues and particularly in the brain[164] and the complex is upregulated at times of hypoxic 
stress.[165]   S100A10 levels are detectable in the blood but the majority of cellular plasmin 
is formed on the endothelium with S100A10 catalysing the t-PA mediated activation of 
plasminogen.[166]  The classical presentation of Acute Promyelocytic Leukaemia (APL) is a 
haemorrhagic and fibrinolytic phenotype characterised by normal levels of tPA but high 
surface expression of S100A10 on APL cells.[167]  Our findings suggest that S100A10 is 
exposed by tissue injury leading to plasmin generation and hyperfibrinolysis without the 
need for high levels of circulating tPA.[168] These findings suggest a direct explanation for 
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the catastrophic coagulopathy often seen with severe traumatic brain injury, the mechanism 
of which has remained elusive and the severity of which is not apparent on diagnostic tests. 
 
Plasmin has a very short half-life and S100A10 is known to increase plasmin 
autoproteolysis.[169]  Ex-vivo detection of fibrinolysis by VHA devices relies on the presence 
of plasmin to lyse clot forming in the measuring cup.  We have shown that the addition of 
S100A10 to blood reduces VHA-detected lysis.  In patients with low tPA levels there is no 
other available activator of plasminogen and no fibrinolysis will be detected.  When tPA 
levels are high, the effect of S100A10 will be overcome and fibrinolysis will be revealed.  
These findings are entirely consistent with all observed studies of hyperfibrinolysis in trauma 
patients.   
 
There has been controversy in the literature as to whether ATC patients with MLLOW+DDHIGH 
have ongoing hyperfibrinolysis or have had their fibrinolysis shutdown at some time 
immediately before blood sampling.  These patients are severely injured and have large on-
going blood product requirements.  They have a high incidence of coagulopathy with an 
underlying biochemistry of high PAP and D-dimer levels.  Taken together these features 
suggest active hyperfibrinolysis.  It is difficult to support a fibrinolysis shutdown model which 
would require explanation of how tPA levels could have suddenly become low given that the 
active pathological processes of injury, shock and bleeding have not yet been controlled and 
PAI-1 levels are not elevated.  Localised hyperfibrinolysis via a cell bound activator of 
plasminogen is a more plausible mechanism and matches the observed on-going bleeding 
and transfusion requirements in these patients.  This occult hyperfibrinolysis in ATC does not 
preclude the likely existence of a later fibrinolytic shutdown in trauma patients due to 
upregulation of PAI-1 and other control mechanisms. 
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Tranexamic acid’s effective reduction of mortality in trauma patients appears to extend 
beyond reducing blood loss and death from bleeding to affect all-cause mortality.[116,117]  
Our results suggest that severe tissue injury can induce hyperfibrinolysis through S100A10 
and tranexamic acid may therefore reduce local as well as systemic haemorrhage.  In 
traumatic brain injury this might have a profound effect on outcome and we found S100A10 
levels correlated closely with coagulopathy, blood use and mortality in severe TBI patients.  
S100A10 may provide the mechanistic rationale for the use of tranexamic acid in TBI and the 
results of on-going clinical trials are anticipated soon.[126,170]  Overall, our results confirm 
an occult hyperfibrinolysis which is prevalent in trauma patients and supports the empiric 
use of tranexamic acid until new diagnostics are available.  Restricting treatment only to 
patients with VHA detected lysis may exclude 80% of trauma patients with high D-dimer 
levels who may benefit from tranexamic acid.  
 
Interestingly, patients with longer durations from injury to baseline sampling, were more 
severely injured, with a greater degree of shock and associated higher D-dimer levels.  Time 
from injury to baseline sampling was not associated with differences in VHA fibrinolysis.  
Blunt trauma predominated in the two D-dimer high groups and one potential explanation 
for this association is that the most severely injured patients had longer on-scene times with 
potential need for extrication, immediate life-saving interventions by the attending HEMS 
team and longer transit times to RLH.  The influence of time on groupings based upon 
fibrinolytic profile, creates a potential bias in that those sampled quickly after trauma may 
have a low D-dimer level which had the time interval to sampling been longer could have 
resulted in a higher D-dimer result and placed the patient within a different phenotype. 
Further research into the temporal changes in fibrinolysis are required to better understand 
the influence time has on the fibrinolytic phenotypes described within this body of work. 
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The inclusion criteria for this study prevent us from determining the absolute incidence of 
each of these subtypes of TIC.  As patients with minor injuries and without shock were 
excluded, overall rates of hyperfibrinolysis are likely to be overestimates compared to a 
general trauma population.  As the MLLOW+DDHIGH S100A10-driven subtype is essentially 
exclusive to blunt trauma, its incidence will also vary depending on rates of blunt trauma 
seen in specific institutions. Our exclusion of patients who had already received tranexamic 
acid is also likely to have led to an underestimate of the numbers in the MLHIGH subtypes.  A 
survivor bias can also not be excluded from this observational study.  Those critically ill 
patients who die early from haemorrhage will then not be alive to go on to develop 
thrombotic complications for example and consequently rates reported within the different 
fibrinolytic phenotypes could be an underestimate.   
 
There are several aspects of this work that require further experimental research.  This 
clinical study cannot definitively state that the MLLOW+DDHIGH patients still have active 
fibrinolysis after the point of sampling.  Our finding of high circulating levels of the primarily 
tissue-bound fibrinolytic activator S100A10 is circumstantial, but coupled with grossly 
elevated PAP & D-dimer and no obvious inhibitors is highly suggestive of active lysis, as are 
subsequent high blood product requirements.  However, it will require both experimental 
evidence of active lysis and clinical trial evidence of the effect of TXA in this subgroup to 
confirm this.  The mechanisms of exposure and release of S100A10 also need exploring, 
especially in the context of traumatic brain injury.  Again, both clinical and experimental 
studies will be required to understand the role of S100A10 in trauma induced coagulopathy.  
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3.6 CONCLUSION 
We have shown that VHA-detected lysis (ML) is a poor indicator of both the fibrinolytic state 
and clinical outcomes of patients.  Absolute D-dimer levels were more strongly associated 
with outcomes.  Patients with low D-dimer levels had good outcomes regardless of ML.  In 
contrast, a specific phenotype of patients exists with elevated D-dimers but low ML who have 
poor outcomes.  These patients are critically injured and have a high incidence of severe 
traumatic brain injury.  We have identified the tissue-bound S100A10 fibrinolytic mediator 
as a candidate mechanism for hyperfibrinolysis in these patients that also results in an 
artificially low ML.  S100A10 exposure after critical injury represents a new precision marker 
and therapeutic opportunity in trauma-induced coagulopathy. 
 
3.7  SPECIFIC CONTRIBUTIONS OF THE AUTHOR 
Following the publication of the concept of “Fibrinolysis Shutdown” by the Denver research 
group, the Author along with supervisors Karim Brohi (KB) and Ross Davenport (RD) 
conceived the idea of replicating the study using ROTEM data.  The Author designed the 
study in conjunction with KB and RD.  Data collection, primary analysis and initial 
interpretation of results was performed by the Author.  Further review of results and data 
interpretation was performed in conjunction with KB and RD.  This written account of our 
research findings was written by and then re-drafted by the Author following review and 
comment by RD and KB.  The Author was responsible for the creation of all tables and figures 
within this chapter. 
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Chapter 4 
 
 
THE EFFECTS OF EARLY EMPIRIC TRANEXAMIC ACID ON TRAUMA-
INDUCED COAGULOPATHY DURING TRAUMA HAEMORRHAGE 
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4.1 CHAPTER ABSTRACT 
BACKGROUND:  Tranexamic acid (TXA) is widely used empirically in trauma haemorrhage.  
However, the effect of early empiric TXA on the coagulation system during haemorrhage has 
not been described. Theoretically both antifibrinolytic and antifibrinogenolytic, it is unknown 
where it exerts most of its effect and whether the standard dose is adequate for trauma 
patients. We aimed to investigate the biochemical and functional coagulation responses of 
early empiric TXA on the fibrinolytic system in patients during major trauma haemorrhage. 
 
METHODS:  Adult trauma patients for whom the major haemorrhage protocol was activated 
were prospectively recruited. Blood was drawn on admission to the emergency department 
and during resuscitation (after transfusion of 4, 8, and 12 red blood cell [PRBC] units) for 
thromboelastometry. Patients who received TXA before admission blood draw (TXA group) 
were compared with patients who did not (No TXA group).  
 
RESULTS:  222 patients were included (113 No TXA group, 109 TXA group) for functional 
coagulation analysis and of these 162 patients (102 No TXA, 60 TXA) had biomarker analysis.  
No patients receiving early empiric TXA (1g) exhibited functional hyperfibrinolysis on 
admission (No TXA vs TXA 20% vs 0%, p<0·0001) or during haemorrhage, despite an equally 
high degree of initial fibrinolytic system activation (plasmin-α2-antiplasmin complex: 10595 
vs 8798µg/L, p=0.41).  Reduced fibrinolysis following massive haemorrhage was evidenced 
by lower D-dimer levels in the TXA group (after 12 PRBC: 30.4 vs 12.1µg/ml, p=0.005).  
Following massive blood transfusion, clot strength was maintained in the TXA group 
compared with the no TXA group (maximum clot firmness after 12 RBC: 44 vs 53mm, 
p=0·008).  TXA was associated with a degree of protection from trauma-induced 
coagulopathy (TIC) during ongoing haemorrhage (TIC after 12 RBC: 100% vs 67%, p=0·21). 
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CONCLUSIONS:  Early empiric TXA avoids functional hyperfibrinolysis during trauma 
haemorrhage and protects against the development of TIC after massive transfusion. 
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4.2 INTRODUCTION 
Tranexamic acid (TXA) is an antifibrinolytic agent which appears to improve outcomes in 
patients with traumatic haemorrhage.  Bleeding kills patients within hours following injury 
and contributes to 40% of all trauma related deaths.[3]   Evidence from the civilian and 
military literature suggests that TXA can improve survival and reduce organ failure in trauma 
patients with suspected active haemorrhage.[116–118]  While the empirical administration 
of TXA has been adopted into guidelines[102,106] and incorporated into institutional 
practices, its uptake worldwide remains variable[171–173], in part because its effects on the 
coagulation system during haemorrhage have not been described.   
 
Trauma-induced coagulopathy (TIC) exacerbates haemorrhage and is associated with greater 
transfusion requirements, higher levels of organ dysfunction and a four-fold increase in 
mortality.[5,6,159]  Fibrinolytic activation is almost universal after severe injury, with 
hyperfibrinolysis now recognized as a key component of TIC.[6,7]  Administration of an 
antifibrinolytic to directly inhibit fibrinolysis is therefore based on a sound biological principle 
with the potential to improve clotting and reduce bleeding.  The effect of TXA on the key 
stages and components of coagulation e.g. initiation, clot formation, fibrinogen and 
fibrinolysis has not been described during active bleeding in trauma.  It is unknown whether 
if dosed empirically (1g) as described in the CRASH-2 trial, TXA fully reverses post-injury 
fibrinolysis and how long this effect persists for in the bleeding patient.[116]  Understanding 
the effect of TXA on coagulation during trauma haemorrhage may provide insights into its 
mechanisms of action and clarify its role in the management of bleeding trauma patients. 
 
The overall objective of this study was to investigate the effect of early TXA on the 
coagulation system in patients with suspected traumatic haemorrhage.  Our first aim was to 
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describe the effect of early TXA on the incidence of hyperfibrinolysis and coagulopathy upon 
arrival in the emergency department (ED) and during trauma haemorrhage.  The second aim 
was to characterize the effect of early TXA on functional coagulation tests.  Third, we aimed 
to investigate the effect of early TXA on plasma markers of fibrinolysis and coagulation.  
Finally, we wished to describe the effect of early TXA on thrombosis risk and overall mortality 
in this cohort.  We analysed data from a prospective cohort study of patients with suspected 
traumatic haemorrhage, presenting to an urban major trauma centre. 
 
4.3 METHODS 
All adult patients (≥16 years) who meet the local criteria for trauma team activation were 
consecutively screened (between 8:00am – 8:00pm daily) for inclusion in the Activation of 
Coagulation and Inflammation in Trauma study (ACIT II; UK CRN ID 5637).  Deferred informed 
written consent was obtained from the patient or their next-of-kin.  The study was approved 
by East London and The City Research Ethics Committee (07/Q0603/29).  Patients were 
excluded if they arrived >2 hours post injury; were transferred from another hospital; 
received >2000ml crystalloid pre-hospital; or had sustained burns >5% of their body surface 
area.  Patients were retrospectively excluded if they declined to give consent to the use of 
their research samples, had severe liver disease, a known pre-existing bleeding diathesis, or 
were taking anticoagulant medication (excluding aspirin) pre-injury. 
   
The empiric administration of TXA at our institution is restricted to patients who activate our 
Major Hemorrhage Protocol (MHP).  The MHP is activated either pre-hospital by the 
physician-led London Air Ambulance (LAA) or in-hospital by the trauma team leader, when a 
patient with suspected traumatic haemorrhage, has a systolic blood pressure below 90 
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mmHg and a poor response to initial fluid resuscitation.  The MHP was implemented in 
September 2008 and updated to formally include TXA in February 2011 (Appendix 2).  Prior 
to February 2011, TXA was administered at the discretion of the trauma team leader within 
the hospital setting when haemorrhage was suspected or diagnosed.  Following its formal 
inclusion within the protocol, TXA is delivered to trauma patients activating the MHP either 
as part of pre-hospital care or in the ED within three hours of injury, as a 1g bolus infused 
over 10 minutes.  In hospital, this is followed by a further 1 g of TXA infused over eight hours.  
All patients in the TXA group received the 1 g bolus dose of TXA only, prior to baseline blood 
sampling on ED arrival.  Pre-hospital blood transfusions are delivered by LAA as part of the 
resuscitation of bleeding trauma patients and were initiated in our trauma system in January 
2014.  For this study we analysed consecutive ACIT II patients who activated the MHP from 
January 2009 up to June 2015.   
   
4.3.1 Data Collection 
Data were collected prospectively and included patient demographics, time of injury, 
mechanism of injury (blunt or penetrating), Injury Severity Score (ISS), vital signs on-scene 
and on arrival in ED, total number of blood products and volume of intravenous fluids 
administered within the first 12 hours from injury.  The administration of TXA and its timing 
relative to baseline blood sampling was documented. 
 
Patients were observed for 28 days from injury for the occurrence of venous 
thromboembolic events (deep vein thrombosis (DVT) or pulmonary embolism (PE)), other 
thrombotic events (including myocardial infarction (MI) and ischemic stroke) and overall 
mortality.  We defined these outcomes as a clinical diagnosis supported by a confirmatory 
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test result: duplex ultrasound for DVT; CT pulmonary angiogram for PE; electrocardiogram 
changes and elevated troponin for MI; and CT head for ischemic stroke. 
      
4.3.2 Blood Sampling 
The baseline research blood sample was drawn within 20 minutes of the patient’s arrival in 
the ED along with standard trauma laboratory tests.  A full blood count and conventional 
coagulation screen was performed as part of the standard trauma laboratory tests for 
determination of haemoglobin, platelet count and prothrombin time (PT) respectively.  A 
point-of-care arterial blood gas analysis was performed simultaneously for base deficit (BD) 
and lactate concentration.  Subsequent blood samples were obtained during the active 
haemorrhage phase: following the transfusion of 4 units of packed red blood cells (4PRBC), 
8 units (8PRBC) and 12 units (12PRBC) from baseline sampling; and at 24 hours. 
 
Blood for rotational thromboelastometry (ROTEM®) analysis, was collected in a 2.7ml 
citrated vacutainer (0.109 Molar / 3.2% sodium citrate; Becton, Dickinson and Company, 
Plymouth, UK).  Blood for coagulation and fibrinolysis protein assays was collected in a 4.5ml 
glass citrated vacutainer (0.109 Molar / 3.2% sodium citrate; Becton, Dickinson and 
Company, Plymouth, UK).  The filled 4.5ml vacutainer was centrifuged for 10 minutes at 
1,750 G within 1 hour of collection. Plasma was removed and then centrifuged for a further 
10 minutes at 1,750 G. The double-spun plasma was subsequently stored at -80°C.     
 
4.3.3 Functional Coagulation Analysis 
Functional coagulation analysis was performed within one hour of blood draw at 37°C on a 
ROTEM® delta instrument (Tem International GmbH, Munich, Germany) using the 
136 
 
automated electronic pipette according to the manufacturer’s instructions.  The 
methodology and parameters of ROTEM® have been described previously.[161]  Two 
separate assays were performed on each blood sample: EXTEM, measuring tissue-factor 
initiated clotting and FIBTEM, for qualitative assessment of fibrinogen levels via the addition 
of the platelet inhibitor, cytochalasin D.  Samples were run for 60 minutes and treating 
clinicians were blinded to the results.  We defined coagulopathy as an EXTEM clot amplitude 
at 5 minutes (CA5) of ≤ 35mm.  This cut-off has been shown to identify ATC and predicts 
transfusion requirements.[100]  Hyperfibrinolysis was defined as an EXTEM maximum lysis 
(ML) of > 15% after a 60 minute assay time.[7] 
 
4.3.4 Coagulation and Fibrinolysis Plasma Protein Assays 
As part of the on-going ACIT II study, the first 1099 patients recruited (up to 15 April 2014) 
had coagulation and fibrinolysis protein assays performed.  102 patients from the No TXA 
group and 60 patients from the TXA group were contained within this cohort.  Plasma stored 
at -80°C was thawed to 37°C immediately before all analyses.  Prothrombin fragment 1+2 (PT 
Frag 1+2; Enzygnost® F 1+2 (monoclonal); Siemens Healthcare Diagnostics Products GmbH, 
Marburg, Germany), tissue plasminogen activator (tPA; Asserachrom® tPA, Diagnostica 
Stago, Asnières sur Seine, France), plasminogen activator inhibitor-1 (PAI-1; Asserchrom® 
PAI-1; Diagnostica Stago), and plasmin-α2-antiplasmin complex (PAP; PAP micro ELISA; DRG 
Instruments GmbH, Marburg, Germany) were measured using sandwich enzyme-linked 
immunosorbent assays (ELISAs).  Coagulation factors II (Siemens Innovin and Siemens Factor 
II deficient plasma, Sysmex UK, Milton Keynes, UK) and XIII (Siemens Berichrom Factor XIII, 
Sysmex UK), fibrinogen levels (Siemens Thrombin reagent, Sysmex UK) and α2-antiplasmin 
(Siemens Berichrom α2-antiplasmin; Sysmex UK) were determined in the hospital 
laboratories with a Sysmex CS2100i automated analyzer (Sysmex UK) according to standard 
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protocols.  Latex immunoassays were used to quantify the levels of D-dimer (Siemens 
Innovance D-dimer; Sysmex UK) and soluble fibrin monomer complexes (sFMC; Stago Liatest 
Fibrin Monomer, Diagnostica Stago) also with the Sysmex CS2100i automated analyser. 
 
4.3.5 Statistical Analysis 
Statistical analysis was performed using GraphPad Prism version 5 (GraphPad Software Inc., 
San Diego, USA) and Microsoft Excel 2013 (Microsoft Inc., Redmond, USA).  Normal quantile 
plots were used to assess normality.  Data without a normal distribution were expressed as 
median (interquartile range) and analysed using Mann-Whitney U-test.  Normally distributed 
data are expressed as mean ± 95% confidence intervals and analysed with Student’s t test.  
Percentages were analysed using Chi-squared or Fisher’s exact tests, with linear trends over 
time analysed with Chi-squared test for trend.  A p value of <0.05 was considered statistically 
significant.  Where multiple time points were analysed (i.e. at baseline, 4PRBC, 8PRBC and 
12PRBC), the two groups at each time point were compared individually and an adjusted p 
value of <0.0125 considered statistically significant to take account of multiple repeated tests 
performed.  Box and whisker plots show median, interquartile range, maximum and 
minimum values unless otherwise stated. 
 
4.4 RESULTS 
A total of 284 patients activated the MHP and were recruited to ACIT II during the study 
period (Figure 28).  Patients were excluded for the following reasons: 21 did not have a 
baseline ROTEM® performed; 14 in whom the timing of TXA administration was not 
documented; three were recruited into the CRASH-3 trial[126] and 24 either refused consent 
or were retrospectively excluded as they did not fulfil ACIT II inclusion criteria.  The exclusion 
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of patients without a baseline ROTEM was necessary since the premise of this study was to 
use ROTEM to evaluate the effects of early TXA on TIC.  The CRASH-3 trial randomised 
patients with traumatic brain injury to receive either TXA or placebo in a blinded manner.  
Patients co-recruited into this trial were excluded as it would not have been known whether 
they had received TXA or not.   
 
A total of 222 patients were available for study analysis - 113 did not receive TXA pre-baseline 
sampling (No TXA group) vs 109 patients who did receive TXA pre-baseline sampling (TXA 
group).  In the No TXA group, 23 patients received TXA post-baseline sampling but within 
three hours of injury.  These patients were included in the No TXA group for the baseline 
analysis but were excluded from all subsequent PRBC, 24-hour and outcome analyses. 
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Figure 28 Flow diagram of study groups and number of patients analysed at each time point 
MHP, major haemorrhage protocol; RCT, randomised control trial; PRBC, packed red blood cells 
   
 
4.4.1 Patient characteristics 
Baseline demographics and clinical characteristics of the patients are shown in Table 11.  The 
median time from injury to ED arrival in the No TXA group vs TXA group was 90 (70 – 107) vs 
85 (70 – 104) minutes, p=0.19.  We observed a clear temporal difference in TXA 
administration during the study period.  No patients received TXA in 2009 or 2010 compared 
with an annual average of 75% of patients who received TXA (pre-baseline blood sampling) 
each subsequent year from 2011 – 2015.  All patients in the TXA group received a 1g bolus 
of TXA pre-baseline (86% administered pre-hospital, 14% in ED).  Data on the administration 
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of the second 1g infusion dose of TXA was only available in 74 cases, with 37 (50%) of these 
patients found to have received the second 1g infusion of TXA.  Patients treated with TXA 
had a greater degree of shock, with a lower on-scene systolic blood pressure and higher 
lactate on ED arrival (Table 11).  Glasgow Coma Score (GCS) was lower in the TXA cohort but 
with no significant difference in Head Abbreviated Injury Scale (AIS) scores between the two 
groups (median 0).   Sex, age, injury severity and vital signs were similar between the two 
groups of patients who had further plasma assay studies.  As in the overall cohort, the TXA 
patients received a greater number of PRBC pre-baseline (median pre-baseline PRBC: No TXA 
vs TXA 0 vs 1 unit, p<0.001).   
 
Blood product and intravenous fluid administration during the first 12 hours post injury are 
detailed in Table 12.  The median time interval from baseline to 4, 8 and 12PRBC sampling 
was 51, 89 and 87 minutes respectively, with no significant difference observed between 
groups.  More patients in the TXA group received a transfusion of at least one unit of PRBC 
pre-baseline (No TXA vs TXA: 26% vs 66%, p<0.0001) (Table 12).  No patients received 
colloids, fresh frozen plasma (FFP), platelets or cryoprecipitate pre-baseline.  During 
resuscitation, blood product and fluid administration was similar between the two groups up 
to the 8 PRBC time point.  Between 8 and 12 units of PRBC, median FFP use was the same, 
however, the TXA group received a higher ratio of FFP with more platelets and 
cryoprecipitate (Table 12).  Massive transfusion rates (≥10 PRBC in 12 hours) were similar 
between the two groups (No TXA vs TXA: 21% vs 22%, p=0.89).  There was no statistical 
difference in the total number of individual blood components transfused to either group at 
12 hours following injury (Table 12).        
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Table 11 Patient characteristics and outcomes 
 No TXA TXA p* 
Patient and Injury Characteristics 
Number of patients 
 
113 
 
109 
 
Age, years 38 (24 – 53) 33 (24 – 53) 0.27 
Male 90 (80) 73 (67) 0.03 
Blunt injury 84 (74) 80 (73) 0.87 
ISS 29 (18 – 37) 29 (20 – 43) 0.21 
ISS > 15 97 (86) 92 (84) 0.76 
 
On Scene Parameters 
   
Scene HR, bpm 113 (94 – 132) 120 (101 – 140) 0.16 
Scene SBP, mmHg 110 (90 – 130) 97 (76 – 115) 0.01 
Scene GCS 14 (8 – 15) 11 (4 – 14) 0.02 
 
ED Admission Parameters 
   
ED HR, bpm 120 (96 – 138) 120 (102 – 135) 0.88 
ED SBP, mmHg 102 (85 – 127) 102 (76 – 124) 0.50 
ED GCS 13 (8 – 14) 10 (4 – 14) 0.03 
Base deficit, mmol/L 6.4 (3.5 – 11.1) 8.3 (4.8 – 16.2) 0.06 
Lactate, mmol/L 3.4 (2.2 – 7.4) 5 (3.0 – 8.4) 0.03 
Hemoglobin, g/dL 12.6 (11.0 – 14.0) 13.3 (11.8 – 14.6) 0.02 
Platelets, x109/L 211 (158 – 253) 207 (166 – 252) 0.89 
Functional coagulation at 24 hours 
Number of patients 
 
55 
 
85 
 
Extem CT at 24hrs, s 61 (53 – 75) 65 (51 - 80) 0.35 
Extem CA5 at 24hrs, mm 40 (33 – 46) 40 (35 – 47) 0.32 
Extem MCF at 24hrs, mm 59 (53 – 63) 62 (58 – 67) 0.01 
Extem ML at 24hrs, % 8 (5 – 10) 4 (1 – 6) <0.0001 
Outcomes 
Number of patients 
 
90 
 
109 
 
Venous thromboembolic events 0 5 (5) 0.07# 
Other thrombotic events 0 5 (5) 0.07# 
24hr Mortality 21 (23) 8 (7) 0.002 
28 Day Mortality 31 (34) 30 (28) 0.29 
 
Values are median (IQR) or number (%).  *χ2 test for categorical variables unless otherwise indicated 
and Mann Whitney U test for continuous variables; # Fisher’s exact test.  ISS, Injury Severity Score; 
HR, heart rate; SBP, systolic blood pressure; GCS, Glasgow Coma Score; ED, Emergency Department; 
CT, clotting time; CA5, clot amplitude at 5 minutes; MCF, maximum clot firmness; ML, maximum 
lysis. 
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Table 12 Blood products and fluids administered during bleeding and for those patients surviving to 12 hours 
 Pre-baseline Baseline – 4PRBC 4PRBC – 8PRBC 8PRBC – 12PRBC Total from Injury – Hour 12 
 
No. of patients 
No TXA 
113 
TXA 
109 
p 
 
No TXA 
43 
TXA 
40 
p 
 
No TXA 
9 
TXA 
18 
p 
 
No TXA 
9 
TXA 
9 
p 
 
No TXA 
74 
TXA 
102 
p 
 
PRBC:FFP:Platelet 
Ratio  
0 : 0 : 0 1 : 0 : 0  1 : 0.75 : 0 1 : 0.75 : 0  1 : 0.75 : 0 1 : 1 : 0.75  1 : 1 : 0 1 : 1 : 1.5  1 : 0.8 : 0.6 1 : 0.7 : 1  
PRBC 0 (0 – 1) 1 (0 – 3) <0.0001 - - - - - - - - - 5 (3 – 8) 6 (4 – 9) 0.14 
FFP  0 (0 – 0) 0 (0 – 0) 0.39 3 (0 – 4) 3 (0 – 4) 0.97 3 (1 – 4) 4 (3 – 4) 0.46 4 (0.5 – 4) 4 (4 – 5) 0.04 4 (2 – 6) 4 (3.75 – 8) 0.06 
PLTS - - - 0 (0 – 0) 0 (0 – 0) 0.85 0 (0 – 1) 0.5 (0 – 1) 0.73 0 (0 – 0.5) 1 (1 – 1) 0.006 0.5 (0 – 1) 1 (0 – 1) 0.16 
CRYO - - - 0 (0 – 0) 0 (0 – 0) 0.40 1 (0 – 2) 0 (0 – 1) 0.13 1 (0 – 2) 2 (2 – 3.5) 0.03 0 (0 – 2) 2 (0 – 2) 0.06 
Colloid, ml - - - 0 (0 – 0) 0 (0 – 0) 0.59 0 (0 – 0) 0 (0 – 125) 0.10 333 (0 – 750) 0 (0 – 0) 0.09 1000 (0 – 1500) 0 (0 – 500) <0.0001 
Crystalloid, ml 500 (0 – 1000) 250 (0 – 675) 0.01 0 (0 – 1000) 0 (0 – 438) 0.21 500 (0 – 1250) 0 (0 – 625) 0.34 500 (0 – 1667) 0 (0 – 400) 0.19 
2889 (1375 – 
4000) 
2200 (1100 – 
3463) 
0.04 
 
Values are median (IQR) and analysed by Mann Whitney U test.  PRBC, packed red blood cell units; FFP, fresh frozen plasma units; PLTS, platelet pools; CRYO, 
cryoprecipitate pools. 
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4.4.2 Incidence of hyperfibrinolysis and coagulopathy 
No patients who received early TXA exhibited hyperfibrinolysis on ROTEM® at any point 
during the acute bleeding phase (Figure 29).  In contrast, 20% of patients who did not receive 
early TXA had hyperfibrinolysis on their admission ROTEM® (p<0.0001 vs TXA group).  During 
on-going haemorrhage, TXA appeared to protect against the development of TIC (Figure 30).  
Despite similar incidence of coagulopathy on admission in both groups (No TXA vs TXA: 40% 
vs 35%, p=0.45), by 8 units more patients in the No TXA group were coagulopathic.  After 
transfusion of 12 units of PRBCs, 100% of patients in the No TXA group were coagulopathic 
compared to 67% of patients in the TXA group (p=0.21).  At the 12 PRBC time point, patients 
in the TXA group were less coagulopathic as defined by both EXTEM CA5 and PT ratio (Figure 
31 & Figure 32). During massive haemorrhage, early empiric TXA avoids functional 
hyperfibrinolysis and is associated with protection against TIC.  
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Figure 29 Incidence of hyperfibrinolysis during trauma haemorrhage 
No patients receiving TXA exhibited hyperfibrinolysis on arrival to the ED (No TXA vs TXA 20 vs 0%, 
p<0.0001) or during ongoing haemorrhage. φ p<0.05, ** p<0.001 
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Figure 30  Incidence of coagulopathy during trauma haemorrhage 
There was a linear trend over time of increasing coagulopathy in both the No TXA (Chi-squared test 
for trend, p<0.0001) and TXA groups (p=0.0008).  After transfusion of 12 units of PRBCs, 100% of 
patients in the No TXA group were coagulopathic compared to 67% of patients in the TXA group 
(p=0.21). 
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Figure 31 Clot amplitude at 5 minutes (CA5) during trauma haemorrhage 
CA5 is relatively maintained during bleeding with TXA.  EXTEM CA5 after 12 units: No TXA vs TXA 22 
vs 31mm, p=0.02.  Dotted line represents cut-off of coagulopathy (CA5≤35mm).  φp<0.05.  
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Figure 32 Prothrombin time ratio (PTr) during trauma haemorrhage 
No statistical difference in prothrombin time ratio (PTr) was identified between the TXA and No TXA 
groups during haemorrhage.  After 12PRBC, 60% of No TXA vs 33% of TXA patients (p=0.30) had a 
prothrombin time ratio (PTr) greater than 1.2.  Whiskers represent 10th and 90th percentiles.  Dotted 
line represents threshold for coagulopathy based upon conventional laboratory coagulation tests 
(PTr > 1.2). 
 
 
4.4.3 Association between early TXA and functional coagulation assays 
Early TXA administration was associated with stronger clot formation and reduced clot 
breakdown.  There was no difference in the ROTEM® time to clot initiation (CT) (Figure 33) 
but the TXA group showed increased clot firmness both upon ED arrival (EXTEM MCF: No 
TXA vs TXA, 58 vs 60mm, p=0.03) and after a massive transfusion (EXTEM MCF after 12 units: 
No TXA vs TXA, 44 vs 53mm, p=0.008) (Figure 34 and Appendix 3 - Figure A66). No significant 
differences in functional fibrinogen or fibrin polymerisation were identified with TXA (Figure 
35). 
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Figure 33 Functional measure of clot initiation during haemorrhage 
No significant differences in clotting time (EXTEM CT), a measure of clot initiation, were identified 
with TXA.  Whiskers represent 5th and 95th percentiles. 
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Figure 34 Functional measure of clot strength during haemorrhage 
Maximum clot firmness (EXTEM MCF) was greater with TXA on admission (No TXA vs TXA 58 vs 
60mm, p=0.03) and significantly enhanced after 12PRBC (No TXA vs TXA 44 vs 53mm, p=0.008). φ 
p<0.05, *p<0.0125. 
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Figure 35 Functional measure of fibrinogen level and fibrin polymerisation during haemorrhage 
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After treatment with TXA, functional fibrinolysis was significantly lower on ED arrival (ML: No 
TXA vs TXA 6 vs 3%, p<0.0001) and throughout active haemorrhage (Figure 36 and Figure 
A67).  There was no significant difference on admission or during bleeding in either EXTEM 
MCF or ML between patients in the TXA group who received the bolus dose only and those 
who received both bolus and infusion doses of TXA.  Overall patients who received TXA had 
increased clot strength and significantly reduced functional lysis by viscoelastic evaluation. 
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Figure 36 Functional measure of fibrinolysis during haemorrhage 
Maximum lysis (EXTEM ML) was reduced with TXA on admission (ML: No TXA vs TXA 6 vs 3%, 
p<0.0001) and throughout bleeding.  φ p<0.05, **p<0.001.  Dotted line represents threshold for 
hyperfibrinolysis (ML>15%). 
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4.4.4 Association between early TXA and plasma markers of fibrinolysis 
There was a marked elevation in PAP levels on admission to the ED demonstrating an initial 
high degree of fibrinolytic system activation post injury in both the No TXA and TXA groups 
(Figure 37 and Figure A68).   
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Figure 37 Plasmin-α2-antiplasmin complex (PAP) levels during haemorrhage 
Significant fibrinolytic activation was seen in both No TXA and TXA groups on admission as 
measured by plasmin-α2-antiplasmin complex (PAP) levels (No TXA vs TXA 10595 vs 8798 µg/L, 
p=0.41). 
 
 
TXA reduced functional lysis to below the diagnostic threshold of hyperfibrinolysis 
irrespective of the level of plasmin generation (Figure 38).   
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Figure 38 Functional fibrinolysis on admission stratified by PAP level 
TXA reduced functional fibrinolysis even in those patients with the highest degree of fibrinolytic 
activation measured by PAP (ML in patients with PAP 7001-20000: No TXA vs TXA 7 vs 3%, p=0.01; 
ML in patients with PAP >20000: No TXA vs TXA 35 vs 2%, p=0.009). *p<0.0125. 
 
 
The anti-fibrinolytic action of TXA in traumatic haemorrhage was evident by the observation 
that TXA patients generated fewer D-dimers after massive haemorrhage compared to the 
No TXA patients (Figure 39 and Figure A69).  Complete data on D-dimer and PAP levels, to 
compare TXA group patients who received bolus dose only vs  bolus + infusion doses was 
only available at baseline and 4 RBC with no significant difference observed.   
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Figure 39 D-dimer levels during trauma haemorrhage 
Patients treated with TXA had significantly lower D-dimer levels after massive haemorrhage (D-
dimer after 12 units: No TXA vs TXA 33.1 vs 12.4µg/ml, *p=0.0013). 
 
 
Measurement of the primary fibrinolytic pathway control proteases during haemorrhage, 
demonstrated no statistical difference in levels of tPA (Figure 40), PAI-1 or α-2-antiplasmin 
with TXA (Figure 41 & Figure 42) at baseline or during haemorrhage other than higher PAI-1 
levels in the TXA group at the 4PRBC time point.     
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Figure 40 Tissue plasminogen activator (tPA) levels during haemorrhage 
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Figure 41 Plasminogen activator inhibitor-1 (PAI-1) levels during trauma haemorrhage 
PAI-1 levels were similar on admission and after 8 and 12PRBC.  Higher PAI-1 levels were noted with 
TXA after 4PRBC (No TXA vs TXA 28.1 vs 54.9ng/ml, p=0.014). φp<0.05 
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Figure 42 α2-antiplasmin levels during haemorrhage 
Bars represent mean ± 95% CI. 
 
 
4.4.5 Association between early TXA and plasma markers of coagulation 
TXA had no discernible effect on plasma fibrinogen levels measured on admission and during 
haemorrhage (Figure 43).  Controlling for α-2-antiplasmin, admission fibrinogen levels fell in 
both No TXA and TXA groups, with no protective effect of TXA on fibrinogen identified (α-2-
antiplasmin lowest quartile (<48u/dL): No TXA vs TXA, fibrinogen 0.89 g/L vs 1.03 g/L, 
p=0.40).   
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Figure 43 Fibrinogen levels during haemorrhage 
Fibrinogen levels were found to be low during haemorrhage but were maintained at a relatively 
constant level irrespective of TXA administration. Bars represent mean ± 95% CI. 
 
 
 
Levels of prothrombin (Figure 44) and prothrombin fragment 1+2 levels (Figure 45) were 
similar between TXA and No TXA groups.  Soluble fibrin monomer complex (sFMC) was 
significantly higher in the No TXA group at baseline (No TXA vs TXA: 238.0 µg/ml vs 
199.4µg/ml, p=0.003).  Patients who received TXA appeared to have preservation of Factor 
XIII levels following a massive transfusion although this did not reach statistical significance 
(Figure 46).  Overall, TXA appeared to ameliorate fibrinolysis throughout the bleeding phase 
with minimal effects on clot generation. 
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Figure 44 Prothrombin (Factor II) levels during haemorrhage 
Prothrombin levels fell during haemorrhage with no significant difference between the two groups.  
Bars represent mean ± 95% CI. 
 
 
158 
 
Baseline 4PRBC 8PRBC 12PRBC
0
5000
10000
15000
20000
No TXA
TXA
PT
 F
ra
g 
1+
2 
(p
m
ol
/L
)
# No TXA 76 37 12 8 
# TXA 52 15 6 2 
 
 
Figure 45 Prothrombin fragment 1+2 (PT Frag 1+2) levels during haemorrhage 
No statistically significant difference in levels of prothrombin fragments 1+2 (PT Frag 1+2) between 
the two groups was identified during haemorrhage. 
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Figure 46 Factor XIII levels during haemorrhage 
Maintained factor XIII levels were observed with TXA compared to falling levels in the No TXA group 
during haemorrhage, although these differences did not reach statistical significance.  Factor XIII 
after 12 PRBC units: No TXA vs TXA 62 (51 – 80) vs 96 (65 – 125) u/dL, p=0.10). 
  
 
4.4.6 Mortality and thrombotic events 
There was no evidence of functional hypercoagulability at 24-hours following TXA 
administration (Table 11), although we observed a small difference in MCF between the two 
groups in addition to a persistent reduction in ML at 24 hours in the TXA cohort.  For patients 
in the TXA group, there was no difference in clot strength (MCF: 62mm vs 65mm, p=0.09) or 
maximum lysis (ML: 4.5 vs 5%, p=0.95) at 24 hours between those who received a bolus dose 
only vs bolus and infusion.      
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Thrombotic complications were observed in the TXA group (Table 11).  Of 109 TXA patients, 
four patients developed a PE and one patient developed an isolated lower limb DVT.  Other 
thrombotic complications in the TXA group were: two ischemic strokes (one stroke patient 
had a cardiac thrombus associated with an incidental finding of a patent foramen ovale), one 
internal jugular vein thrombosis, one MI and one of the patients with bilateral PE also 
required a femoral embolectomy for an acutely ischemic lower limb post arterial line 
removal.  No venous or arterial thrombotic events were identified in patients who did not 
receive TXA.  The 23 patients from the No TXA group who later received TXA post baseline 
blood sampling are excluded from the outcome data in Table 11.  Two patients who received 
late TXA (post-baseline) developed a PE and an ischemic stroke respectively.  Patients in the 
early TXA group had an improved overall 24-hour survival (24-hour mortality: No TXA vs TXA 
23 vs 7%, p=0.002) (Table 11).  All-cause mortality at 28-days was lower in the early TXA 
group but did not reach statistical significance.   
 
4.5 DISCUSSION 
This study has assessed the impact of early TXA on measures of functional coagulation and 
fibrinolysis during trauma haemorrhage.  Patients who received TXA prior to, or immediately 
in, the ED had no functional hyperfibrinolysis as measured by ROTEM®. This effect persisted 
throughout the bleeding episode.  TXA was associated with improved clot strength, lower 
maximum lysis and a degree of protection against TIC during ongoing haemorrhage. 
Consistent with the CRASH-2 trial[116] and large military studies in bleeding trauma 
patients[118,134], TXA was associated with a significant reduction in early deaths.  Survivors 
receiving TXA had a higher unadjusted incidence of arterial and venous thrombotic events.  
28-day mortality in the TXA group was 6% lower than in controls although this did not reach 
statistical significance.  Early TXA prevents the development of functional hyperfibrinolysis 
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during active haemorrhage and provides some protection against resuscitation associated 
TIC.  
 
Both groups in this study had evidence of initial fibrinolytic system activation (PAP >12x 
upper limit of normal) on arrival.  In patients who had received TXA, this was not associated 
with functional hyperfibrinolysis. TXA was associated with a degree of protection from TIC 
during bleeding and improved clot strength without evidence of enhanced clot generation.  
TXA is postulated to also reduce fibrinogenolysis, especially when antiplasmin levels fall 
below 60%.[174] However, we did not observe any protective effect of TXA on fibrinogen 
levels regardless of antiplasmin levels. The effect of TXA on the coagulation system therefore 
appears to be primarily related to its anti-fibrinolytic action.  This effect persisted throughout 
the acute bleeding episode despite many patients receiving only a single dose of TXA.  TXA is 
regarded as a relatively weak antifibrinolytic and the recommended dose of 1g is at the lower 
end of those used in elective procedures such as cardiac surgery.[175] Whilst further studies 
are required to determine the optimal dose-response in trauma, the currently recommended 
dose of TXA appears effective at preventing functional hyperfibrinolysis during 
haemorrhage, at least up to the 12th unit of RBC transfusions and as measured by this 
viscoelastic assay. 
 
Thrombotic complications were observed more frequently in those patients treated with TXA 
and of similar incidence to those reported in the MATTERs study.[118] Severely injured 
bleeding patients have a high baseline risk of developing thrombotic complications.[176,177] 
In this study, those treated with TXA were both more severely shocked and more likely to 
survive beyond 24-hours, both of which may explain the increased rate of thrombotic events. 
At 24-hours there was no evidence of functional hypercoagulability in those patients who 
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received TXA except a small and likely clinically insignificant difference in maximum clot 
strength.  However, we did observe a 50% lower maximum lysis in the TXA group at 24-hours 
and further studies to correlate this finding with biochemical markers of fibrinolysis, 
transfusion products and dosing of TXA is required to ascertain the significance of this 
observation. 
 
This study has several limitations.  A temporal change in resuscitation practice of bleeding 
trauma patients was observed during the study period with TXA included in the MHP from 
2011.  However, from 2011-2015 an average of 25% of patients did not receive early TXA and 
therefore the No TXA group are not simply a historic control group.  Data on administration 
of the second TXA infusion dose was only available for 68% in the TXA group.  In those 
patients for whom data was available, only 50% received both the bolus + infusion doses of 
TXA, reflecting the real-life challenge of administering drugs to the acutely bleeding trauma 
patient.  It does suggest, however, that for many patients, a single 1g bolus of TXA may be 
sufficient to ameliorate functional hyperfibrinolysis although further studies on optimal 
dosing are required.   
 
The TXA group in this study were more likely to receive transfusion of PRBC pre-baseline 
blood draw and between 8-12 units of PRBC, received higher ratios of FFP, cryoprecipitate 
and platelets, likely reflecting temporal differences between the groups.  Whilst the TXA 
group were more shocked on admission, pre-hospital blood transfusion[178] and 
cryoprecipitate[59] have in pre-clinical studies been shown capable of modulating TIC.  The 
potential effects of TXA seen in this study should therefore be interpreted with these group 
differences in mind.  As highlighted in the military setting, it is likely that TXA combined with 
cryoprecipitate as part of a balanced transfusion strategy, exhibits a synergistic effect on 
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survival.[134] Cause of death was not ascertained in this study.  Although 24-hour mortality 
was lower in patients receiving early TXA, we are unable to confirm whether this was due to 
fewer people bleeding to death as a direct result of TXA.  Finally, we have focused this paper 
on a description of the effect of TXA on the coagulation system, and we have only presented 
crude outcome rates, without adjustment or survivorship analysis.  Our crude outcome rates 
are broadly consistent with our previous study of outcomes associated with TXA use in a 
whole civilian trauma cohort.[117]   
 
4.6 CONCLUSION 
In this prospective cohort study of bleeding trauma patients, we have characterised the 
effect of early TXA on the coagulation system.  Early TXA at the currently recommended dose 
avoids functional hyperfibrinolysis and appears to provide a degree of protection against the 
development of TIC during massive haemorrhage.  These benefits are likely greatest when 
early and empiric TXA is combined with a balanced transfusion strategy as part of damage 
control resuscitation. 
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Chapter 5 
 
 
 
 
AN INVESTIGATION INTO THE EFFECT OF THE TRANEXAMIC ACID 
INFUSION AND TIMING OF TREATMENT ON CLINICAL OUTCOMES 
INCLUDING THROMBOTIC EVENTS FOLLOWING TRAUMA 
HAEMORRHAGE 
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5.1 CHAPTER ABSTRACT 
BACKGROUND:  Despite evidence of an outcome benefit associated with Tranexamic acid 
(TXA) therapy in trauma haemorrhage, there is a disparity in its use worldwide.  The 
resistance to using it centres on a concern of precipitating thrombotic complications.  The 
aim of this study was to explore the effect of the TXA infusion and timing of TXA treatment 
on clinical outcomes including thrombotic complications.     
 
METHODS:  A prospective observational cohort study was conducted at a single major 
trauma centre.  Patients activating the major haemorrhage protocol and receiving TXA were 
included.  Blood was drawn on arrival, during bleeding and at 24 and 72-hours from injury 
for thromboelastometry and D-dimer quantification.  Patients were observed for 28-days or 
until death or discharge for occurrence of thrombotic events.   
 
RESULTS:  215 patients were included of whom 134 received a single TXA bolus only, 76 
received a TXA bolus + infusion and 5 received a double TXA bolus.  There was no difference 
in clot strength or functional fibrinolysis (ML) between the single bolus vs bolus + infusion 
groups throughout bleeding and including the 24-hour sampling point.  At 72-hours those 
receiving bolus + infusion had increased clot strength (70 vs 68 mm, p=0.03) and associated 
reduced ML (5 vs 7 %, p=0.007) compared with single bolus.  On univariate analysis there 
was a non-statistically significant increase in thrombotic events in the bolus + infusion group 
(18 vs 11% in single bolus, p=0.15) and a linear increase in thrombotic events with later TXA 
treatment after injury in those receiving a TXA infusion.  However, on multivariate analysis, 
neither the TXA infusion nor the time from injury to administration of TXA bolus were 
associated with development of thromboses, MODS or 28-day mortality.  
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CONCLUSIONS:  Thrombotic events increased in a linear fashion over time in patients 
receiving a TXA infusion, although, on multivariate analysis the effect of the TXA infusion and 
time to TXA bolus were not associated with development of thrombotic events in this cohort.    
A single TXA bolus may provide a lower effective therapeutic dose in trauma haemorrhage 
with potential for reduced thrombotic complications. 
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5.2 INTRODUCTION 
Seven years following the landmark publication of the CRASH-2 trial[116] showing improved 
outcomes in trauma haemorrhage associated with the use of Tranexamic acid (TXA), debate 
regarding its role in trauma resuscitation persists and as a result there is disparity in its use 
worldwide.  The primary issue raised regarding the use of the antifibrinolytic agent is over 
concern that treatment could cause harm by potentiating later thrombotic complications.  
Trauma patients have a high baseline risk of developing thromboses even with the use of 
modern thromboprophylaxis techniques.[154,179]  Despite existence of evidence to suggest 
that TXA is safe in both trauma[116,118] and the elective surgical setting[156], the temporal 
changes that occur in the coagulation and fibrinolytic systems after severe injury have yet to 
be fully characterised.  The mechanism by which tranexamic acid administered beyond three 
hours of injury appears to have a deleterious effect on outcomes is not known.[139]     In this 
study of bleeding trauma patients, we aimed to explore the effect of the TXA infusion and 
timing of TXA treatment on clinical outcomes including thrombotic complications.      
 
In Chapter 4, early empiric TXA was found to be effective at avoiding functional fibrinolysis 
on admission and throughout bleeding despite many patients receiving the 1g bolus dose 
only.  In this study, thrombotic complications were only encountered in patients receiving 
TXA although potentially explainable by the fact patients receiving TXA were more severely 
shocked and more likely to survive beyond 24-hours than those who received no TXA.  
However, a single 1g bolus may provide a lower effective therapeutic dose compared to the 
bolus + infusion regimen.  The effects of the TXA infusion over a single TXA bolus on 
functional measures of coagulation and on outcomes following trauma haemorrhage have 
not previously been investigated. 
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Analysis of the CRASH-2 trial dataset identified the importance of early treatment with 
TXA.[139]  The risk of death due to bleeding was found to be significantly reduced if TXA was 
given early, within the first hour from injury with a lesser but still beneficial effect in 
treatment up to three hours.  TXA administered after three hours was paradoxically found 
to increase the risk of death due to bleeding.  The reason for this time-effect has yet to be 
fully explained.  One hypothesis from an experimental model of traumatic brain injury 
suggests that temporal differences in levels of the plasminogen activators tPA and uPA could 
provide the explanation.[143,144]  TXA blocks early tPA-mediated lysis but later uPA-
mediated lysis could be potentiated by TXA with resultant worsening of bleeding.  Whilst the 
first TXA bolus appears beneficial in reversing hyperfibrinolysis, it remains unclear whether 
the infusion dose provides additional benefit or whether prolonged exposure to TXA with an 
8-hour infusion may potentially cause harm as the trauma patient evolves from the initial 
hypocoagulable to a hypercoagulable state.[63,64,66]  
 
The hypothesis of this study was that a single bolus of TXA would be as effective as a bolus + 
infusion in trauma haemorrhage and that later exposure to TXA was associated with 
increased thrombotic complications.  Our first aim was to assess the effect of two different 
dosing regimens of TXA on functional measures of coagulation and fibrinolysis and on 
outcomes.  The second aim was to investigate the effect of the TXA infusion and time from 
injury of TXA treatment on clinical outcomes including thrombotic complications.  Finally, we 
wished to characterise patients developing a thrombotic complication and determine any 
effect of TXA therapy in this cohort.  We conducted a prospective observational cohort study 
of trauma patients activating the Major Haemorrhage Protocol within a single Major Trauma 
Centre.   
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5.3 METHODS 
All adult patients (≥16 years) who meet the local criteria for trauma team activation, were 
consecutively screened (between 8:00am – 8:00pm daily until January 2016 after which 
screening was 24-hours) for inclusion in the Activation of Coagulation and Inflammation in 
Trauma study (ACIT II; UK CRN ID 5637).  Deferred informed written consent was obtained 
from the patient or their next-of-kin.  The study was approved by East London and The City 
Research Ethics Committee (07/Q0603/29).  The inclusion and exclusion criteria of the ACIT 
II study are detailed in sections 2.2.1 and 2.2.2.  
   
For this study we analysed consecutive ACIT II patients enrolled at The Royal London Hospital 
who activated the Major Hemorrhage Protocol (MHP) from January 2013 to 31 July 2017.  
The MHP is activated either pre-hospital by the physician-led London Air Ambulance (LAA) 
or in-hospital by the trauma team leader, when a patient with suspected traumatic 
haemorrhage, has a systolic blood pressure below 90 mmHg and a poor response to initial 
fluid resuscitation.  The empiric administration of TXA at our institution is restricted to 
patients who activate our MHP.  As detailed in section 4.3, TXA was formally introduced into 
the MHP in February 2011 (Figure A64) as a 1g IV bolus over 10 minutes (within three hours 
of injury) followed by a 1g IV infusion over eight hours.  The MHP protocol was further revised 
in August 2016 (Figure A65) and the 1g infusion of TXA over 8-hours removed based on 
expert consensus of opinion.  Therefore, from August 2016, patients activating the MHP 
received a single bolus of 1g IV TXA over 10 minutes (within three hours of injury).  
 
5.3.1 Data Collection 
ACIT II data collection was carried out as detailed in section 4.3.1. 
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The timing of TXA administration from injury was documented.  Patients were observed for 
28 days from injury or until hospital discharge for the occurrence of thrombotic events or 
death.  Length of either critical care or overall hospital stay was calculated for patients 
surviving to hospital discharge or day 28 from injury only.  Cause of death was determined 
by retrospective review of case notes, trauma department morbidity and mortality meeting 
outcome reports and post mortem reports where applicable.   
 
5.3.2 Blood Sampling 
Research blood samples were obtained alongside clinical laboratory tests at baseline as 
detailed previously in section 4.3.2.  Further blood samples were obtained during 
haemorrhage after transfusion of 4, 8 and 12 units packed red blood cells (PRBC) and at 24 
and 72 hours following injury.   
 
The D-dimer concentration was determined by the RLH central Haematology laboratory 
using a Sysmex CS2100i automated analyser (Sysmex, UK).  For the D-dimer assay, 
concentrations above the assay upper measurement limit of 80.00 mg/L FEU [fibrin 
equivalent units] are reported as 80.00 mg/L FEU. 
 
5.3.3 Functional Coagulation Analysis 
Functional coagulation analysis was performed within one hour of blood draw at 37°C on 
either a ROTEM® delta instrument (Tem International GmbH, Munich, Germany) using the 
automated electronic pipette or a ROTEM Sigma instrument (Tem International GmbH, 
Munich, Germany) according to the manufacturer’s instructions.  Patients co-enrolled in the 
iTACTIC randomised control trial[157] had samples analysed on the automated ROTEM 
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Sigma instrument.  The manufacturer states that the two platforms are comparable since the 
technical method used in each is identical.  Two separate 60-minute assays were performed 
on each blood sample: EXTEM, measuring tissue-factor initiated clotting and FIBTEM, for 
qualitative assessment of fibrinogen levels via the addition of the platelet inhibitor, 
cytochalasin D.   
 
5.3.4 Definitions 
Major haemorrhage and massive haemorrhage were defined as transfusion within the first 
24-hours of injury of at least 4 PRBC or at least 10 PRBC respectively.[180]  Multiple Organ 
Dysfunction Syndrome (MODS) was determined for those surviving at least 24-hours and 
admitted to a critical care setting (either High Dependency or Intensive Care) and defined as 
the occurrence of a total SOFA score greater than 5 during the first 7 days of admission.[151]  
Thrombotic events included deep vein thrombosis (DVT), pulmonary embolism (PE), arterial 
thrombosis, myocardial infarction (MI) and ischemic stroke.  Thrombotic events were 
defined as a clinical diagnosis supported by a confirmatory test result: duplex ultrasound for 
DVT; CT pulmonary angiogram for PE; arterial thrombosis requiring surgical intervention e.g. 
embolectomy; electrocardiogram changes and elevated troponin for MI; and CT head for 
ischaemic stroke.  Univariate and multivariate analysis of the effect of TXA on late outcomes 
(28-day mortality, thrombotic events and MODS) included those patients surviving beyond 
24 hours from injury only.   
 
5.3.5 Statistical Analysis 
Statistical analysis was performed using GraphPad Prism version 5 (GraphPad Software Inc., 
San Diego, USA) and Microsoft Excel 2013 (Microsoft Inc., Redmond, USA).  Normal quantile 
plots were used to assess normality.  Data without a normal distribution were expressed as 
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median (interquartile range) and analysed using Mann-Whitney U-test or Kruskal-Wallis test 
with Dunn’s multiple comparison.  Percentages were analysed using Chi-squared or Fisher’s 
exact tests, with linear trends over time analysed with Chi-squared test for trend.    
Multivariate analysis was performed using IBM SPSS Statistics version 25 (IBM, Armonk, 
United States).  Multivariate logistic regression models were created to investigate the effect 
on late outcomes, of TXA infusion (binary variable [yes/no]) or time from injury to TXA bolus 
(continuous variable in minutes) alongside other factors achieving a univariate significance 
of p < 0.2.  A p value of <0.05 was considered statistically significant. Box-whisker plots 
represent median, interquartile range, 5th – 95th percentiles unless otherwise stated.        
 
5.4 RESULTS 
A total of 281 patients activated the major haemorrhage protocol and were enrolled in the 
ACIT II study during the study period.  Patients were excluded for the following reasons: 14 
patients or their next-of-kin withdrew consent; 7 found retrospectively not to have met the 
ACIT II inclusion criteria; 20 did not receive any TXA; 6 in whom it was unknown if they had 
received a TXA bolus and/or infusion; 1 recruited into the CRASH-3 trial and 18 with no 
ROTEM performed at baseline.  A total of 215 patients were included within the analysis, of 
whom 82% were severely injured (ISS > 15) and 93% were transfused at least one unit of red 
blood cells. 
 
5.4.1 Patient characteristics and unadjusted clinical outcomes 
Three TXA dosing regimens were identified: a single 1g bolus (single bolus group); initial 1g 
bolus followed by a later 2nd 1g bolus (double bolus group) and 1g bolus followed by a 1g 
infusion over 8 hours (bolus + infusion group).  Patient and injury characteristics stratified by 
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TXA dosage regimen are shown in Table 13.  Patients receiving a single TXA bolus and those 
receiving a bolus + infusion were similar in terms of sex, injury severity, mechanism of injury 
and time to administration of first TXA dose following injury.  The bolus + infusion patients 
differed from the single bolus group in that they were younger, with a slightly greater degree 
of shock on admission.   
 
Rates of major haemorrhage and total 24 hour PRBC transfusion requirements were greater 
in the bolus + infusion group compared to the single bolus group (Table 13).  Massive 
haemorrhage and MODS rates were found to be similar.  The incidence of thrombotic events 
occurring in the bolus + infusion group was greater although not statistically significant (18% 
vs 11% in single bolus, p=0.15).  Overall 24-hour mortality was lower in the bolus + infusion 
group, although this did not reach statistical significance compared to the single bolus group 
(7.9% vs 17.9%, p=0.06) and by 28-days, overall mortality rates were similar.  There were no 
significant differences in cause of death between the single bolus and bolus + infusion groups 
and in particular, no statistically significant difference in deaths secondary to haemorrhage 
(9.0% vs 5.3%, p=0.42; Table 14).   
 
The five patients who received a double bolus of TXA suffered from predominantly 
penetrating injury (80%), with evidence of severe shock (median BD 22.2 mmol/L) on 
admission and the greatest blood transfusion requirement of any group, with 80% suffering 
massive haemorrhage.  By day 28, four out of these five patients had died and there were no 
recorded thrombotic events in this group of patients.    
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Table 13  Patient characteristics and unadjusted outcomes stratified by TXA dosing regimen 
 
Number of Patients 
Single bolus 
134 
Double bolus 
5 
Bolus + infusion 
76 
Timings 
Injury - ED admission, minutes 79 (61 – 100) 80 (74 – 99) 84 (56 – 104) 
1st TXA bolus pre-hospital (%) 102 (76%) 2 (40%) 55 (72%) 
Injury - 1st TXA bolus, minutes 69 (52 – 90) 84 (73 – 106) 74 (51 – 94) 
Injury - 2nd TXA bolus  or infusion, minutes - 151 (135 – 714) 158 (116 – 220) 
    
Injury & patient admission characteristics 
Age, years 36 (26 – 52) 50 (27 – 55) 27 (22 – 49)* 
Male, n (%) 104 (78%) 5 (100%) 54 (71%) 
Blunt, n (%) 95 (71%) 1 (20%)^ 51 (67%) 
Injury Severity Score (ISS) 27 (17 – 39) 21 (11 – 25) 29 (22 – 43) 
Base Deficit (BD), mmol/L 7.4 (3.8 – 14.2) 22.2 (7.9 – 63.6) 9.2 (6.2 – 17)* 
EXTEM CA5, mm 35 (30 – 43) 36 (16 – 41) 37 (29 – 44) 
EXTEM ML, % 3 (1 – 6) 11 (1 – 94) 3 (1 – 5) 
    
Blood product totals 
24hr PRBC, units 5 (2 – 8) 19 (5 – 37)^ 7 (4 – 10)* 
    
Outcomes 
Major haemorrhage, n (%) 83 (62%) 4 (80%) 59 (78%)* 
Massive haemorrhage, n (%) 24 (18%) 4 (80%)^ 21 (28%) 
Incidence of MODS, n (%) 
n = 95 
77 (81%) 
n = 3 
3 (100%) 
n = 65 
58 (89%) 
All thrombotic events, n (%) 15 (11.2%) 0 14 (18.4%) 
24hr mortality, n (%) 24 (17.9%) 2 (40%) 6 (7.9%) 
28 day mortality, n (%) 37 (27.6%) 4 (80%)^ 20 (26.3%) 
 
^p<0.05, Double TXA bolus vs single TXA bolus; *p<0.05, TXA bolus + infusion vs single TXA bolus.  
MODS, multiple organ dysfunction syndrome: includes patients surviving beyond 24 hours and 
admitted to a critical care unit. 
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Table 14  Cause of death stratified by TXA dosing regimen 
 
Number of patients 
Single bolus 
134 
Double bolus 
5 
Bolus + infusion 
76 
Haemorrhage 12 (9.0%) 1 (20%) 4 (5.3%) 
Head injury 15 (11.2%) 0 6 (7.9%) 
Multi-organ failure/sepsis 2 (1.5%) 1 (20%) 5 (6.6%) 
Multiple injuries 4 (3.0%) 0 1 (1.3%) 
Hypoxic brain injury 0 1 (20%)^ 2 (2.6%) 
Thrombotic event 1 (0.7%) 0 0 
Unknown 3 (2.2%) 1 (20%) 2 (2.6%) 
 
Values are n (%).  ^p<0.05, Double TXA bolus vs single TXA bolus.   
 
 
5.4.2 Effect of TXA infusion on functional coagulation and D-dimer levels 
There was no significant difference on admission or during bleeding (up to the 12th PRBC 
sampling time point) in clotting time (Figure 47), clot strength (Figure 48 and Figure 49) or 
maximum lysis (Figure 50) between patients who received a bolus + infusion vs single bolus 
of TXA.  At 24 hours, again no difference in functional coagulation was identified, according 
to administered TXA dosing regimen.  At 72 hours, clotting time was similar, however, EXTEM 
clot strength (70 vs 68 mm, p=0.03) and FIBTEM clot strength (34 vs 30 mm, p=0.006) were 
increased with a correspondingly lower maximum lysis (5 vs 7 %, p=0.007) detected in those 
patients receiving TXA bolus + infusion vs single bolus only.  D-dimer levels were similarly 
elevated in both the bolus + infusion and single bolus groups on admission, with levels found 
to have reduced by the 24-hour and again by the 72-hour time points, with no significant 
difference identified between the two groups (Figure 51).   
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Figure 47  Clotting time (EXTEM CT) on admission, during bleeding and at 24 and 72 hours comparing 
patients who received TXA bolus vs bolus + infusion 
Whiskers represent 10 – 90th percentiles.  PRBC, packed red blood cells. 
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Figure 48  Maximum clot firmness (EXTEM MCF) on admission, during bleeding and at 24 and 72 
hours comparing patients who received TXA bolus vs bolus + infusion 
*p=0.03 
  Baseline  4PRBC   8PRBC   12PRBC   24hr   72hr
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TXA Bolus + Infusion
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Figure 49  FIBTEM maximum clot firmness (MCF) on admission, during bleeding and at 24 and 72 
hours comparing patients who received TXA bolus vs bolus + infusion 
**p=0.006 
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Figure 50  Functional fibrinolysis (EXTEM ML) on admission, during bleeding and at 24 and 72 hours 
comparing patients who received TXA bolus vs bolus + infusion 
Whiskers represent minimum and maximum values. **p=0.007 
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Figure 51  D-dimer levels on admission, at 24 and 72 hours comparing patients who received TXA 
bolus vs bolus + infusion 
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5.4.3 Effect of timing of TXA administration on unadjusted outcomes 
The majority (92%) of patients started to receive a first bolus dose of TXA within 120 minutes 
of injury with only one patient’s bolus starting beyond the three hour mark at 190 minutes 
from injury (Figure 52).  Patients in the double bolus group received their second bolus of 
TXA a median of 151 minutes from injury (Table 13), with the latest dose administered over 
16 hours from injury.  Patients in the bolus + infusion group started to receive the infusion 
after a median of 158 minutes from injury (Table 13), with 36% of patients beginning their 
infusion greater than three hours following injury.  The maximum length of time from injury 
to a TXA infusion starting was 11.5 hours. 
 
 
Figure 52  Histogram illustrating time from injury to start of TXA administration for patients in single 
bolus and bolus + infusion groups 
Red dashed line represents three hours from injury 
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To explore the effect of timing of TXA therapy on patient outcomes, patients were stratified 
into 30-minute time windows based upon when their TXA therapy (either bolus or infusion) 
finished.  Patient and injury characteristics are demonstrated in Table 15 and Table 16 along 
with clinical outcomes.   
 
In the single bolus group, patients completing TXA therapy within 60-minutes of injury were 
significantly younger than those in the 90-119 minute window (29 vs 45 years, p<0.01; Table 
15) and had a higher incidence of penetrating injury (50% vs 13%, p=0.003).  There was no 
difference in injury severity or degree of shock across the 30-minute time windows.  No 
significant differences in incidence of major or massive haemorrhage, thrombotic events 
(Figure 53), critical care or overall hospital LOS associated with timing of TXA bolus therapy 
were identified.  Mortality at 24-hours and 28-days was greatest in those completing 
treatment between 60 – 89 minutes from injury. 
 
No significant differences in patient characteristics, severity of injury or degree of shock were 
identified when assessing the bolus + infusion group according to time of infusion completion 
(Table 16).  Incidence of major or massive haemorrhage did not vary significantly over time.  
Patients who started the TXA infusion later and therefore were exposed to TXA for a longer 
duration after injury, had an associated increase in subsequent thrombotic events (Chi-
square test for trend p=0.0007; Figure 54).  Patients completing the TXA bolus + infusion 
within 10.5 hours of injury were found to have a low incidence of thrombotic events, whilst 
those completing therapy beyond 11 hours had a 6-fold higher incidence of thromboses.  
Later TXA therapy was also associated with an increased overall hospital LOS (Table 16).   
 
182 
 
Table 15  Characteristics and outcomes for the single bolus group, stratified by time from injury to TXA 10-minute bolus finishing 
 Time from injury to TXA finishing (minutes)  
 < 60 60-89 90-119 ≥ 120 p 
Number of survivors at time window 130 130 126 122  
Number completing TXA bolus during time window 32 56 30 12  
      
Age, years 29 (24 – 37) 39 (26 – 55) 45 (31 – 59) 36 (25 – 54) 0.008 
Male, n (%) 26 (81%) 45 (80%) 20 (67%) 9 (75%) 0.47 
Blunt, n (%) 16 (50%) 43 (77%) 26 (87%) 9 (75%) 0.009 
Injury Severity Score 25 (16 – 43) 31 (18 – 43) 27 (19 – 36) 22 (18 – 34) 0.83 
Base Deficit, mmol/L 9.4 (4.3 – 20.0) 6.6 (3.1 – 15.2) 7.3 (3.5 – 11.9) 5.6 (2.5 – 7.9) 0.16 
Major haemorrhage, n (%) 20 (63%) 34 (61%) 17 (57%) 9 (75%) 0.74 
Massive haemorrhage, n (%) 8 (25%) 13 (23%) 1 (3%) 2 (17%) 0.10 
24hr mortality, n (%) 5 (3.8%) 13 (10%) 4 (3.2%) 1 (0.82%) 0.004 
28-day mortality, n (%) 7 (5.4%) 17 (13.1%) 9 (7.1%) 3 (2.5%) 0.009 
Time to death, hours 4 (2 – 36) 5 (3 – 25) 57 (4 – 130) 55 (12 – 208) 0.13 
MODS, n (%) 16 (17%) 31 (33%) 20 (21%) 8 (8%) 0.0004 
Thrombotic events, n (%) 3 (2.3%) 5 (3.8%) 6 (4.8%) 1 (0.8%) 0.27 
Critical Care LOS, days 8 (1 – 18) 11 (4 – 21) 9 (6 – 22) 5 (1 – 11) 0.17 
Hospital LOS, days 18 (7 – 32) 28 (13 – 49) 39 (15 – 58) 24 (11 – 61) 0.055 
 
Includes data from n=130/134 patients with known timing of TXA administration.  Mortality and thrombotic events calculated as % of survivors at each time window.  % 
MODS based upon 95 patients surviving beyond 24hrs and admitted to Critical Care.  Length of stay (LOS) for survivors only. 
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Table 16  Characteristics and outcomes for the bolus + infusion group, stratified by time from injury to TXA 8-hour infusion finishing 
 Time from injury to TXA infusion finishing (minutes)  
  < 570 570-599 600-629 630-659 ≥ 660 p 
Total number of survivors to this time window  63 63 63 63 63  
Number completing TXA bolus during time window 7 11 11 12 27  
       
Age, years 24 (19 – 40) 27 (22 – 58) 27 (21 – 34) 35 (19 – 46) 32 (24 – 58) 0.34 
Male, n (%) 7 (100%) 8 (73%) 5 (45%) 9 (75%) 19 (70%) 0.17 
Blunt, n (%) 3 (43%) 6 (55%) 7 (64%) 9 (75%) 21 (78%) 0.35 
ISS 26 (25 – 54) 22 (17 – 38) 35 (16 – 58) 32 (19 – 43) 33 (22 – 45) 0.45 
BD, mmol/L 10.2 (8.8 – 22.4) 9.2 (4.4 – 16.0) 12.0 (10.1 – 21.8) 8.8 (5.7 – 18.7) 7.6 (5.0 – 12.2) 0.09 
Major haemorrhage, n (%) 6 (86%) 8 (73%) 9 (82%) 9 (75%) 21 (78%) 0.58 
Massive haemorrhage, n (%) 2 (29%) 4 (36%) 4 (36%) 4 (33%) 5 (19%) 0.71 
24hr mortality, n (%) 0 (0%) 2 (3.2%) 2 (3.2%) 1 (1.6%) 1 (1.6%) 0.67 
28-day mortality, n (%) 3 (4.8%) 3 (4.8%) 5 (7.9%) 2 (3.2%) 6 (9.5%) 0.55 
Time to death, hours 35 (29 – 93) 8 (4 – 60) 27 (4 – 76) 36 (6 – 66) 97 (22 – 199) 0.36 
MODS, n (%) 6 (9%) 6 (9%) 7 (11%) 10 (15%) 22 (34%) 0.0003 
Thrombotic events, n (%) 0 (0%) 1 (1.6%) 1 (1.6%) 4 (6.3%) 7 (11.1%) 0.01 
Critical Care LOS, days 4 (1 – 10) 6 (4 – 12) 9 (3 – 16) 18 (11 – 32) 10 (5 – 24) 0.11 
Hospital LOS, days 8 (3 – 47) 17 (8 – 38) 14 (9 – 36) 51 (24 – 75) 42 (22 – 60) 0.03 
 
Includes data from n=68/76 patients with known timing of TXA infusion administration.  Mortality and thrombotic events calculated as % of survivors at each time 
window.  % MODS based upon 65 patients surviving beyond 24hrs and admitted to Critical Care.  Length of stay (LOS) for survivors only. 
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Figure 53  Thrombotic events in survivors from single bolus group only, stratified by time TXA bolus 
ends 
Chi-square test for trend p=0.62 
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Figure 54  Thrombotic events in survivors from bolus + infusion group only, stratified by time TXA 
infusion ends 
Chi-square test for trend ***p=0.0007 
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5.4.4 Thrombotic Events 
Patients experiencing a thrombotic event within 28 days of injury were compared to those 
who did not (Table 17).  Although not statistically significant, a pattern towards more women 
developing a thrombotic event was noted (p=0.05).  There was no significant difference in 
age, mechanism or severity of injury and degree of shock on admission.  Admission ROTEM 
parameters were similar with no evidence of hypercoagulability on admission in those 
developing thromboses.  Although not reaching statistically significance, 28-day mortality 
differed between the two subgroups, with 96% of those who developed a thrombotic event 
surviving beyond 28-days from injury.  Patients with a thrombotic event had a tendency 
towards greater blood transfusion requirements during the first 24 hours from injury and 
higher rates of MODS although neither of these differences reached statistical significance.  
Both critical care and hospital lengths of stay were greater in those survivors who developed 
a thrombotic complication.     
 
All patients received at least a bolus dose of TXA, but patients with thrombotic events tended 
towards later administration of the bolus (78 vs 70 minutes, p=0.13), with fewer receiving 
the bolus either pre-hospital or within the first hour from injury, although these differences 
were not statistically significant (Table 17).  However, the time from injury to the TXA infusion 
beginning was significantly longer in patients who proceeded to develop a thrombotic 
complication (239 vs 154 minutes, p=0.048).   
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Table 17  Characteristics of patients surviving beyond 24 hours from injury who did and did not 
develop a thrombotic event 
 No Thrombotic Event Positive Thrombotic Event p 
Number of patients 156 27  
Number of thrombotic events 0 29  
Number of venous events - 14  
Number of arterial events - 15  
    
Age, years 32 (24 – 50) 38 (28 – 58) 0.12 
Male, n (%) 121 (78%) 16 (59%) 0.05 
Blunt, n (%) 104 (67%) 21 (78%) 0.37 
Injury Severity Score 26 (17 – 38) 29 (20 – 43) 0.42 
Glasgow Coma Scale 12 (6 – 15) 14 (9 – 15) 0.21 
Base deficit, mmol/L 7.5 (4.1 – 12.3) 7.6 (4.6 – 11.9) 0.91 
INR > 1.2, n (%) 44 (28%) 8 (30%) 1.00 
Admission EXTEM MCF, mm 59 (54 - 63) 56 (51 – 63) 0.50 
Admission FIBTEM MCF, mm 11 (7 – 15) 11 (8 – 13) 0.91 
Admission EXTEM ML, % 4 (2 – 6) 4 (2 – 6) 0.78 
    
Pre-hospital TXA, n (%) 114 (73%) 18 (67%) 0.49  
Received TXA bolus within first hour, n (%) 52 (34%) 6 (22%) 0.37 
Time from injury to 1st bolus, minutes 70 (47 – 91) 78 (60 – 99) 0.13 
Received TXA Infusion, n (%) 58 (37%) 12 (44%) 0.52  
Time from injury to infusion, minutes 154 (112 – 209) 239 (150 – 360) 0.048 
    
Major Haemorrhage, n (%) 99 (63%) 22 (81%) 0.08 
Massive Haemorrhage, n (%) 27 (17%) 9 (33%) 0.07 
28-day mortality, n (%) 28 (17.9%) 1 (3.7%) 0.08 
 
MODS, n (%) 
n=137 
113 (82%) 
n=26 
25 (96%) 
 
0.13 
Critical care LOS, days 7 (3 – 17) 14 (8 – 23) 0.006 
Hospital LOS, days 24 (10 – 47) 35 (24 – 56) 0.04 
 
LOS, length of stay for survivors only.  MODS, multiple organ dysfunction syndrome for those 
patients admitted to critical care. 
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Functional coagulation on admission and at 24- and 72-hours was compared between those 
who did and did not develop a later thrombotic complication.  There was no evidence of 
hypercoagulability in terms of ROTEM clot strength at any sampling point during the first 72-
hours from injury in the thrombosis group (Figure 55).  Twenty-four hours after injury, the 
thrombosis group did, however, have lower levels of functional fibrinolysis (ML: 3 vs 5 %, 
p=0.002; Figure 56) and higher D-dimer levels (23.9 vs 13.3 mg/L FEU, p=0.02; Figure 57) 
compared to the no thrombosis group.  By 72-hours there was no apparent difference 
between the groups.    
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Figure 55  EXTEM Maximum clot firmness (MCF) over the first 72-hours from injury 
 
188 
 
   Baseline    24 hour    72 hour
0
5
10
15
20
**
No thrombosis
Thrombosis
EX
TE
M
 M
L 
(%
)
# No Thrombosis 184 126 117 
# Thrombosis 27 23 23 
 
 
Figure 56  EXTEM Maximum lysis (ML) over the first 72-hours from injury 
**p=0.002 
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Figure 57  D-dimer levels over the first 72-hours from injury 
*p=0.02 
 
 
 
The no thrombosis and thrombosis groups were further subdivided by dosing regimen of TXA 
received.  A similar pattern at 24-hours of lower ML (Figure 58) and higher D-dimer (Figure 
59) levels in patients who developed thrombosis was seen, with no statistically significant 
difference in levels identified between the single bolus and bolus + infusion treatment 
regimens.   
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Figure 58  EXTEM Maximum lysis (ML) over the first 72-hours from injury stratified by TXA dosing 
regimen and thrombotic events 
**p=0.006 comparing the four groups at 24-hours (Kruskal-Wallis) with ML in TXA bolus + infusion 
& thrombosis group significantly lower than in the TXA bolus only & no thrombosis group on Dunn’s 
multiple comparison test (2 vs 5 %, p<0.05).    
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Figure 59  D-dimer levels over the first 72-hours from injury stratified by TXA dosing regimen and 
thrombotic events 
D-dimer levels at 24-hours were higher in patients with thrombosis in both the single bolus and 
bolus + infusion TXA groups, but did not reach statistical significance (Kruskal-Wallis test at 24 hours, 
p=0.08).   
 
 
5.4.5 Risk-adjusted effect of TXA infusion and time to bolus on late outcomes 
The previous univariate analysis suggested that TXA therapy may be associated with the 
development of later thrombotic events and MODS.  Late TXA therapy is known to be 
associated with an increased risk of mortality.  Therefore, to investigate the independence 
of the effect the TXA infusion versus a single bolus of TXA and the effect time from injury to 
first TXA bolus has on the outcomes of 28-day mortality, MODS and thrombotic events, 
several multi-variate models were created.  Patients surviving beyond 24 hours were 
included in the analysis. 
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5.4.5.1 28-day mortality 
Univariate analysis of all admission variables on 28-day mortality was performed (Table 18) 
and factors achieving a univariate significance of p<0.2 were entered into a multivariate 
logistic analysis.   
 
Table 18  Univariate analysis of admission variables on 28-day mortality 
 Survived Died p 
Number of patients 154 29  
    
Age, years 33 (24 – 50) 34 (26 – 54) 0.51 
Male, n (%) 118 (77%) 19 (66%) 0.24 
Blunt, n (%) 103 (67%) 22 (76%) 0.39 
Injury Severity Score 25 (17 – 38) 38 (26 – 52) 0.0007 
ED Admission SBP, mmHg 100 (82 – 122) 91 (69 – 126) 0.39 
ED Glasgow Coma Scale 14 (8 – 15) 3 (3 – 9) <0.0001 
Base deficit, mmol/L 7.3 (3.8 – 11.3) 11.3 (6.6 – 22.0) 0.0009 
INR 1.2 (1.1 – 1.3) 1.3 (1.2 – 1.5) 0.009 
24hr PRBC total, units 5 (2 – 8) 9 (5 – 16) 0.002 
    
Time: injury - TXA bolus, minutes 71 (52 – 92) 70 (46 – 96) 0.93 
Received TXA Infusion, n (%) 56 (36%) 14 (48%) 0.23 
 
Receiving the TXA infusion was not associated with 28-day mortality following multivariate 
analysis (Table 19).  Factors associated with mortality were admission GCS and base deficit. 
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Table 19  Multivariate logistic regression: the effect of TXA infusion on 28-day mortality  
Variable Odds Ratio (95% CI) p 
ISS 1.03 (0.99 – 1.08) 0.15 
GCS 0.80 (0.70 – 0.91) 0.001 
Base deficit 1.09 (1.01 – 1.18) 0.03 
INR 1.55 (0.06 – 44.09) 0.80 
24hr PRBC total 1.03 (0.95 – 1.12) 0.49 
TXA Infusion 0.49 (0.14 – 1.80) 0.29 
 
There was a positive signal towards a longer time from injury to administration of the TXA 
bolus being associated with 28-day mortality following multivariate analysis although the 
significance did not reach the p<0.05 threshold (Table 20). Admission GCS and base deficit 
were again associated with mortality in this model.   
 
Table 20  Multivariate logistic regression: the effect of time from injury to TXA bolus on 28-day 
mortality 
Variable Odds Ratio (95% CI) p 
ISS 1.02 (0.98 – 1.07) 0.31 
GCS 0.80 (0.70 – 0.91) 0.001 
Base deficit 1.09 (1.01 – 1.18) 0.02 
INR 2.58 (0.10 – 64.33) 0.56 
24hr PRBC total 1.01 (0.93 – 1.11) 0.76 
Minutes from injury – TXA bolus 1.02 (1.00 – 1.04) 0.06 
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5.4.5.2 Thrombotic events 
Univariate analysis of all admission variables on occurrence of thrombotic events within 28-
days of injury was performed (Table 21) and factors achieving a univariate significance of 
p<0.2 were entered into a multivariate logistic analysis. 
 
Table 21  Univariate analysis of admission variables on occurrence of thrombotic events 
 No thrombotic event Thrombotic event p 
Number of patients 153 27  
    
Age, years 32 (24 – 50) 38 (28 – 58) 0.12 
Male, n (%) 118 (77%) 16 (59%) 0.05 
Blunt, n (%) 103 (67%) 21 (78%) 0.37 
Injury Severity Score 26 (17 – 38) 29 (20 – 43) 0.42 
ED Admission SBP, mmHg 98 (81 – 122) 102 (75 – 127) 0.83 
ED Glasgow Coma Scale 12 (6 – 15) 14 (9 – 15) 0.21 
Base deficit, mmol/L 7.5 (4.1 – 12.3) 7.6 (4.6 – 11.9) 0.91 
INR 1.2 (1.1 – 1.3) 1.2 (1.1 – 1.3) 0.24 
24hr PRBC total 5 (2 – 8) 7 (4 – 10) 0.03 
    
Time: injury - TXA bolus, minutes 70 (47 – 91) 78 (60 – 99) 0.11 
Received TXA Infusion, n (%) 58 (38%) 12 (44%) 0.52 
   
The TXA infusion was found not to be associated with thrombotic events after risk-
adjustment with multivariate analysis (Table 22).  The time from injury to delivery of the TXA 
bolus was also not associated with thrombotic events on multivariate analysis (Table 23).  
There was a signal towards female gender being associated with thrombotic event 
occurrence, but this factor did not reach statistical significance.   
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Table 22  Multivariate logistic regression: the effect of TXA infusion on thrombotic events 
Variable Odds Ratio (95% CI) p 
Age 1.01 (0.99 – 1.04) 0.34 
Male Gender 0.48 (0.20 – 1.18) 0.11 
24hr PRBC total 1.04 (0.98 – 1.09) 0.22 
TXA Infusion 1.23 (0.52 – 2.93) 0.64 
 
 
Table 23  Multivariate logistic regression: the effect of time from injury to TXA bolus on thrombotic 
events 
Variable Odds Ratio (95% CI) p 
Age 1.01 (0.98 – 1.03) 0.53 
Male Gender 0.44 (0.19 – 1.09) 0.08 
24hr PRBC total 1.03 (0.97 – 1.09) 0.30 
Minutes from injury – TXA bolus 1.01 (0.99 – 1.02) 0.28 
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5.4.5.3 MODS 
Univariate analysis of all admission variables on occurrence of MODS within 7-days of injury 
was performed (Table 24) and factors achieving a univariate significance of p<0.2 were 
entered into a multivariate logistic analysis. 
 
Table 24  Univariate analysis of admission variables on occurrence of MODS 
 No MODS MODS p 
Number of patients 25 135  
    
Age, years 29 (23 – 48) 36 (25 – 52) 0.22 
Male, n (%) 21 (84%) 95 (70%) 0.22 
Blunt, n (%) 13 (52%) 107 (79%) 0.004 
Injury Severity Score 19 (11 – 31) 30 (22 – 43) 0.0007 
ED Glasgow Coma Scale 15 (14 – 15) 10 (3 – 14) <0.0001 
Base deficit, mmol/L 5.4 (3.4 – 10.3) 7.9 (4.9 – 13.8) 0.08 
INR 1.1 (1.1 – 1.2) 1.2 (1.1 – 1.3) 0.01 
24hr PRBC total 3 (2 – 6) 6 (3 – 9) 0.0001 
    
Time: injury - TXA bolus, minutes 73 (46 – 82) 70 (52 – 94) 0.88 
Received TXA Infusion, n (%) 7 (28%) 58 (43%) 0.19 
 
Receiving the TXA infusion was not found to be associated with development of MODS after 
multivariate analysis (Table 25).  A higher GCS was protective against MODS whilst higher 
blood transfusion requirements were independently associated with MODS development.  
There was a signal towards blunt rather than penetrating injury being associated with MODS 
development.   
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Table 25  Multivariate logistic regression: the effect of TXA infusion on MODS 
Variable Odds Ratio (95% CI) p 
Penetrating injury 0.20 (0.04 – 1.09) 0.06 
ISS 1.04 (0.98 – 1.10) 0.26 
GCS 0.71 (0.57 – 0.88) 0.002 
Base deficit 0.99 (0.88 – 1.12) 0.89 
INR 0.39 (0.00 – 70.63) 0.73 
24hr PRBC total 1.64 (1.21 – 2.21) 0.001 
TXA Infusion 2.43 (0.56 – 10.52) 0.23 
 
The time from injury to treatment with the TXA bolus was not independently associated 
with MODS after multivariate analysis (Table 26). 
 
Table 26  Multivariate logistic regression: the effect of time from injury to TXA bolus on MODS 
Variable Odds Ratio (95% CI) p 
Penetrating injury 0.19 (0.03 – 1.12) 0.07 
ISS 1.05 (0.99 – 1.11) 0.14 
GCS 0.68 (0.54 – 0.86) 0.001 
Base deficit 1.02 (0.90 – 1.15) 0.80 
INR 0.20 (0.00 – 43.92) 0.56 
24hr PRBC total 1.68 (1.24 – 2.27) 0.001 
Minutes from injury – TXA bolus 1.01 (0.99 – 1.04) 0.42 
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5.4.5.4 Summary of the effect of TXA on late clinical outcomes after multivariate analysis 
The effect of the TXA infusion on late outcomes and the effect of time from injury to receiving 
the TXA bolus on late outcomes after risk-adjustment by multivariate analysis are 
summarised in Figure 60 and Figure 61 respectively.   
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Figure 60  The effect of the TXA infusion on late clinical outcomes 
Forest plot shows odds ratio and 95% confidence intervals. 
 
0.9 1.0 1.1
Mortality
Thrombotic event
MODS
Odds Ratio (95% CI)
1.01 (0.99 - 1.04)
1.01 (0.99 - 1.02)
1.02 (1.00 - 1.04)
Odds ratio
 
Figure 61  The effect of time from injury to receiving the TXA bolus on late clinical outcomes 
Forest plot shows odds ratio and 95% confidence intervals. 
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5.5 DISCUSSION 
In this study of 215 patients treated with TXA for traumatic haemorrhage, no beneficial effect 
in functional coagulation or fibrinolysis on admission, during bleeding or at 24-hours was 
measured from the TXA bolus + infusion over a single bolus.  A non-statistically significant 
higher rate of thrombotic events was identified on univariate analysis in those receiving 
bolus + infusion, in the context of increased clot strength and reduced fibrinolysis on ROTEM 
at 72-hours in this group compared to patients receiving a single TXA bolus.  TXA dosed as a 
bolus + infusion has previously been shown to reduce the risk of death from haemorrhage 
and in this study we found no significant difference in haemorrhage-related deaths between 
the two dosing regimens studied.  A linear trend between later completion of the TXA 
infusion and increased thrombotic events was identified in this cohort of patients on 
univariate analysis.  However, after adjusting for all variables with multivariate analysis, 
receiving the TXA infusion was not associated with thrombotic events, MODS or mortality.  
The odds ratio of the TXA infusion was 0.5 for mortality suggesting a possible underpowered 
effect and highlighting the need for clinical trial data to explore this effect further.  Time from 
injury to treatment with the TXA bolus was similarly not associated with development of 
MODS or thrombosis but there was a non-statistically significant signal towards this variable 
being associated with mortality.  Patients who developed a thrombotic event had lower 
ROTEM ML and yet higher D-dimers at 24-hours.   
 
In this observational study, timing of administration of the TXA infusion was seen to vary 
widely.  Whilst this likely reflects the difficulty of implementing a specific IV treatment for a 
bleeding trauma patient for clinical teams who find themselves within a stressful situation 
requiring prioritisation of many competing tasks, the reality of the treatment actually 
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delivered is that it was not as described in the CRASH-2 trial.  The median time from bolus to 
infusion starting was 84 minutes.  One factor likely contributing to this delay is that the bolus 
was given pre-hospital in the majority of cases whilst the infusion would not be expected to 
start until arrival in the hospital.  It is not known whether a bolus followed by immediate 
infusion within the three hour window post-injury has the same beneficial effect as a bolus 
followed by a delayed infusion.  However, the finding of increased subsequent thrombotic 
events in patients who had TXA infusions running beyond 10.5 hours after injury on 
univariate analysis suggests that any delay in therapy may be important with regards to 
development of thrombotic complications.   
 
Earlier treatment with TXA following injury is known to provide the most beneficial effects in 
terms of reducing the risk of bleeding due to haemorrhage.[139]  A recently published meta-
analysis of the CRASH-2 trial data combined with data from the WOMAN trial, which assessed 
the effects of TXA in post-partum haemorrhage, examined the effect of delay in treatment 
on the effectiveness of TXA.[140]  In a combined analysis of data from over 40,000 patients, 
the study reported that whilst immediate treatment resulted in the greatest improvement 
in survival (by at least 70%), for every 15 minute delay in treatment, the survival benefit 
reduced by 10%.  After three hours, there was no improvement in survival with TXA.  
Treatment delay was not found to alter the risk of vascular occlusive events.  The current 
study has also shown no association between time to receiving the TXA bolus and 
development of thrombotic complications.  Only one patient in this study received the TXA 
bolus beyond three hours from injury.  In spite of this our analysis suggests that increased 
time from injury to administration of the TXA bolus could be associated with mortality, even 
when the TXA bolus is administered within three hours from injury.  Increasing the sample 
size could help to elucidate whether this factor becomes more significant.     
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Accurate diagnosis of fibrinolytic status in a clinically useful timeframe is challenging.  The 
methods currently available to the clinician include laboratory measurement of D-dimer or 
point-of-care diagnostics such as TEG and ROTEM.  However, as we have demonstrated in 
this body of work (Chapter 3), current ROTEM assays are capable of detecting only the 
highest extremes of tPA-mediated hyperfibrinolysis and do not detect all increased 
fibrinolytic activity.  Trauma resuscitation guidelines recommend empiric treatment with TXA 
in suspected trauma haemorrhage for this reason.  The challenge, however, is knowing if a 
patient is still lytic or not after treatment with the first 1g bolus of TXA.  A patient with 
persistently high fibrinolytic activity may derive benefit from an additional dosage of TXA 
whilst in another patient whose fibrinolytic system has already been effectively ‘switched-
off’ any further TXA treatment could potentially cause harm. Mapping the timescale for the 
temporal changes in the fibrinolytic system in response to initial injury, blood product 
resuscitation, therapeutics such as TXA and surgery through use of existing biomarker assays 
e.g. tPA, PAP is a priority.  This may lead to improved understanding with regards the optimal 
timing for TXA therapy or other haemostatic agents post injury.  In addition, development of 
improved point-of-care diagnostics capable of rapid, accurate assessment of fibrinolytic 
activity is required.   
 
However, despite a recent change in practice at the RLH with omission of the TXA infusion 
based on expert opinion and increased use of VHA in the clinical setting, the current best 
evidence-based practice in order to improve trauma haemorrhage outcomes is to deliver 
TXA in-line with the CRASH-2 trial of a bolus followed by immediate infusion.  The Author 
acknowledges that deviation from this evidence-based practice has the potential to result in 
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poorer outcomes for patients.  This further strengthens the argument for another trial to 
urgently investigate the optimal dose of TXA in trauma haemorrhage.  
 
This study has a number of limitations.  Firstly, it was an observational study that recorded 
the incidence of symptomatic thrombotic events, with no routine screening for 
asymptomatic VTE and therefore the incidence of thrombotic events reported may be an 
underestimate.  A standardised mechanical and pharmacological thromboprophylaxis 
protocol is in place within our institution, although methods of thromboprophylaxis and 
adherence with the guideline were not recorded in this study and therefore the influence of 
prophylaxis in the reported results is unknown.  The number of patients studied and the 
number of thrombotic events identified were relatively small, which may have limited our 
ability to detect differences in outcomes associated with the different TXA dosing regimens.  
In particular, we are able to make no assessment of the effect later TXA treatment had in 
protecting against death due to bleeding due to the small sample size and small number of 
deaths secondary to haemorrhage.  The difference identified in deaths secondary to 
haemorrhage in the unadjusted analysis did not reach statistical significance, however, a lack 
of power in this study limits our ability to know if there is a true difference or not in this 
outcome between dosing regimens.  
 
5.6 CONCLUSION 
The principle findings of this study are that a single bolus of TXA appears to exert the same 
effect as measured by functional coagulation and D-dimer as a bolus + infusion.  In patients 
receiving the TXA infusion, thrombotic complications increased in a linear fashion the longer 
the delay to starting the infusion and therefore the later patients were exposed to a TXA 
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infusion after injury.  However, after adjusting for all other variables, neither the TXA infusion 
nor the time from injury to administration of the TXA bolus were found to be associated with 
development of thrombotic events.  A single bolus of TXA may, however, provide a lower 
effective therapeutic dose in trauma haemorrhage with reduced potential for thrombotic 
complications.  This theory would require further testing in a randomised control trial.  
Future research should aim to improve point of care diagnostics of fibrinolytic activity status 
and characterise the temporal changes in the coagulation and fibrinolytic systems that occur 
in response to injury and resuscitation which could enable individualised therapies such as 
early high dose thromboprophylaxis in an individual at high-risk of thrombotic complications.  
 
5.7  SPECIFIC CONTRIBUTIONS OF THE AUTHOR 
Having attended several trauma conferences where concerns had been raised surrounding 
the potential thrombotic complications of TXA use, the Author conceived this study to 
investigate the effect of the TXA infusion and timing of TXA treatment on outcomes in our 
patients recruited to RLH.  The Author created the dataset used within this study.  The study 
design was planned with KB and RD.  The analysis was performed by the Author.  Data 
interpretation was carried out by the Author, KB and RD.  This chapter was written and edited 
by the Author after receiving comments from RD and KB.  The Author created all data tables 
and figures within the chapter.   
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Chapter 6 
 
 
 
 
CONCLUSIONS, LIMITATIONS & FUTURE RESEARCH DIRECTIONS 
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6.1 SUMMARY OF FINDINGS 
The focus of this thesis has been to explore the different fibrinolytic phenotypes which 
contribute towards early trauma-induced coagulopathy (TIC) and to examine the effects of 
the antifibrinolytic Tranexamic acid (TXA) in trauma haemorrhage. 
 
The role for TXA in patients presenting to hospital with low levels of fibrinolysis as detected 
by VHA was uncertain.  In Chapter 3, patients presenting with low levels of ROTEM detected 
fibrinolysis were characterised and discovered in fact to be a heterogeneous group.  D-dimer 
level in combination with ML is able to discriminate those patients with poor clinical 
outcomes.  Patients with the MLLOW+DDLOW phenotype have low injury severity and good 
outcomes.  However, those with the MLLOW+DDHIGH phenotype are severely injured, 
coagulopathic, with a hyperfibrinolytic biomarker profile and associated poor clinical 
outcomes.  The mechanism of occult hyperfibrinolysis in this phenotype does not appear to 
be driven by tPA and instead a potential alternative mechanism of plasminogen activation, 
mediated by S100A10, was identified which also artificially lowers ML ex-vivo.  The finding of 
an occult hyperfibrinolytic phenotype supports the continued empiric use of TXA in trauma 
haemorrhage. 
 
In order to address the knowledge gap around the effect TXA has on TIC, Chapter 4 examined 
the effect of TXA on functional coagulation and fibrinolysis during trauma haemorrhage.  
Early empiric TXA completely avoids functional hyperfibrinolysis both on admission and 
during haemorrhage (up to transfusion of the 12 unit PRBC).  D-dimer levels in those treated 
with TXA were correspondingly lower at the end of massive transfusion.  TXA additionally 
provided a degree of protection against TIC with greater clot strength after massive 
haemorrhage in those receiving TXA compared to patients who did not.   
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Finally, Chapter 5 investigated the effect of the TXA infusion and timing of treatment on 
clinical outcomes including thrombotic events.  In a separate study of bleeding trauma 
patients, those receiving a TXA bolus + infusion were compared to those receiving a single 
TXA bolus.  No difference in functional measures of coagulation were identified between the 
dosing regimens during initial haemorrhage or at 24-hours.  However, at 72-hours, those 
receiving TXA bolus + infusion demonstrated increased clot strength and a correspondingly 
lower ML.  In those treated with a TXA bolus + infusion, thrombotic events were discovered 
on univariate analysis to increase in a linear fashion the longer the time to administering the 
TXA infusion after injury.  The incidence of thrombotic events increased if exposure to the 
TXA infusion continued beyond 10.5 hours from injury.  However on multivariate analysis, 
the TXA infusion and time from injury to TXA bolus administration were not associated with 
thrombotic events.  In theory, a single TXA bolus may provide a lower effective therapeutic 
dose in trauma haemorrhage; countering hyperfibrinolysis yet with a reduced potential for 
thrombotic complications.  This theory requires further evaluation in a randomised control 
trial to investigate the effect of only administering a TXA bolus on patient outcomes.       
 
6.2 STRENGTHS & LIMITATIONS OF THIS WORK 
The collaboration of researchers from six European trauma centres working together as part 
of the INTRN partnership is an important feature of the work contained within the thesis.  
The study described in Chapter 3 involved over 900 patients recruited to the ACIT II study 
from five out of these six partner sites.  This greatly enhanced the study sample size and 
dataset available which in turn strengthened the results and enabled robust conclusions to 
be made.  No previous study has assayed plasma samples from as many trauma patients for 
biomarkers of coagulation and fibrinolysis to investigate VHA-hypofibrinolysis.  On a personal 
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level, collaboration with international partner sites provided me the opportunity to meet 
and engage with fellow researchers abroad and develop connections for future work and 
research.   
 
The Royal London Hospital is the busiest major trauma centre in the United Kingdom and 
treats a large volume of severely injured and bleeding trauma patients.  This permitted the 
recruitment of a large volume of bleeding ‘code-red’ patients over a relatively short time 
period and enabled the effect of TXA in this cohort of patients to be studied.  In the final 
study described, patients were enrolled 24 hours a day, seven days a week, further increasing 
study recruitment.  A strength of the study is that Nominated Consultee agreement allows 
rapid patient enrolment and permits baseline blood samples to be taken as soon as the 
patient arrives in the ED and within 2 hours of injury.  This early sampling time point permits 
investigation of the early fibrinolytic component of Acute Traumatic Coagulopathy.  One 
limitation of attempting to obtain serial samples from severely injured bleeding patients for 
an observational study of this nature is that occasionally clinical need takes priority and for 
example a PRBC unit sample may not be possible to obtain if the patient is transferred 
between resus and the operating theatre during the sampling window.  Whilst correct that 
clinical need takes priority over the observational study, this results in missing data and fewer 
data points available for the PRBC unit samples in particular within the datasets analysed.   
 
A limitation of the results presented within this thesis is that they are obtained from 
observational data and can therefore suggest associations but not determine causation.  This 
should be borne in mind when considering patient outcome data in particular.  
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Despite the documented limitations of both D-dimer levels and ROTEM-detected fibrinolysis, 
these were the only measures of fibrinolysis by which the two TXA dosages in chapter 5 could 
be compared.  Due to limitations on time it was not possible to measure biomarkers of 
fibrinolysis e.g. PAP, for this study cohort.  It is planned that these stored samples will be 
analysed by our group in the future in order to expand on the work presented here. 
 
6.3 FUTURE RESEARCH DIRECTIONS 
This body of work represents our research groups initial steps towards understanding the 
changes in the fibrinolytic system following injury and in doing so has raised further 
important questions and opened many potential avenues for future research to investigate.   
 
Accurate assessment of fibrinolytic activity is limited by the current lack of a sufficiently rapid 
yet sensitive diagnostic tool.  The work presented within this thesis has highlighted the 
limitations of current ROTEM assays to detect fibrinolytic activity.  As understanding of the 
drivers and control mechanisms for fibrinolytic activation are better understood, 
collaboration between trauma researchers and the medical device industries should be 
encouraged with an aim of developing novel assays and point-of-care platforms which permit 
serial assessment of fibrinolytic status to aid clinical acumen and guide treatment. 
 
In the meantime, future studies aimed at better understanding the mechanisms of 
fibrinolytic activation should utilise measurement of specific individual protein biomarkers 
e.g. PAP, tPA, PAI-1.  The novel finding of a potential role for S100A10 in mediating increased 
fibrinolytic activity in those patients who present with elevated D-dimers yet low ML requires 
further evaluation.  Whilst we have identified a potential explanation for “fibrinolytic 
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shutdown”, this work represents merely the start of our journey towards fully understanding 
the fibrinolytic changes following injury.  A later fibrinolytic shutdown may exist and 
experimental models to measure fibrinolytic protein mediators including S100A10 during the 
first 24 – 48 hours are required.  The effect of TXA in this specific phenotype is unclear and 
will require further clinical trial investigation.  The mechanisms of exposure and shedding of 
membrane-bound S100A10 and its function when free in the plasma requires exploration.  
Both clinical and experimental studies will be required to understand the role of S100A10 
and assess its potential as a therapeutic target in trauma-induced coagulopathy. 
 
Given the advances in pharmaceutical engineering since TXA was first described over 50 
years ago, it seems unlikely that such an old drug will remain the optimal agent to treat 
trauma patients. Whilst it remains the only evidence-based therapy available for treatment 
of hyperfibrinolysis in trauma, a randomised trial to determine optimal therapeutic dose 
should be considered.  As understanding of the pathways that drive excessive fibrinolytic 
activation advances, including the role of uPA and S100A10, this may lead to the 
development of novel and more efficacious therapeutics. The fibrinolytic system is highly 
dynamic, evolving over time following injury and yet studies have on the whole been limited 
to measurement of fibrinolysis at the point of ED arrival. Future studies should focus on serial 
sampling to fully characterise the temporal changes that occur in the coagulation and 
fibrinolytic systems in response not just to the initial trauma, but over subsequent hours and 
days following resuscitation, surgery and antifibrinolytic therapy.    
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6.4 FINAL CONCLUSIONS 
Trauma haemorrhage remains a leading cause of morbidity and mortality worldwide.  
Advances in our understanding of the pathophysiology leading to trauma-induced 
coagulopathy are an important means by which targeted therapeutic interventions can be 
developed.  Tranexamic acid in trauma haemorrhage is known to improve survival and in this 
body of work has been shown to reduce overt functional hyperfibrinolysis and if dosed 
empirically has the potential to also be of benefit to patients with an occult hyperfibrinolytic 
phenotype.  The findings of this work represent an initial step towards understanding the 
fibrinolytic response to traumatic injury and understanding the effect of TXA in trauma 
haemorrhage.  Future research is required to define the mechanisms driving 
hyperfibrinolysis and trauma-induced coagulopathy, with the aim of enabling superior 
diagnostics and novel therapeutics to be developed in order to improve overall outcomes for 
trauma patients. 
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APPENDIX 1 
 
Mechanism of occult hyperfibrinolysis in trauma patients 
Clinical characteristics and coagulation profiles were similar to the main cohort (Table A27 
and Table A28).  Urokinase-type plasminogen activator (uPA) levels were similar across all 
ML and DD groups (Figure A62).  Plasma S100A10 levels were low in the DDLOW cohorts but 
significantly elevated in both the MLLOW+DDHIGH and MLHIGH+DDHIGH patients (Figure A63A). 
Plasma S100A10 levels were strongly correlated with both PAP (r=0.58, p<0.001) and D-
dimer (r=0.56, p<0.001) levels (Figure A63B & C). S100A10 levels were strongly associated 
with injury severity (Figure A63D). In particular, patients with TBI (AIS Head 3+) had much 
higher plasma levels of S100A10 than those without (S100A10: 437 vs 55 pg/ml, p<0.001). 
TBI patients with higher plasma S100A10 (above the median 120pg/ml) had a 58% mortality, 
compared to only 6% for those with low S100A10 levels (p<0.001), as well as a higher 
incidence of coagulopathy (31% vs 0%, p=0.009) and PRBC transfusion (38% vs 6%, p=0.01). 
 
As S100A10 is known to bind tPA and plasmin, we further hypothesized that S100A10 would 
bind these in the ROTEM cup, thus reducing ex-vivo the availability of plasmin and therefore 
the VHA-measured fibrinolysis. We added 10ng/ml S100A10 to the whole blood of 6 healthy 
volunteers and saw a significant reduction in %ML (Figure A63E). In the MLLOW and MLNORMAL 
combined cohort, plasma S100A10 levels negatively correlated with %ML (r=-0.26, p<0.001, 
Figure A63F) but were still positively correlated with PAP (r=0.56, p<0.001) and D-dimer 
levels (r=0.28, p<0.001). There was no relationship between plasma levels of S100A10 and 
plasma tPA levels.  
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Table A27    Characteristics and outcomes of the extended biomarker subgroup 
 
Number of Patients 
MLNORMAL 
68 
MLLOW + DDLOW 
51 
MLLOW + DDHIGH 
45 
MLHIGH + DDLOW 
8 
MLHIGH + DDHIGH 
7 
 
Admission characteristics 
     
Age, years 28 (23-45) 38 (27- 50)^ 50 (34-62)* 27 (23-45) 58 (24-59) 
Male, n (%) 58 (85%) 44 (86%) 34 (76%) 7 (88%) 6 (86%) 
GCS 15 (14-15) 15 (14-15) 11 (4-15)** 15 (13-15) 8 (4-12) 
SBP, mmHg 138 (116-154) 138 (118-151) 128 (99-164) 131 (120-175) 120 (78-162) 
BD, mmol/L 0 (-1-1) 1.5 (-1-4)^ 2.5 (-1-5)* 1 (-2-16) 17 (9-23)++ 
INR > 1.2, n (%) 3 (1%) 0 (0%) 10 (24%)** 1 (13%) 3 (43%) 
EXTEM ML, % 7 (6-10) 3 (2-4)^^ 3 (2-4) 17 (16-96) 100 (23-100) 
D-Dimer, ng/ml 4124 (664 – 11356) 4224 (1041 – 11260) 91700 (59388 – 140173)** 2824 (689 – 1658) 109193 (46600 – 336490) 
Injury to sample time, minutes 83 (62-99) 88 (67-103) 98 (82-110)* 85 (73-115) 104 (85-106) 
 
Injury characteristics      
Blunt, n (%) 47 (69%) 40 (78%) 44 (98%)* 6 (75%) 7 (100%) 
ISS 10 (5-21) 10 (4-17) 29 (20-38)** 9 (5-29) 27 (25-41) 
AIS Head & Neck ≥ 3, n (%) 0 (0-1) 0 (0-2) 4 (0-5)** 0 (0-0) 0 (0-5) 
AIS Thorax ≥ 3, n (%) 0 (0-3) 0 (0-3) 3 (1-4)** 0 (0-3) 3 (0-4) 
AIS Abdo/pelvis ≥ 3, n (%) 0 (0-2) 0 (0-0) 0 (0-2) 0 (0-2) 0 (0-1) 
AIS Extremity ≥ 3, n (%) 1 (0-2) 1 (0-2) 2 (0-3) 2 (0-3) 0 (0-4) 
 
Fluid & Blood product totals      
Pre-baseline crystalloid, ml 0 (0-0) 0 (0-250)^^ 225 (0-500)* 0 (0-450) 500 (250-1500) 
Pre-baseline PRBC, units 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 
12hr Crystalloid, ml 100 (0-2075) 250 (0-1500) 1500 (400-2900)* 0 (0-2000) 1250 (500-4900) 
12hr PRBC, units 0 (0-0) 0 (0-0) 0 (0-4)** 0 (0-20) 11 (4-20)++ 
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Outcomes 
Massive Transfusion, n (%) 0 (0%) 0 (0%) 2 (4%) 2 (29%) 4 (50%)+ 
VTE, n (%) 0 (0%) 0 (0%) 1 (2%) 0 (0%) 0 (0%) 
Critical Care LOS (survivors) 0 (0-0) 0 (0-0) 5 (1-12)** 0 (0-0) 10 (8-11) 
Hospital LOS (survivors) 7 (2-15) 7 (2-13) 24 (14-45)** 6 (1-12) 39 (38-39) 
24hr mortality, n (%) 1 (2%) 1 (2%) 6 (13%)* 1 (13%) 5 (71%)+ 
28-day mortality, n (%) 2 (3%) 2 (4%) 15 (33%)** 2 (25%) 5 (71%) 
Time to death, days 2 (1-2) 3 (1-11) 1 (0-6) 2 (0-3) 0 (0-0) + 
 
All values are median with interquartile range unless specified. Continuous data compared with Mann-Whitney U-test. Categorical data compared with Fisher’s exact 
test. ^p<0.05, ^^p<0.001, MLNORMAL vs MLLOW + DDLOW. *p<0.05, **p<0.001, MLLOW + DDHIGH vs MLLOW + DDLOW. +p<0.05, ++p<0.001, MLHIGH + DDHIGH vs MLLOW + DDHIGH. GCS, 
Glasgow coma score. SBP, systolic blood pressure. BD, base deficit. INR, international normalized ratio. ML, maximum lysis. ISS, injury severity score. AIS, abbreviated 
injury score. PRBC, packed red blood cells. VTE, venous thromboembolism. LOS, length of stay in days 
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Table A28  Coagulation profiles in the extended biomarker subgroup 
 
Number of Patients 
MLNORMAL 
68 
MLLOW + DDLOW 
51 
MLLOW + DDHIGH 
45 
MLHIGH + DDLOW 
8 
MLHIGH + DDHIGH 
7 
      
Fibrinogen, g/L 2.2 (1.7-2.7) 2.1 (1.7-2.5) 1.6 (1.1-2.0)** 1.8 (0.7-2.5) 0.7 (0.5-1.2)+ 
Prothrombin Fragments 1+2, pmol/L 694 (335-1457) 818 (393-1420) 4924 (2966-8293)** 492 (432-1149) 4491 (1789-11738) + 
α2 antiplasmin, u/dL 103 (90-114) 93 (102-116) 71 (53-93)** 108 (31-140) 51 (10-59)+ 
Plasminogen Activator Inhibitor-1, ng/ml 18.3 (10.5-26.1) 24.9 (14.3-58.0)^ 30.2 (19.2-49.3) 18.3 (9.2-35.3) 25.35 (15.6-44.2) + 
Tissue plasminogen activator, ng/ml 11.1 (7.1-16.6) 17.5 (8.4-23.5)^ 15.4 (10.5-26.5) 9.5 (5.5-27.8) 51.0 (23.6-84.8)+ 
Plasmin-antiplasmin complex, ng/ml 2544 (1716-4690) 1536 (1012-3053)^ 16094 (9539-20261)** 2231 (1309-6849) 33816 (14587-37768)+ 
Urinary plasminogen activator, pg/ml 126 (0-233) 104 (0-249) 134 (33-212) 12 (0-221) 81 (0-215) + 
S100A10, pg/ml 50 (0-185) 9 (0-187) 1333 (128-2553)** 25 (0-322) 1281 (308-2869)+ 
 
 
Mann-Whitney U-test for all comparisons. ^p<0.05, ^^p<0.001, MLNORMAL vs MLLOW + DDLOW. *p<0.05, **p<0.001, MLLOW + DDHIGH vs MLLOW + DDLOW. +p<0.05, ++p<0.001, 
MLHIGH + DDHIGH vs MLLOW + DDHIGH. 
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Figure A62  Urokinase-type plasminogen activator (uPA) levels in patients grouped by fibrinolytic 
profile 
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Figure A63  S100A10 is associated with occult hyperfibrinolysis but reduces clot breakdown on viscoelastic testing. 
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A: Levels of S100A10 in trauma patients grouped by fibrinolytic profile. ***p<0.001, MLLOWDDHIGH vs MLNORMAL, Mann-Whitney U-test. B and C: Relationship between 
S100A10 and plasmin-antiplasmin (PAP) complex levels (B) and D-Dimer levels (C). S100A10 in quartiles; *p<0.05, ***p<0.001 vs Q1, Kruskall-Wallis test with Dunn’s 
multiple comparisons test D: S100A10 levels in patients with mild (ISS 1-4), moderate (ISS 5-15), severe (ISS 16-25) and critical (ISS>25) injuries. ** p<0.01, ***p<0.001 vs 
ISS 0-4, Kruskall-Wallis test with Dunn’s multiple comparisons test. E: Effect of S100A10 on maximum clot lysis (ML) measured by viscoelastic testing. Rotational 
thromboelastometry (ROTEM) was performed in tissue factor-stimulated blood samples from healthy volunteers (n=6) in the presence of recombinant S100A10 (10ng/ml) 
or vehicle. Lines indicate mean. ***p<0.001, paired T-test. F: Clot lysis on ROTEM in trauma patients from MLLOW and MLNORMAL groups stratified by S100A10 quartiles. ** 
p<0.01 vs Q1, Kruskall-Wallis test with Dunn’s multiple comparisons test. Box-whisker plots represent interquartile range with 10th-90th percentiles. 
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APPENDIX 2 
 
Figure A64  The Royal London Hospital Major Haemorrhage Protocol (revised July 2011) 
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Figure A65  The Royal London Hospital Major Haemorrhage Protocol (Revised Aug 2016) 
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APPENDIX 3  
 
Figure A66  Change in EXTEM Maximum Clot Firmness (MCF) during bleeding episode stratified by 
PRBC transfusion requirements. 
A. Patients receiving 4 – 7 units PRBC.  B.  Patients receiving 8 – 11 units PRBC.  C.  Patients receiving 
12 units or more PRBC.  EXTEM MCF at baseline: No TXA vs TXA 51 (22 – 56) vs 57 (48 – 61) mm, 
p=0.02.  EXTEM MCF after 12 units PRBC: No TXA vs TXA 44 (29 – 48) vs 54 (51- 56), p=0.005.  Box 
and whisker plots show median, interquartile range, maximum and minimum values. φp<0.05, 
**p<0.001.  PRBC, packed red blood cells. 
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Figure A67  Change in EXTEM Maximum Lysis (ML) during bleeding episode stratified by PRBC 
transfusion requirements.   
A. Patients receiving 4 – 7 units PRBC.  EXTEM ML at baseline: No TXA vs TXA 6 (3 – 9) vs 4 (2 – 5) %, 
p=0.03.  B.  Patients receiving 8 – 11 units PRBC.  EXTEM ML at baseline: No TXA vs TXA 8 (4 – 15) vs 
3 (1 – 5) %, p=0.001.  C.  Patients receiving 12 units or more PRBC.  EXTEM ML at baseline: No TXA 
vs TXA 14 (7 – 100) vs 2 (1 – 4) %, p<0.0001.  EXTEM ML after 4 units PRBC: No TXA vs TXA 10 (6 – 
100) vs 2 (1 – 3) %, p=0.0005.  Box and whisker plots show median, interquartile range, maximum 
and minimum values. φp<0.05, **p<0.01.  PRBC, packed red blood cells. 
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Figure A68  Change in plasmin-α2-antiplasmin complex (PAP) levels during bleeding episode 
stratified by PRBC transfusion requirements.   
A. Patients receiving 4 – 7 units PRBC.  B.  Patients receiving 8 – 11 units PRBC.  C.  Patients receiving 
12 units or more PRBC.  Box and whisker plots show median, interquartile range, maximum and 
minimum values. PRBC, packed red blood cells. 
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Figure A69  Change in D-dimer levels during bleeding episode stratified by PRBC transfusion 
requirements.   
A. Patients receiving 4 – 7 units PRBC.  B.  Patients receiving 8 – 11 units PRBC.  C.  Patients receiving 
12 units or more PRBC.  D-dimer level after 12PRBC: No TXA vs TXA 30380 (22710 – 54960) vs 12050 
(5843 – 16780) ng/ml, p=0.005.  Box and whisker plots show median, interquartile range, maximum 
and minimum values. **p<0.01.  PRBC, packed red blood cells. 
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